Abacavir|P|ethanol|abacavir|BIOENTITY decrease_BE12 the_BE12 elimination_BE12 of_BE12 BIOENTITY cause_RE2 increase_RE2 in_RE2 overall_RE2 exposure_RE2 the_RE2 addition_RE2 of_RE2 BIOGENERAL_RE2 have_RE2 no_RE2 clinical_RE2 significant_RE2 effect_RE2 on_RE2 the_RE2 pharmacokinetic_RE2 property_RE2 of_RE2 BIOGENERAL_RE2 
Abacavir|P|methadone|ziagen|In_LE1 study_LE1 of_LE1 NUM_LE1 hivinfected_LE1 patient_LE1 receive_LE1 BIOENTITY therapy_BE12 -LRB-_BE12 NUM_BE12 mg_BE12 and_BE12 NUM_BE12 mg_BE12 daily_BE12 -RRB-_BE12 with_BE12 NUM_BE12 mg_BE12 of_BE12 BIOENTITY twice_RE2 daily_RE2 -LRB-_RE2 twice_RE2 the_RE2 current_RE2 recommend_RE2 dose_RE2 -RRB-_RE2 oral_RE2 BIOGENERAL_RE2 clearance_RE2 increase_RE2 NUM_RE2 -LRB-_RE2 NUM_RE2 ci_RE2 NUM_RE2 to_RE2 NUM_RE2 %rrb._RE2 
Ezetimibe|P|cholestyramine|ezetimibe|BIOGENERAL_LE1 :_LE1 concomitant_LE1 BIOENTITY administration_BE12 decrease_BE12 the_BE12 mean_BE12 auc_BE12 of_BE12 total_BE12 BIOENTITY approximate_RE2 NUM_RE2 %._RE2 
Ezetimibe|P|ezetimibe|cholestyramine|the_LE1 incremental_LE1 ldlc_LE1 reduction_LE1 due_LE1 to_LE1 add_LE1 BIOENTITY to_BE12 BIOENTITY may_RE2 be_RE2 reduce_RE2 by_RE2 this_RE2 interaction_RE2 
Ezetimibe|P|zetia|fibrate|coadministration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 until_RE2 use_RE2 in_RE2 patient_RE2 be_RE2 study_RE2 
Ezetimibe|P|fenofibrate|ezetimibe|BIOGENERAL_LE1 :_LE1 In_LE1 pharmacokinetic_LE1 study_LE1 concomitant_LE1 BIOENTITY administration_BE12 increase_BE12 total_BE12 BIOENTITY concentration_RE2 approximate_RE2 .fold_RE2 
Ezetimibe|P|ezetimibe|cyclosporine|BIOGENERAL_LE1 :_LE1 the_LE1 total_LE1 BIOENTITY level_BE12 increase_BE12 fold_BE12 in_BE12 one_BE12 renal_BE12 transplant_BE12 patient_BE12 receive_BE12 multiple_BE12 medication_BE12 including_BE12 BIOENTITY 
Ezetimibe|P|ezetimibe|cyclosporine|patient_LE1 who_LE1 take_LE1 both_LE1 BIOENTITY and_BE12 BIOENTITY shall_RE2 be_RE2 careful_RE2 monitor_RE2 
Fluconazole|P|diflucan|hypoglycemic agent|these_LE1 be_LE1 describe_LE1 in_LE1 great_LE1 detail_LE1 below_LE1 :_LE1 oral_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 oral_LE1 BIOGENERAL_LE1 :_LE1 clinical_LE1 significant_LE1 hypoglycemia_LE1 may_LE1 be_LE1 precipitated_LE1 by_LE1 the_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 oral_BE12 BIOENTITY 
Fluconazole|P|diflucan|glyburide|one_LE1 fatality_LE1 have_LE1 be_LE1 report_LE1 from_LE1 hypoglycemia_LE1 in_LE1 association_LE1 with_LE1 combined_LE1 BIOENTITY and_BE12 BIOENTITY use_RE2 
Fluconazole|P|diflucan|tolbutamide|BIOENTITY reduce_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 and_RE2 increase_RE2 the_RE2 plasma_RE2 concentration_RE2 of_RE2 these_RE2 agent_RE2 
Fluconazole|P|diflucan|glyburide|BIOENTITY reduce_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 and_RE2 increase_RE2 the_RE2 plasma_RE2 concentration_RE2 of_RE2 these_RE2 agent_RE2 
Fluconazole|P|diflucan|glipizide|BIOENTITY reduce_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY and_RE2 increase_RE2 the_RE2 plasma_RE2 concentration_RE2 of_RE2 these_RE2 agent_RE2 
Fluconazole|P|diflucan|sulfonylurea oral hypoglycemic agent|when_LE1 BIOENTITY be_BE12 use_BE12 concomitant_BE12 with_BE12 these_BE12 or_BE12 other_BE12 BIOENTITY blood_RE2 glucose_RE2 concentration_RE2 shall_RE2 be_RE2 careful_RE2 monitor_RE2 and_RE2 the_RE2 dose_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 shall_RE2 be_RE2 adjust_RE2 as_RE2 necessary_RE2 
Fluconazole|P|diflucan|coumarin-type anticoagulant|BIOGENERAL_LE1 :_LE1 prothrombin_LE1 time_LE1 may_LE1 be_LE1 increase_LE1 in_LE1 patient_LE1 receive_LE1 concomitant_LE1 BIOENTITY and_BE12 BIOENTITY 
Fluconazole|P|fluconazole|warfarin|In_LE1 postmarketing_LE1 experience_LE1 as_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 bleeding_LE1 event_LE1 -LRB-_LE1 bruising_LE1 epistaxis_LE1 gastrointestinal_LE1 bleeding_LE1 hematuria_LE1 and_LE1 melena_LE1 -RRB-_LE1 have_LE1 be_LE1 report_LE1 in_LE1 association_LE1 with_LE1 increase_LE1 in_LE1 prothrombin_LE1 time_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY concurrent_BE12 with_BE12 BIOENTITY 
Fluconazole|P|diflucan|coumarin-type anticoagulant|careful_LE1 monitoring_LE1 of_LE1 prothrombin_LE1 time_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 recommend_RE2 
Fluconazole|P|diflucan|phenytoin|BIOGENERAL_LE1 :_LE1 BIOENTITY increase_BE12 the_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY 
Fluconazole|P|diflucan|phenytoin|careful_LE1 monitoring_LE1 of_LE1 BIOGENERAL_LE1 concentration_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 recommend_RE2 
Fluconazole|P|diflucan|cyclosporine|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 significant_BE12 increase_BE12 BIOENTITY level_RE2 in_RE2 renal_RE2 transplant_RE2 patient_RE2 with_RE2 or_RE2 without_RE2 renal_RE2 impairment_RE2 
Fluconazole|P|diflucan|cyclosporine|careful_LE1 monitoring_LE1 of_LE1 BIOGENERAL_LE1 concentration_LE1 and_LE1 serum_LE1 creatinine_LE1 be_LE1 recommend_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY and_BE12 BIOENTITY 
Fluconazole|P|rifampin|diflucan|BIOGENERAL_LE1 :_LE1 BIOENTITY enhance_BE12 the_BE12 metabolism_BE12 of_BE12 concurrent_BE12 administer_BE12 BIOENTITY 
Fluconazole|P|diflucan|rifampin|Depending_LE1 on_LE1 clinical_LE1 circumstance_LE1 consideration_LE1 shall_LE1 be_LE1 give_LE1 to_LE1 increase_LE1 the_LE1 dose_LE1 of_LE1 BIOENTITY when_BE12 it_BE12 be_BE12 administer_BE12 with_BE12 BIOENTITY 
Fluconazole|P|diflucan|rifampin|Depending_LE1 on_LE1 clinical_LE1 circumstance_LE1 consideration_LE1 shall_LE1 be_LE1 give_LE1 to_LE1 increase_LE1 the_LE1 dose_LE1 of_LE1 BIOENTITY when_BE12 it_BE12 be_BE12 administer_BE12 with_BE12 BIOENTITY 
Fluconazole|P|diflucan|theophylline|BIOGENERAL_LE1 :_LE1 BIOENTITY increase_BE12 the_BE12 serum_BE12 concentration_BE12 of_BE12 BIOENTITY 
Fluconazole|P|diflucan|theophylline|careful_LE1 monitoring_LE1 of_LE1 serum_LE1 BIOGENERAL_LE1 concentration_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 recommend_RE2 
Fluconazole|P|azole antifungal|terfenadine|BIOGENERAL_LE1 :_LE1 because_LE1 of_LE1 the_LE1 occurrence_LE1 of_LE1 serious_LE1 cardiac_LE1 dysrhythmia_LE1 secondary_LE1 to_LE1 prolongation_LE1 of_LE1 the_LE1 qtc_LE1 interval_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY in_BE12 conjunction_BE12 with_BE12 BIOENTITY interaction_RE2 study_RE2 have_RE2 be_RE2 perform_RE2 
Fluconazole|P|diflucan|terfenadine|another_LE1 study_LE1 at_LE1 mg_LE1 and_LE1 mg_LE1 daily_LE1 dose_LE1 of_LE1 BIOGENERAL_LE1 demonstrate_LE1 that_LE1 BIOENTITY take_BE12 in_BE12 dose_BE12 of_BE12 NUM_BE12 mg_BE12 per_BE12 day_BE12 or_BE12 great_BE12 significant_BE12 increase_BE12 plasma_BE12 level_BE12 of_BE12 BIOENTITY when_RE2 take_RE2 concomitant_RE2 
Fluconazole|P|fluconazole|terfenadine|the_LE1 combined_LE1 use_LE1 of_LE1 BIOENTITY at_BE12 dose_BE12 of_BE12 NUM_BE12 mg_BE12 or_BE12 great_BE12 with_BE12 BIOENTITY be_RE2 contraindicate_RE2 
Fluconazole|P|fluconazole|terfenadine|the_LE1 coadministration_LE1 of_LE1 BIOENTITY at_BE12 dose_BE12 low_BE12 than_BE12 NUM_BE12 mg_BE12 with_BE12 BIOENTITY shall_RE2 be_RE2 careful_RE2 monitor_RE2 
Fluconazole|P|fluconazole|cisapride|BIOGENERAL_LE1 :_LE1 there_LE1 have_LE1 be_LE1 report_LE1 of_LE1 cardiac_LE1 event_LE1 including_LE1 torsade_LE1 de_LE1 pointe_LE1 in_LE1 patient_LE1 to_LE1 who_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 coadminister_RE2 
Fluconazole|P|fluconazole|cisapride|controlled_LE1 study_LE1 find_LE1 that_LE1 concomitant_LE1 BIOENTITY NUM_BE12 mg_BE12 once_BE12 daily_BE12 and_BE12 BIOENTITY NUM_RE2 mg_RE2 four_RE2 time_RE2 day_RE2 yield_RE2 significant_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 plasma_RE2 level_RE2 and_RE2 prolongation_RE2 of_RE2 qtc_RE2 interval_RE2 
Fluconazole|P|fluconazole|cisapride|the_LE1 combined_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY be_RE2 contraindicate_RE2 
Fluconazole|P|fluconazole|astemizole|BIOGENERAL_LE1 :_LE1 the_LE1 use_LE1 of_LE1 BIOENTITY in_BE12 patient_BE12 concurrent_BE12 take_BE12 BIOENTITY or_RE2 other_RE2 drug_RE2 metabolize_RE2 by_RE2 the_RE2 cytochrome_RE2 system_RE2 may_RE2 be_RE2 associate_RE2 with_RE2 elevation_RE2 in_RE2 serum_RE2 level_RE2 of_RE2 these_RE2 drug_RE2 
Fluconazole|P|fluconazole|rifabutin|BIOGENERAL_LE1 :_LE1 there_LE1 have_LE1 be_LE1 report_LE1 of_LE1 uveitis_LE1 in_LE1 patient_LE1 to_LE1 who_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 coadminister_RE2 
Fluconazole|P|rifabutin|fluconazole|patient_LE1 receive_LE1 BIOENTITY and_BE12 BIOENTITY concomitant_RE2 shall_RE2 be_RE2 careful_RE2 monitor_RE2 
Fluconazole|P|fluconazole|tacrolimu|BIOGENERAL_LE1 :_LE1 there_LE1 have_LE1 be_LE1 report_LE1 of_LE1 nephrotoxicity_LE1 in_LE1 patient_LE1 to_LE1 who_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 coadminister_RE2 
Fluconazole|P|tacrolimu|fluconazole|patient_LE1 receive_LE1 BIOENTITY and_BE12 BIOENTITY concomitant_RE2 shall_RE2 be_RE2 careful_RE2 monitor_RE2 
Fluconazole|P|midazolam|fluconazole|BIOGENERAL_LE1 :_LE1 Following_LE1 oral_LE1 administration_LE1 of_LE1 BIOENTITY BIOENTITY result_RE2 in_RE2 substantial_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 concentration_RE2 and_RE2 psychomotor_RE2 effect_RE2 
Fluconazole|P|midazolam|fluconazole|this_LE1 effect_LE1 on_LE1 BIOENTITY appear_BE12 to_BE12 be_BE12 much_BE12 pronounced_BE12 follow_BE12 oral_BE12 administration_BE12 of_BE12 BIOENTITY than_RE2 with_RE2 BIOGENERAL_RE2 administer_RE2 intravenous_RE2 
Fluconazole|P|short-acting benzodiazepine|fluconazole|if_LE1 BIOENTITY which_BE12 be_BE12 metabolize_BE12 by_BE12 the_BE12 cytochrome_BE12 system_BE12 be_BE12 concomitant_BE12 administer_BE12 with_BE12 BIOENTITY consideration_RE2 shall_RE2 be_RE2 give_RE2 to_RE2 decrease_RE2 the_RE2 BIOGENERAL_RE2 dosage_RE2 and_RE2 the_RE2 patient_RE2 shall_RE2 be_RE2 appropriate_RE2 monitor_RE2 
Fluconazole|P|fluconazole|ethinyl estradiol|BIOENTITY tablet_BE12 coadminister_BE12 with_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 produce_RE2 overall_RE2 mean_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 level_RE2 
Fluconazole|P|fluconazole|levonorgestrel|BIOENTITY tablet_BE12 coadminister_BE12 with_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY oral_RE2 BIOGENERAL_RE2 produce_RE2 overall_RE2 mean_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 level_RE2 
Fluconazole|P|fluconazole|ethinyl estradiol|while_LE1 there_LE1 be_LE1 evidence_LE1 that_LE1 BIOENTITY can_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 there_RE2 be_RE2 no_RE2 evidence_RE2 that_RE2 BIOGENERAL_RE2 be_RE2 net_RE2 inducer_RE2 of_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 metabolism_RE2 
Fluconazole|P|fluconazole|levonorgestrel|while_LE1 there_LE1 be_LE1 evidence_LE1 that_LE1 BIOENTITY can_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY there_RE2 be_RE2 no_RE2 evidence_RE2 that_RE2 BIOGENERAL_RE2 be_RE2 net_RE2 inducer_RE2 of_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 metabolism_RE2 
Mazindol|P|mazindol|nardil|you_LE1 can_LE1 take_LE1 BIOENTITY if_BE12 you_BE12 have_BE12 take_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 in_RE2 the_RE2 last_RE2 NUM_RE2 day_RE2 
Mazindol|P|mazindol|parnate|you_LE1 can_LE1 take_LE1 BIOENTITY if_BE12 you_BE12 have_BE12 take_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 or_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 in_RE2 the_RE2 last_RE2 NUM_RE2 day_RE2 
Mazindol|P|mazindol|phenelzine|you_LE1 can_LE1 take_LE1 BIOENTITY if_BE12 you_BE12 have_BE12 take_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 in_RE2 the_RE2 last_RE2 NUM_RE2 day_RE2 
Mazindol|P|mazindol|marplan|you_LE1 can_LE1 take_LE1 BIOENTITY if_BE12 you_BE12 have_BE12 take_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 in_RE2 the_RE2 last_RE2 NUM_RE2 day_RE2 
Mazindol|P|mazindol|tranylcypromine|you_LE1 can_LE1 take_LE1 BIOENTITY if_BE12 you_BE12 have_BE12 take_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 in_RE2 the_RE2 last_RE2 NUM_RE2 day_RE2 
Mazindol|P|mazindol|maoi|you_LE1 can_LE1 take_LE1 BIOENTITY if_BE12 you_BE12 have_BE12 take_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 in_RE2 the_RE2 last_RE2 NUM_RE2 day_RE2 
Mazindol|P|mazindol|isocarboxazid|you_LE1 can_LE1 take_LE1 BIOENTITY if_BE12 you_BE12 have_BE12 take_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 such_BE12 as_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 in_RE2 the_RE2 last_RE2 NUM_RE2 day_RE2 
Mazindol|P|mazindol|monoamine oxidase inhibitor|you_LE1 can_LE1 take_LE1 BIOENTITY if_BE12 you_BE12 have_BE12 take_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 in_RE2 the_RE2 last_RE2 NUM_RE2 day_RE2 
Mazindol|P|insulin|mazindol|change_LE1 in_LE1 BIOENTITY and_BE12 other_BE12 diabetes_BE12 drug_BE12 therapy_BE12 may_BE12 be_BE12 necessary_BE12 during_BE12 treatment_BE12 with_BE12 BIOENTITY 
Mazindol|P|mazindol|ismelin|BIOENTITY may_BE12 reduce_BE12 the_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY 
Mazindol|P|mazindol|guanethidine|BIOENTITY may_BE12 reduce_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 
Mebendazole|P|cimetidine|mebendazole|preliminary_LE1 evidence_LE1 suggest_LE1 that_LE1 BIOENTITY inhibit_BE12 BIOENTITY metabolism_RE2 and_RE2 may_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 plasma_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 
Mecamylamine|P|sulfonamide|ganglion blocker|patient_LE1 receive_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY general_BE12 shall_BE12 not_BE12 be_BE12 treat_BE12 with_BE12 BIOENTITY 
Mecamylamine|P|antibiotic|ganglion blocker|patient_LE1 receive_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 general_BE12 shall_BE12 not_BE12 be_BE12 treat_BE12 with_BE12 BIOENTITY 
Mecamylamine|P|mecamylamine|alcohol|the_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 anesthesia_BE12 other_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Mecamylamine|P|mecamylamine|antihypertensive drug|the_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 anesthesia_BE12 other_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Medroxyprogesterone|P|aminoglutethimide|depo-subq provera 104|BIOENTITY administer_BE12 concomitant_BE12 with_BE12 BIOENTITY may_RE2 significant_RE2 decrease_RE2 the_RE2 serum_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 
Megestrol|P|megestrol acetate|indinavir|pharmacokinetic_LE1 study_LE1 demonstrate_LE1 that_LE1 coadministration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY result_RE2 in_RE2 significant_RE2 decrease_RE2 in_RE2 the_RE2 pharmacokinetic_RE2 parameter_RE2 -LRB-_RE2 for_RE2 cmax_RE2 and_RE2 for_RE2 auc_RE2 -RRB-_RE2 of_RE2 BIOGENERAL_RE2 
Megestrol|P|indinavir|megestrol acetate|administration_LE1 of_LE1 high_LE1 dose_LE1 of_LE1 BIOENTITY shall_BE12 be_BE12 consider_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Melatonin|P|melatonin|beta blocker|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 following_BE12 drug_BE12 :_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 may_BE12 low_BE12 BIOGENERAL_BE12 level_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 bioavailability_BE12 of_BE12 oral_BE12 BIOGENERAL_BE12 be_BE12 increase_BE12 with_BE12 coadministration_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 may_RE2 decrease_RE2 BIOGENERAL_RE2 level_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 report_RE2 of_RE2 psychotic_RE2 episode_RE2 when_RE2 coadminister_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 coadministration_RE2 of_RE2 BIOGENERAL_RE2 with_RE2 BIOGENERAL_RE2 can_RE2 inhibit_RE2 ovarian_RE2 function_RE2 in_RE2 woman_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 sedating_RE2 drug_RE2 -LRB-_RE2 may_RE2 result_RE2 in_RE2 additive_RE2 sedation_RE2 and_RE2 increase_RE2 incidence_RE2 of_RE2 adverse_RE2 effect_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 coadministration_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 interfere_RE2 with_RE2 the_RE2 efficacy_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 rrb._RE2 
Melatonin|P|melatonin|fluvoxamine|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 following_BE12 drug_BE12 :_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 may_BE12 low_BE12 BIOGENERAL_BE12 level_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 bioavailability_RE2 of_RE2 oral_RE2 BIOGENERAL_RE2 be_RE2 increase_RE2 with_RE2 coadministration_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 may_RE2 decrease_RE2 BIOGENERAL_RE2 level_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 report_RE2 of_RE2 psychotic_RE2 episode_RE2 when_RE2 coadminister_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 coadministration_RE2 of_RE2 BIOGENERAL_RE2 with_RE2 BIOGENERAL_RE2 can_RE2 inhibit_RE2 ovarian_RE2 function_RE2 in_RE2 woman_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 sedating_RE2 drug_RE2 -LRB-_RE2 may_RE2 result_RE2 in_RE2 additive_RE2 sedation_RE2 and_RE2 increase_RE2 incidence_RE2 of_RE2 adverse_RE2 effect_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 coadministration_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 interfere_RE2 with_RE2 the_RE2 efficacy_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 rrb._RE2 
Melatonin|P|melatonin|aspirin|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 following_BE12 drug_BE12 :_BE12 BIOENTITY and_RE2 other_RE2 BIOGENERAL_RE2 -LRB-_RE2 may_RE2 low_RE2 BIOGENERAL_RE2 level_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 bioavailability_RE2 of_RE2 oral_RE2 BIOGENERAL_RE2 be_RE2 increase_RE2 with_RE2 coadministration_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 may_RE2 decrease_RE2 BIOGENERAL_RE2 level_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 report_RE2 of_RE2 psychotic_RE2 episode_RE2 when_RE2 coadminister_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 coadministration_RE2 of_RE2 BIOGENERAL_RE2 with_RE2 BIOGENERAL_RE2 can_RE2 inhibit_RE2 ovarian_RE2 function_RE2 in_RE2 woman_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 sedating_RE2 drug_RE2 -LRB-_RE2 may_RE2 result_RE2 in_RE2 additive_RE2 sedation_RE2 and_RE2 increase_RE2 incidence_RE2 of_RE2 adverse_RE2 effect_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 coadministration_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 interfere_RE2 with_RE2 the_RE2 efficacy_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 rrb._RE2 
Melatonin|P|melatonin|nsaid|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 following_BE12 drug_BE12 :_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOENTITY -LRB-_RE2 may_RE2 low_RE2 BIOGENERAL_RE2 level_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 bioavailability_RE2 of_RE2 oral_RE2 BIOGENERAL_RE2 be_RE2 increase_RE2 with_RE2 coadministration_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 may_RE2 decrease_RE2 BIOGENERAL_RE2 level_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 report_RE2 of_RE2 psychotic_RE2 episode_RE2 when_RE2 coadminister_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 coadministration_RE2 of_RE2 BIOGENERAL_RE2 with_RE2 BIOGENERAL_RE2 can_RE2 inhibit_RE2 ovarian_RE2 function_RE2 in_RE2 woman_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 sedating_RE2 drug_RE2 -LRB-_RE2 may_RE2 result_RE2 in_RE2 additive_RE2 sedation_RE2 and_RE2 increase_RE2 incidence_RE2 of_RE2 adverse_RE2 effect_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 coadministration_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 interfere_RE2 with_RE2 the_RE2 efficacy_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 rrb._RE2 
Melatonin|P|melatonin|progestin|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 following_BE12 drug_BE12 :_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 may_BE12 low_BE12 BIOGENERAL_BE12 level_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 bioavailability_BE12 of_BE12 oral_BE12 BIOGENERAL_BE12 be_BE12 increase_BE12 with_BE12 coadministration_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 may_BE12 decrease_BE12 BIOGENERAL_BE12 level_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 report_BE12 of_BE12 psychotic_BE12 episode_BE12 when_BE12 coadminister_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 coadministration_RE2 of_RE2 BIOGENERAL_RE2 with_RE2 BIOGENERAL_RE2 can_RE2 inhibit_RE2 ovarian_RE2 function_RE2 in_RE2 woman_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 sedating_RE2 drug_RE2 -LRB-_RE2 may_RE2 result_RE2 in_RE2 additive_RE2 sedation_RE2 and_RE2 increase_RE2 incidence_RE2 of_RE2 adverse_RE2 effect_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 coadministration_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 interfere_RE2 with_RE2 the_RE2 efficacy_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 rrb._RE2 
Melatonin|P|melatonin|fluoxetine|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 following_BE12 drug_BE12 :_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 may_BE12 low_BE12 BIOGENERAL_BE12 level_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 bioavailability_BE12 of_BE12 oral_BE12 BIOGENERAL_BE12 be_BE12 increase_BE12 with_BE12 coadministration_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 may_BE12 decrease_BE12 BIOGENERAL_BE12 level_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 report_RE2 of_RE2 psychotic_RE2 episode_RE2 when_RE2 coadminister_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 coadministration_RE2 of_RE2 BIOGENERAL_RE2 with_RE2 BIOGENERAL_RE2 can_RE2 inhibit_RE2 ovarian_RE2 function_RE2 in_RE2 woman_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 sedating_RE2 drug_RE2 -LRB-_RE2 may_RE2 result_RE2 in_RE2 additive_RE2 sedation_RE2 and_RE2 increase_RE2 incidence_RE2 of_RE2 adverse_RE2 effect_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 coadministration_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 interfere_RE2 with_RE2 the_RE2 efficacy_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 rrb._RE2 
Melatonin|P|melatonin|corticosteroid|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 following_BE12 drug_BE12 :_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 may_BE12 low_BE12 BIOGENERAL_BE12 level_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 bioavailability_BE12 of_BE12 oral_BE12 BIOGENERAL_BE12 be_BE12 increase_BE12 with_BE12 coadministration_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 may_BE12 decrease_BE12 BIOGENERAL_BE12 level_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 report_BE12 of_BE12 psychotic_BE12 episode_BE12 when_BE12 coadminister_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 coadministration_BE12 of_BE12 BIOGENERAL_BE12 with_BE12 BIOGENERAL_BE12 can_BE12 inhibit_BE12 ovarian_BE12 function_BE12 in_BE12 woman_BE12 -RRB-_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 sedating_BE12 drug_BE12 -LRB-_BE12 may_BE12 result_BE12 in_BE12 additive_BE12 sedation_BE12 and_BE12 increase_BE12 incidence_BE12 of_BE12 adverse_BE12 effect_BE12 -RRB-_BE12 and_BE12 BIOENTITY -LRB-_RE2 coadministration_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 interfere_RE2 with_RE2 the_RE2 efficacy_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 rrb._RE2 
Melatonin|P|melatonin|corticosteroid|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 following_BE12 drug_BE12 :_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 may_BE12 low_BE12 BIOGENERAL_BE12 level_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 bioavailability_BE12 of_BE12 oral_BE12 BIOGENERAL_BE12 be_BE12 increase_BE12 with_BE12 coadministration_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 may_BE12 decrease_BE12 BIOGENERAL_BE12 level_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 report_BE12 of_BE12 psychotic_BE12 episode_BE12 when_BE12 coadminister_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 coadministration_BE12 of_BE12 BIOGENERAL_BE12 with_BE12 BIOGENERAL_BE12 can_BE12 inhibit_BE12 ovarian_BE12 function_BE12 in_BE12 woman_BE12 -RRB-_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 sedating_BE12 drug_BE12 -LRB-_BE12 may_BE12 result_BE12 in_BE12 additive_BE12 sedation_BE12 and_BE12 increase_BE12 incidence_BE12 of_BE12 adverse_BE12 effect_BE12 -RRB-_BE12 and_BE12 BIOENTITY -LRB-_RE2 coadministration_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 interfere_RE2 with_RE2 the_RE2 efficacy_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 rrb._RE2 
Melatonin|P|melatonin|benzodiazepene|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 following_BE12 drug_BE12 :_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 may_BE12 low_BE12 BIOGENERAL_BE12 level_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 bioavailability_BE12 of_BE12 oral_BE12 BIOGENERAL_BE12 be_BE12 increase_BE12 with_BE12 coadministration_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 may_BE12 decrease_BE12 BIOGENERAL_BE12 level_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 report_BE12 of_BE12 psychotic_BE12 episode_BE12 when_BE12 coadminister_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 coadministration_BE12 of_BE12 BIOGENERAL_BE12 with_BE12 BIOGENERAL_BE12 can_BE12 inhibit_BE12 ovarian_BE12 function_BE12 in_BE12 woman_BE12 -RRB-_BE12 BIOENTITY and_RE2 other_RE2 sedating_RE2 drug_RE2 -LRB-_RE2 may_RE2 result_RE2 in_RE2 additive_RE2 sedation_RE2 and_RE2 increase_RE2 incidence_RE2 of_RE2 adverse_RE2 effect_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 coadministration_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 interfere_RE2 with_RE2 the_RE2 efficacy_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 rrb._RE2 
Melatonin|P|melatonin|corticosteroid|BIOGENERAL_LE1 may_LE1 interact_LE1 with_LE1 the_LE1 following_LE1 drug_LE1 :_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 BIOGENERAL_LE1 -LRB-_LE1 may_LE1 low_LE1 BIOGENERAL_LE1 level_LE1 -RRB-_LE1 BIOGENERAL_LE1 -LRB-_LE1 bioavailability_LE1 of_LE1 oral_LE1 BIOGENERAL_LE1 be_LE1 increase_LE1 with_LE1 coadministration_LE1 -RRB-_LE1 BIOGENERAL_LE1 -LRB-_LE1 may_LE1 decrease_LE1 BIOGENERAL_LE1 level_LE1 -RRB-_LE1 BIOGENERAL_LE1 -LRB-_LE1 report_LE1 of_LE1 psychotic_LE1 episode_LE1 when_LE1 coadminister_LE1 -RRB-_LE1 BIOGENERAL_LE1 -LRB-_LE1 coadministration_LE1 of_LE1 BIOGENERAL_LE1 with_LE1 BIOGENERAL_LE1 can_LE1 inhibit_LE1 ovarian_LE1 function_LE1 in_LE1 woman_LE1 -RRB-_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 sedating_LE1 drug_LE1 -LRB-_LE1 may_LE1 result_LE1 in_LE1 additive_LE1 sedation_LE1 and_LE1 increase_LE1 incidence_LE1 of_LE1 adverse_LE1 effect_LE1 -RRB-_LE1 and_LE1 BIOGENERAL_LE1 -LRB-_LE1 coadministration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 interfere_RE2 with_RE2 the_RE2 efficacy_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 rrb._RE2 
Melatonin|P|melatonin|progestin|BIOGENERAL_LE1 may_LE1 interact_LE1 with_LE1 the_LE1 following_LE1 drug_LE1 :_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 BIOGENERAL_LE1 -LRB-_LE1 may_LE1 low_LE1 BIOGENERAL_LE1 level_LE1 -RRB-_LE1 BIOGENERAL_LE1 -LRB-_LE1 bioavailability_LE1 of_LE1 oral_LE1 BIOGENERAL_LE1 be_LE1 increase_LE1 with_LE1 coadministration_LE1 -RRB-_LE1 BIOGENERAL_LE1 -LRB-_LE1 may_LE1 decrease_LE1 BIOGENERAL_LE1 level_LE1 -RRB-_LE1 BIOGENERAL_LE1 -LRB-_LE1 report_LE1 of_LE1 psychotic_LE1 episode_LE1 when_LE1 coadminister_LE1 -RRB-_LE1 BIOGENERAL_LE1 -LRB-_LE1 coadministration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY can_RE2 inhibit_RE2 ovarian_RE2 function_RE2 in_RE2 woman_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 sedating_RE2 drug_RE2 -LRB-_RE2 may_RE2 result_RE2 in_RE2 additive_RE2 sedation_RE2 and_RE2 increase_RE2 incidence_RE2 of_RE2 adverse_RE2 effect_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 coadministration_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 interfere_RE2 with_RE2 the_RE2 efficacy_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 rrb._RE2 
Meloxicam|P|nsaid|angiotensin-converting enzyme (ace) inhibitor|BIOGENERAL_LE1 report_LE1 suggest_LE1 that_LE1 BIOENTITY may_BE12 diminish_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 -LRB-_BE12 ace_BE12 -RRB-_BE12 BIOENTITY 
Meloxicam|P|nsaid|ace inhibitor|this_LE1 interaction_LE1 shall_LE1 be_LE1 give_LE1 consideration_LE1 in_LE1 patient_LE1 take_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOENTITY 
Meloxicam|P|aspirin|meloxicam|BIOGENERAL_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 tid_BE12 -RRB-_BE12 to_BE12 healthy_BE12 volunteer_BE12 tend_BE12 to_BE12 increase_BE12 the_BE12 auc_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 and_BE12 cmax_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 of_BE12 BIOENTITY 
Meloxicam|P|meloxicam|aspirin|however_LE1 as_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 not_RE2 general_RE2 recommend_RE2 because_RE2 of_RE2 the_RE2 potential_RE2 for_RE2 increase_RE2 adverse_RE2 effect_RE2 
Meloxicam|P|nsaid|aspirin|however_LE1 as_LE1 with_LE1 other_LE1 BIOENTITY concomitant_BE12 administration_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY be_RE2 not_RE2 general_RE2 recommend_RE2 because_RE2 of_RE2 the_RE2 potential_RE2 for_RE2 increase_RE2 adverse_RE2 effect_RE2 
Meloxicam|P|aspirin|mobic|concomitant_LE1 administration_LE1 of_LE1 lowdose_LE1 BIOENTITY with_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 increase_RE2 rate_RE2 of_RE2 gi_RE2 ulceration_RE2 or_RE2 other_RE2 complication_RE2 compared_RE2 to_RE2 use_RE2 of_RE2 BIOGENERAL_RE2 alone_RE2 
Meloxicam|P|cholestyramine|meloxicam|BIOGENERAL_LE1 :_LE1 pretreatment_LE1 for_LE1 four_LE1 day_LE1 with_LE1 BIOENTITY significant_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY by_RE2 NUM_RE2 %._RE2 
Meloxicam|P|nsaid|thiazide diuretic|BIOGENERAL_LE1 :_LE1 clinical_LE1 study_LE1 as_LE1 well_LE1 as_LE1 postmarketing_LE1 observation_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 natriuretic_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY in_RE2 some_RE2 patient_RE2 
Meloxicam|P|nsaid|furosemide|BIOGENERAL_LE1 :_LE1 clinical_LE1 study_LE1 as_LE1 well_LE1 as_LE1 postmarketing_LE1 observation_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 natriuretic_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 in_RE2 some_RE2 patient_RE2 
Meloxicam|P|furosemide|mobic|nevertheless_LE1 during_LE1 concomitant_LE1 therapy_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY patient_RE2 shall_RE2 be_RE2 observe_RE2 close_RE2 for_RE2 sign_RE2 of_RE2 decline_RE2 renal_RE2 function_RE2 as_RE2 well_RE2 as_RE2 to_RE2 assure_RE2 diuretic_RE2 efficacy_RE2 
Meloxicam|P|nsaid|lithium|BIOGENERAL_LE1 :_LE1 In_LE1 clinical_LE1 trial_LE1 BIOENTITY have_BE12 produce_BE12 elevation_BE12 of_BE12 plasma_BE12 BIOENTITY level_RE2 and_RE2 reduction_RE2 in_RE2 renal_RE2 BIOGENERAL_RE2 clearance_RE2 
Meloxicam|P|lithium|meloxicam|In_LE1 study_LE1 conduct_LE1 in_LE1 healthy_LE1 subject_LE1 mean_LE1 predose_LE1 BIOGENERAL_LE1 concentration_LE1 and_LE1 auc_LE1 be_LE1 increase_LE1 by_LE1 NUM_LE1 in_LE1 subject_LE1 receive_LE1 BIOENTITY dose_BE12 range_BE12 from_BE12 NUM_BE12 to_BE12 NUM_BE12 mg_BE12 bid_BE12 with_BE12 BIOENTITY NUM_RE2 mg_RE2 qd_RE2 as_RE2 compare_RE2 to_RE2 subject_RE2 receive_RE2 BIOGENERAL_RE2 alone_RE2 
Meloxicam|P|lithium|mobic|patient_LE1 on_LE1 BIOENTITY treatment_BE12 shall_BE12 be_BE12 close_BE12 monitor_BE12 when_BE12 BIOENTITY be_RE2 introduce_RE2 or_RE2 withdraw_RE2 
Meloxicam|P|lithium|mobic|patient_LE1 on_LE1 BIOENTITY treatment_BE12 shall_BE12 be_BE12 close_BE12 monitor_BE12 when_BE12 BIOENTITY be_RE2 introduce_RE2 or_RE2 withdraw_RE2 
Meloxicam|P|mobic|warfarin|BIOGENERAL_LE1 :_LE1 anticoagulant_LE1 activity_LE1 shall_LE1 be_LE1 monitor_LE1 particular_LE1 in_LE1 the_LE1 first_LE1 few_LE1 day_LE1 after_LE1 initiate_LE1 or_LE1 change_LE1 BIOENTITY therapy_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY or_RE2 similar_RE2 agent_RE2 since_RE2 these_RE2 patient_RE2 be_RE2 at_RE2 increase_RE2 risk_RE2 of_RE2 bleeding_RE2 
Meloxicam|P|mobic|warfarin|caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 administer_LE1 BIOENTITY with_BE12 BIOENTITY since_RE2 patient_RE2 on_RE2 BIOGENERAL_RE2 may_RE2 experience_RE2 change_RE2 in_RE2 inr_RE2 and_RE2 increase_RE2 risk_RE2 of_RE2 bleeding_RE2 complication_RE2 when_RE2 new_RE2 medication_RE2 be_RE2 introduce_RE2 
Melphalan|P|nalidixic acid|melphalan|drug_LE1 interaction_LE1 there_LE1 be_LE1 no_LE1 known_LE1 drug_LE1 interaction_LE1 with_LE1 oral_LE1 BIOGENERAL_LE1 vaccinations_LE1 with_LE1 BIOGENERAL_LE1 be_LE1 not_LE1 recommend_LE1 in_LE1 immunocompromised_LE1 individual_LE1 BIOENTITY together_BE12 with_BE12 highdose_BE12 intravenous_BE12 BIOENTITY have_RE2 cause_RE2 death_RE2 in_RE2 child_RE2 due_RE2 to_RE2 haemorrhagic_RE2 enterocolitis_RE2 
Melphalan|P|melphalan|cyclosporin|impaired_LE1 renal_LE1 function_LE1 have_LE1 be_LE1 describe_LE1 in_LE1 bone_LE1 marrow_LE1 transplant_LE1 patient_LE1 who_LE1 be_LE1 condition_LE1 with_LE1 highdose_LE1 intravenous_LE1 BIOENTITY and_BE12 who_BE12 subsequent_BE12 receive_BE12 BIOENTITY to_RE2 prevent_RE2 graftversushost_RE2 disease_RE2 
Mepenzolate|P|anticholinergic drug|tricyclic antidepressant|the_LE1 follow_LE1 may_LE1 increase_LE1 certain_LE1 action_LE1 or_LE1 side_LE1 effect_LE1 BIOENTITY :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 other_RE2 drug_RE2 have_RE2 anticholinergic_RE2 activity_RE2 
Mepenzolate|P|anticholinergic drug|sympathomimetic agent|the_LE1 follow_LE1 may_LE1 increase_LE1 certain_LE1 action_LE1 or_LE1 side_LE1 effect_LE1 BIOENTITY :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 other_RE2 drug_RE2 have_RE2 anticholinergic_RE2 activity_RE2 
Mepenzolate|P|anticholinergic drug|nitrite|the_LE1 follow_LE1 may_LE1 increase_LE1 certain_LE1 action_LE1 or_LE1 side_LE1 effect_LE1 BIOENTITY :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 drug_RE2 have_RE2 anticholinergic_RE2 activity_RE2 
Mepenzolate|P|anticholinergic drug|nitrate|the_LE1 follow_LE1 may_LE1 increase_LE1 certain_LE1 action_LE1 or_LE1 side_LE1 effect_LE1 BIOENTITY :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 drug_RE2 have_RE2 anticholinergic_RE2 activity_RE2 
Mepenzolate|P|anticholinergic drug|quinidine|the_LE1 follow_LE1 may_LE1 increase_LE1 certain_LE1 action_LE1 or_LE1 side_LE1 effect_LE1 BIOENTITY :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 drug_RE2 have_RE2 anticholinergic_RE2 activity_RE2 
Mepenzolate|P|anticholinergic drug|antiarrhythmic agents of class i|the_LE1 follow_LE1 may_LE1 increase_LE1 certain_LE1 action_LE1 or_LE1 side_LE1 effect_LE1 BIOENTITY :_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 drug_RE2 have_RE2 anticholinergic_RE2 activity_RE2 
Mepenzolate|P|anticholinergic drug|antipsychotic agent|the_LE1 follow_LE1 may_LE1 increase_LE1 certain_LE1 action_LE1 or_LE1 side_LE1 effect_LE1 BIOENTITY :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 drug_RE2 have_RE2 anticholinergic_RE2 activity_RE2 
Mepenzolate|P|anticholinergic drug|antihistamine|the_LE1 follow_LE1 may_LE1 increase_LE1 certain_LE1 action_LE1 or_LE1 side_LE1 effect_LE1 BIOENTITY :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 drug_RE2 have_RE2 anticholinergic_RE2 activity_RE2 
Mepenzolate|P|anticholinergic drug|benzodiazepine|the_LE1 follow_LE1 may_LE1 increase_LE1 certain_LE1 action_LE1 or_LE1 side_LE1 effect_LE1 BIOENTITY :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 drug_RE2 have_RE2 anticholinergic_RE2 activity_RE2 
Mepenzolate|P|anticholinergic drug|phenothiazine|the_LE1 follow_LE1 may_LE1 increase_LE1 certain_LE1 action_LE1 or_LE1 side_LE1 effect_LE1 BIOENTITY :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 drug_RE2 have_RE2 anticholinergic_RE2 activity_RE2 
Mepenzolate|P|anticholinergic drug|narcotic analgesic|the_LE1 follow_LE1 may_LE1 increase_LE1 certain_LE1 action_LE1 or_LE1 side_LE1 effect_LE1 BIOENTITY :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 drug_RE2 have_RE2 anticholinergic_RE2 activity_RE2 
Mepenzolate|P|anticholinergic drug|mao inhibitor|the_LE1 follow_LE1 may_LE1 increase_LE1 certain_LE1 action_LE1 or_LE1 side_LE1 effect_LE1 BIOENTITY :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 drug_RE2 have_RE2 anticholinergic_RE2 activity_RE2 
Mepenzolate|P|anticholinergic drug|meperidine|the_LE1 follow_LE1 may_LE1 increase_LE1 certain_LE1 action_LE1 or_LE1 side_LE1 effect_LE1 BIOENTITY :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 drug_RE2 have_RE2 anticholinergic_RE2 activity_RE2 
Mepenzolate|P|anticholinergic drug|amantadine|the_LE1 follow_LE1 may_LE1 increase_LE1 certain_LE1 action_LE1 or_LE1 side_LE1 effect_LE1 BIOENTITY :_BE12 BIOENTITY BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 drug_RE2 have_RE2 anticholinergic_RE2 activity_RE2 
Mepenzolate|P|anticholinergic|antiglaucoma agent|BIOENTITY antagonize_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY 
Mepenzolate|P|anticholinergic drug|corticosteroid|BIOENTITY in_BE12 the_BE12 presence_BE12 of_BE12 increase_BE12 intraocular_BE12 pressure_BE12 may_BE12 be_BE12 hazardous_BE12 when_BE12 take_BE12 concurrent_BE12 with_BE12 agent_BE12 such_BE12 as_BE12 BIOENTITY 
Mepenzolate|P|anticholinergic agent|digoxin|BIOENTITY may_BE12 affect_BE12 gastrointestinal_BE12 absorption_BE12 of_BE12 various_BE12 drug_BE12 such_BE12 as_BE12 slow_BE12 dissolve_BE12 dosage_BE12 form_BE12 of_BE12 BIOENTITY 
Mepenzolate|P|anticholinergic drug|metoclopramide|BIOENTITY may_BE12 antagonize_BE12 the_BE12 effect_BE12 of_BE12 drug_BE12 that_BE12 alter_BE12 gastrointestinal_BE12 motility_BE12 such_BE12 as_BE12 BIOENTITY 
Mepenzolate|P|antacid|anticholinergic agent|because_LE1 BIOENTITY may_BE12 interfere_BE12 with_BE12 the_BE12 absorption_BE12 of_BE12 BIOENTITY simultaneous_RE2 use_RE2 of_RE2 these_RE2 drug_RE2 shall_RE2 be_RE2 avoid_RE2 
Meperidine|P|meperidine|narcotic analgesic|interaction_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY shall_BE12 be_BE12 use_BE12 WITH_BE12 great_BE12 caution_BE12 AND_BE12 in_BE12 reduce_BE12 dosage_BE12 IN_BE12 patient_BE12 WHO_BE12 be_BE12 concurrent_BE12 receive_BE12 other_BE12 BIOENTITY general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 include_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 AND_RE2 other_RE2 BIOGENERAL_RE2 -LRB-_RE2 include_RE2 BIOGENERAL_RE2 rrb._RE2 
Meperidine|P|meperidine|narcotic analgesic|interaction_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY shall_BE12 be_BE12 use_BE12 WITH_BE12 great_BE12 caution_BE12 AND_BE12 in_BE12 reduce_BE12 dosage_BE12 IN_BE12 patient_BE12 WHO_BE12 be_BE12 concurrent_BE12 receive_BE12 other_BE12 BIOENTITY general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 include_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 AND_RE2 other_RE2 BIOGENERAL_RE2 -LRB-_RE2 include_RE2 BIOGENERAL_RE2 rrb._RE2 
Meperidine|P|meperidine|anesthetic|interaction_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY shall_BE12 be_BE12 use_BE12 WITH_BE12 great_BE12 caution_BE12 AND_BE12 in_BE12 reduce_BE12 dosage_BE12 IN_BE12 patient_BE12 WHO_BE12 be_BE12 concurrent_BE12 receive_BE12 other_BE12 BIOGENERAL_BE12 general_BE12 BIOENTITY BIOGENERAL_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 include_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 AND_RE2 other_RE2 BIOGENERAL_RE2 -LRB-_RE2 include_RE2 BIOGENERAL_RE2 rrb._RE2 
Meperidine|P|meperidine|phenothiazine|interaction_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY shall_BE12 be_BE12 use_BE12 WITH_BE12 great_BE12 caution_BE12 AND_BE12 in_BE12 reduce_BE12 dosage_BE12 IN_BE12 patient_BE12 WHO_BE12 be_BE12 concurrent_BE12 receive_BE12 other_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOENTITY other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 include_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 AND_RE2 other_RE2 BIOGENERAL_RE2 -LRB-_RE2 include_RE2 BIOGENERAL_RE2 rrb._RE2 
Meperidine|P|meperidine|tranquilizer|interaction_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY shall_BE12 be_BE12 use_BE12 WITH_BE12 great_BE12 caution_BE12 AND_BE12 in_BE12 reduce_BE12 dosage_BE12 IN_BE12 patient_BE12 WHO_BE12 be_BE12 concurrent_BE12 receive_BE12 other_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 other_BE12 BIOENTITY BIOGENERAL_RE2 -LRB-_RE2 include_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 AND_RE2 other_RE2 BIOGENERAL_RE2 -LRB-_RE2 include_RE2 BIOGENERAL_RE2 rrb._RE2 
Meperidine|P|meperidine|sedative-hypnotic|interaction_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY shall_BE12 be_BE12 use_BE12 WITH_BE12 great_BE12 caution_BE12 AND_BE12 in_BE12 reduce_BE12 dosage_BE12 IN_BE12 patient_BE12 WHO_BE12 be_BE12 concurrent_BE12 receive_BE12 other_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 other_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 include_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 AND_RE2 other_RE2 BIOGENERAL_RE2 -LRB-_RE2 include_RE2 BIOGENERAL_RE2 rrb._RE2 
Meperidine|P|meperidine|barbiturate|interaction_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY shall_BE12 be_BE12 use_BE12 WITH_BE12 great_BE12 caution_BE12 AND_BE12 in_BE12 reduce_BE12 dosage_BE12 IN_BE12 patient_BE12 WHO_BE12 be_BE12 concurrent_BE12 receive_BE12 other_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 include_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 AND_RE2 other_RE2 BIOGENERAL_RE2 -LRB-_RE2 include_RE2 BIOGENERAL_RE2 rrb._RE2 
Meperidine|P|meperidine|tricyclic antidepressant|interaction_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY shall_BE12 be_BE12 use_BE12 WITH_BE12 great_BE12 caution_BE12 AND_BE12 in_BE12 reduce_BE12 dosage_BE12 IN_BE12 patient_BE12 WHO_BE12 be_BE12 concurrent_BE12 receive_BE12 other_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 include_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY AND_RE2 other_RE2 BIOGENERAL_RE2 -LRB-_RE2 include_RE2 BIOGENERAL_RE2 rrb._RE2 
Meperidine|P|meperidine|cns depressant|interaction_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY shall_BE12 be_BE12 use_BE12 WITH_BE12 great_BE12 caution_BE12 AND_BE12 in_BE12 reduce_BE12 dosage_BE12 IN_BE12 patient_BE12 WHO_BE12 be_BE12 concurrent_BE12 receive_BE12 other_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 include_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 AND_BE12 other_BE12 BIOENTITY -LRB-_RE2 include_RE2 BIOGENERAL_RE2 rrb._RE2 
Meperidine|P|meperidine|alcohol|interaction_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY shall_BE12 be_BE12 use_BE12 WITH_BE12 great_BE12 caution_BE12 AND_BE12 in_BE12 reduce_BE12 dosage_BE12 IN_BE12 patient_BE12 WHO_BE12 be_BE12 concurrent_BE12 receive_BE12 other_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 include_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 AND_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 include_BE12 BIOENTITY rrb._RE2 
Mephenytoin|P|anticonvulsant|mephenytoin|some_LE1 BIOENTITY may_BE12 interact_BE12 with_BE12 BIOENTITY 
Mephenytoin|P|mephenytoin|steroid medication|BIOENTITY may_BE12 also_BE12 affect_BE12 the_BE12 effect_BE12 of_BE12 other_BE12 drug_BE12 which_BE12 include_BE12 some_BE12 BIOENTITY BIOGENERAL_RE2 certain_RE2 heart_RE2 medicine_RE2 birth_RE2 control_RE2 pill_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 please_RE2 note_RE2 that_RE2 BIOGENERAL_RE2 may_RE2 interact_RE2 with_RE2 other_RE2 drug_RE2 that_RE2 be_RE2 not_RE2 list_RE2 here_RE2 
Mephenytoin|P|mephenytoin|steroid medication|BIOENTITY may_BE12 also_BE12 affect_BE12 the_BE12 effect_BE12 of_BE12 other_BE12 drug_BE12 which_BE12 include_BE12 some_BE12 BIOENTITY BIOGENERAL_RE2 certain_RE2 heart_RE2 medicine_RE2 birth_RE2 control_RE2 pill_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 please_RE2 note_RE2 that_RE2 BIOGENERAL_RE2 may_RE2 interact_RE2 with_RE2 other_RE2 drug_RE2 that_RE2 be_RE2 not_RE2 list_RE2 here_RE2 
Mephenytoin|P|mephenytoin|furosemide|BIOENTITY may_BE12 also_BE12 affect_BE12 the_BE12 effect_BE12 of_BE12 other_BE12 drug_BE12 which_BE12 include_BE12 some_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 certain_BE12 heart_BE12 medicine_BE12 birth_BE12 control_BE12 pill_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 please_RE2 note_RE2 that_RE2 BIOGENERAL_RE2 may_RE2 interact_RE2 with_RE2 other_RE2 drug_RE2 that_RE2 be_RE2 not_RE2 list_RE2 here_RE2 
Mephenytoin|P|mephenytoin|theophylline|BIOENTITY may_BE12 also_BE12 affect_BE12 the_BE12 effect_BE12 of_BE12 other_BE12 drug_BE12 which_BE12 include_BE12 some_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 certain_BE12 heart_BE12 medicine_BE12 birth_BE12 control_BE12 pill_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY please_RE2 note_RE2 that_RE2 BIOGENERAL_RE2 may_RE2 interact_RE2 with_RE2 other_RE2 drug_RE2 that_RE2 be_RE2 not_RE2 list_RE2 here_RE2 
Mephenytoin|P|mephenytoin|warfarin|BIOENTITY may_BE12 also_BE12 affect_BE12 the_BE12 effect_BE12 of_BE12 other_BE12 drug_BE12 which_BE12 include_BE12 some_BE12 BIOGENERAL_BE12 BIOENTITY certain_RE2 heart_RE2 medicine_RE2 birth_RE2 control_RE2 pill_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 please_RE2 note_RE2 that_RE2 BIOGENERAL_RE2 may_RE2 interact_RE2 with_RE2 other_RE2 drug_RE2 that_RE2 be_RE2 not_RE2 list_RE2 here_RE2 
Mephenytoin|P|mephenytoin|warfarin|BIOENTITY may_BE12 also_BE12 affect_BE12 the_BE12 effect_BE12 of_BE12 other_BE12 drug_BE12 which_BE12 include_BE12 some_BE12 BIOGENERAL_BE12 BIOENTITY certain_RE2 heart_RE2 medicine_RE2 birth_RE2 control_RE2 pill_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 please_RE2 note_RE2 that_RE2 BIOGENERAL_RE2 may_RE2 interact_RE2 with_RE2 other_RE2 drug_RE2 that_RE2 be_RE2 not_RE2 list_RE2 here_RE2 
Mephenytoin|P|mephenytoin|anti-infective medicine|BIOENTITY may_BE12 also_BE12 affect_BE12 the_BE12 effect_BE12 of_BE12 other_BE12 drug_BE12 which_BE12 include_BE12 some_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 certain_BE12 heart_BE12 medicine_BE12 birth_BE12 control_BE12 pill_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 please_RE2 note_RE2 that_RE2 BIOGENERAL_RE2 may_RE2 interact_RE2 with_RE2 other_RE2 drug_RE2 that_RE2 be_RE2 not_RE2 list_RE2 here_RE2 
Mephenytoin|P|mephenytoin|anti-infective medicine|BIOENTITY may_BE12 also_BE12 affect_BE12 the_BE12 effect_BE12 of_BE12 other_BE12 drug_BE12 which_BE12 include_BE12 some_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 certain_BE12 heart_BE12 medicine_BE12 birth_BE12 control_BE12 pill_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 please_RE2 note_RE2 that_RE2 BIOGENERAL_RE2 may_RE2 interact_RE2 with_RE2 other_RE2 drug_RE2 that_RE2 be_RE2 not_RE2 list_RE2 here_RE2 
Mequitazine|P|mequitazine|cns depressant|BIOENTITY can_BE12 interact_BE12 with_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mequitazine|P|mequitazine|maoi|BIOENTITY can_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Mequitazine|P|mequitazine|alcohol|BIOENTITY can_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Mequitazine|P|mequitazine|antichlolinergic|BIOENTITY can_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mequitazine|P|mequitazine|tca|BIOENTITY can_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Meropenem|P|probenecid|meropenem|BIOENTITY compete_BE12 with_BE12 BIOENTITY for_RE2 active_RE2 tubular_RE2 secretion_RE2 and_RE2 thus_RE2 inhibit_RE2 the_RE2 renal_RE2 excretion_RE2 of_RE2 BIOGENERAL_RE2 
Meropenem|P|probenecid|meropenem|therefore_LE1 the_LE1 coadministration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 
Meropenem|P|meropenem|valproic acid|there_LE1 be_LE1 evidence_LE1 that_LE1 BIOENTITY may_BE12 reduce_BE12 serum_BE12 level_BE12 of_BE12 BIOENTITY to_RE2 subtherapeutic_RE2 level_RE2 -LRB-_RE2 therapeutic_RE2 range_RE2 consider_RE2 to_RE2 be_RE2 NUM_RE2 to_RE2 NUM_RE2 total_RE2 BIOGENERAL_RE2 rrb._RE2 
Metaraminol|P|digitali|sympathomimetic amine|BIOGENERAL_LE1 shall_LE1 be_LE1 use_LE1 with_LE1 caution_LE1 in_LE1 digitalized_LE1 patient_LE1 since_LE1 the_LE1 combination_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 cause_RE2 ectopic_RE2 arrhythmia_RE2 
Metaraminol|P|monoamine oxidase inhibitor|sympathomimetic amine|BIOENTITY or_BE12 BIOGENERAL_BE12 may_BE12 potentiate_BE12 the_BE12 action_BE12 of_BE12 BIOENTITY 
Metaraminol|P|tricyclic antidepressant|sympathomimetic amine|BIOGENERAL_LE1 or_LE1 BIOENTITY may_BE12 potentiate_BE12 the_BE12 action_BE12 of_BE12 BIOENTITY 
Metaxalone|P|skelaxin|alcohol|BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 other_RE2 BIOGENERAL_RE2 
Metaxalone|P|skelaxin|barbiturate|BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 other_RE2 BIOGENERAL_RE2 
Metaxalone|P|skelaxin|cns depressant|BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOENTITY 
Methazolamide|P|aspirin|methazolamide|caution_LE1 be_LE1 advise_LE1 for_LE1 patient_LE1 receive_LE1 highdose_LE1 BIOENTITY and_BE12 BIOENTITY concomitant_RE2 as_RE2 anorexia_RE2 tachypnea_RE2 lethargy_RE2 coma_RE2 and_RE2 death_RE2 have_RE2 be_RE2 report_RE2 with_RE2 concomitant_RE2 use_RE2 of_RE2 highdose_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Methazolamide|P|aspirin|carbonic anhydrase inhibitor|caution_LE1 be_LE1 advise_LE1 for_LE1 patient_LE1 receive_LE1 highdose_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 concomitant_LE1 as_LE1 anorexia_LE1 tachypnea_LE1 lethargy_LE1 coma_LE1 and_LE1 death_LE1 have_LE1 be_LE1 report_LE1 with_LE1 concomitant_LE1 use_LE1 of_LE1 highdose_LE1 BIOENTITY and_BE12 BIOENTITY 
Methimazole|P|anticoagulant|methimazole|BIOGENERAL_LE1 -LRB-_LE1 oral_LE1 -RRB-_LE1 :_LE1 the_LE1 activity_LE1 of_LE1 oral_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 antivitamink_BE12 activity_BE12 attribute_BE12 to_BE12 BIOENTITY 
Methotrimeprazine|P|levomepromazine|opioid|dosage_LE1 of_LE1 concomitant_LE1 administer_LE1 BIOGENERAL_LE1 shall_LE1 be_LE1 reduce_LE1 by_LE1 approximate_LE1 half_LE1 because_LE1 BIOENTITY amplify_BE12 the_BE12 therapeutic_BE12 action_BE12 and_BE12 sideeffect_BE12 of_BE12 BIOENTITY 
Methotrimeprazine|P|opioid|levomepromazine|dosage_LE1 of_LE1 concomitant_LE1 administer_LE1 BIOENTITY shall_BE12 be_BE12 reduce_BE12 by_BE12 approximate_BE12 half_BE12 because_BE12 BIOENTITY amplify_RE2 the_RE2 therapeutic_RE2 action_RE2 and_RE2 sideeffect_RE2 of_RE2 BIOGENERAL_RE2 
Methotrimeprazine|P|levomepromazine|benzodiazepine|additive_LE1 sedative_LE1 effect_LE1 and_LE1 confusional_LE1 state_LE1 may_LE1 emerge_LE1 if_LE1 BIOENTITY be_BE12 give_BE12 with_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Methotrimeprazine|P|levomepromazine|barbiturate|additive_LE1 sedative_LE1 effect_LE1 and_LE1 confusional_LE1 state_LE1 may_LE1 emerge_LE1 if_LE1 BIOENTITY be_BE12 give_BE12 with_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Methotrimeprazine|P|levomepromazine|antiparkinsonian-agent|exert_LE1 particular_LE1 caution_LE1 in_LE1 combine_LE1 BIOENTITY with_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -RRB-_RE2 :_RE2 particular_RE2 the_RE2 elderly_RE2 may_RE2 develop_RE2 delirium_RE2 high_RE2 fever_RE2 severe_RE2 obstipation_RE2 even_RE2 ileus_RE2 and_RE2 glaucoma_RE2 
Methotrimeprazine|P|levomepromazine|tricyclic antidepressant|exert_LE1 particular_LE1 caution_LE1 in_LE1 combine_LE1 BIOENTITY with_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -RRB-_RE2 :_RE2 particular_RE2 the_RE2 elderly_RE2 may_RE2 develop_RE2 delirium_RE2 high_RE2 fever_RE2 severe_RE2 obstipation_RE2 even_RE2 ileus_RE2 and_RE2 glaucoma_RE2 
Methotrimeprazine|P|levomepromazine|anticholinergic drug|exert_LE1 particular_LE1 caution_LE1 in_LE1 combine_LE1 BIOENTITY with_BE12 other_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 :_RE2 particular_RE2 the_RE2 elderly_RE2 may_RE2 develop_RE2 delirium_RE2 high_RE2 fever_RE2 severe_RE2 obstipation_RE2 even_RE2 ileus_RE2 and_RE2 glaucoma_RE2 
Methotrimeprazine|P|amphetamine|levomepromazine|BIOGENERAL_LE1 and_LE1 stimulantes_LE1 of_LE1 the_LE1 BIOENTITY type_BE12 may_BE12 counteract_BE12 the_BE12 specific_BE12 action_BE12 of_BE12 BIOENTITY 
Methotrimeprazine|P|amphetamine|levomepromazine|BIOGENERAL_LE1 and_LE1 stimulantes_LE1 of_LE1 the_LE1 BIOENTITY type_BE12 may_BE12 counteract_BE12 the_BE12 specific_BE12 action_BE12 of_BE12 BIOENTITY 
Methotrimeprazine|P|caffeine|levomepromazine|BIOENTITY and_BE12 stimulantes_BE12 of_BE12 the_BE12 BIOGENERAL_BE12 type_BE12 may_BE12 counteract_BE12 the_BE12 specific_BE12 action_BE12 of_BE12 BIOENTITY 
Methsuximide|P|celontin|antiepileptic drug|since_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 interact_BE12 with_BE12 concurrent_BE12 administer_BE12 BIOENTITY periodic_RE2 serum_RE2 level_RE2 determination_RE2 of_RE2 these_RE2 drug_RE2 may_RE2 be_RE2 necessary_RE2 -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 may_RE2 increase_RE2 the_RE2 plasma_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 rrb._RE2 
Methsuximide|P|methsuximide|antiepileptic drug|since_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 may_BE12 interact_BE12 with_BE12 concurrent_BE12 administer_BE12 BIOENTITY periodic_RE2 serum_RE2 level_RE2 determination_RE2 of_RE2 these_RE2 drug_RE2 may_RE2 be_RE2 necessary_RE2 -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 may_RE2 increase_RE2 the_RE2 plasma_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 rrb._RE2 
Methsuximide|P|methsuximide|phenytoin|since_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 may_LE1 interact_LE1 with_LE1 concurrent_LE1 administer_LE1 BIOGENERAL_LE1 periodic_LE1 serum_LE1 level_LE1 determination_LE1 of_LE1 these_LE1 drug_LE1 may_LE1 be_LE1 necessary_LE1 -LRB-_LE1 eg_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 rrb._RE2 
Methsuximide|P|methsuximide|phenobarbital|since_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 may_LE1 interact_LE1 with_LE1 concurrent_LE1 administer_LE1 BIOGENERAL_LE1 periodic_LE1 serum_LE1 level_LE1 determination_LE1 of_LE1 these_LE1 drug_LE1 may_LE1 be_LE1 necessary_LE1 -LRB-_LE1 eg_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY rrb._RE2 
Methyclothiazide|P|thiazide|norepinephrine|BIOENTITY may_BE12 decrease_BE12 arterial_BE12 responsiveness_BE12 to_BE12 BIOENTITY 
Methyclothiazide|P|thiazide drug|tubocurarine|BIOENTITY may_BE12 increase_BE12 the_BE12 responsiveness_BE12 of_BE12 BIOENTITY 
Methyclothiazide|P|lithium|thiazide|BIOENTITY renal_BE12 clearance_BE12 be_BE12 reduce_BE12 by_BE12 BIOENTITY increase_RE2 the_RE2 risk_RE2 of_RE2 BIOGENERAL_RE2 toxicity_RE2 
Methyclothiazide|P|thiazide|antihypertensive drug|BIOENTITY may_BE12 add_BE12 to_BE12 or_BE12 potentiate_BE12 the_BE12 action_BE12 of_BE12 other_BE12 BIOENTITY 
Methyldopa|P|methyldopa|antihypertensive drug|when_LE1 BIOENTITY be_BE12 use_BE12 with_BE12 other_BE12 BIOENTITY potentiation_RE2 of_RE2 antihypertensive_RE2 effect_RE2 may_RE2 occur_RE2 
Methyldopa|P|anesthetic|methyldopa|patient_LE1 may_LE1 require_LE1 reduce_LE1 dose_LE1 of_LE1 BIOENTITY when_BE12 on_BE12 BIOENTITY 
Methyldopa|P|methyldopa|lithium|when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 give_RE2 concomitant_RE2 the_RE2 patient_RE2 shall_RE2 be_RE2 careful_RE2 monitor_RE2 for_RE2 symptom_RE2 of_RE2 BIOGENERAL_RE2 toxicity_RE2 
Methyldopa|P|methyldopa|ferrous sulfate|several_LE1 study_LE1 demonstrate_LE1 decrease_LE1 in_LE1 the_LE1 bioavailability_LE1 of_LE1 BIOENTITY when_BE12 it_BE12 be_BE12 ingest_BE12 with_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Methyldopa|P|methyldopa|ferrous gluconate|several_LE1 study_LE1 demonstrate_LE1 decrease_LE1 in_LE1 the_LE1 bioavailability_LE1 of_LE1 BIOENTITY when_BE12 it_BE12 be_BE12 ingest_BE12 with_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Methyldopa|P|methyldopa|ferrous gluconate|coadministration_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 
Methyldopa|P|methyldopa|ferrous sulfate|coadministration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 be_RE2 not_RE2 recommend_RE2 
Methylergonovine|P|methylergonovine maleate|vasoconstrictor|caution_LE1 shall_LE1 be_LE1 exercise_LE1 when_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 be_BE12 use_BE12 concurrent_BE12 with_BE12 other_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Methylergonovine|P|methergine|ergot alkaloid|caution_LE1 shall_LE1 be_LE1 exercise_LE1 when_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 be_BE12 use_BE12 concurrent_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Methylergonovine|P|methergine|vasoconstrictor|caution_LE1 shall_LE1 be_LE1 exercise_LE1 when_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 be_BE12 use_BE12 concurrent_BE12 with_BE12 other_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Methylphenidate|P|ritalin|guanethidine|BIOENTITY may_BE12 decrease_BE12 the_BE12 hypotensive_BE12 effect_BE12 of_BE12 BIOENTITY 
Methylphenidate|P|ritalin|imipramine|human_LE1 pharmacologic_LE1 study_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY may_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylphenidate|P|ritalin|tricyclic drug|human_LE1 pharmacologic_LE1 study_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY may_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylphenidate|P|ritalin|desipramine|human_LE1 pharmacologic_LE1 study_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY may_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY rrb._RE2 
Methylphenidate|P|ritalin|clomipramine|human_LE1 pharmacologic_LE1 study_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY may_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 rrb._RE2 
Methylphenidate|P|ritalin|diphenylhydantoin|human_LE1 pharmacologic_LE1 study_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY may_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylphenidate|P|ritalin|phenobarbital|human_LE1 pharmacologic_LE1 study_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY may_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylphenidate|P|ritalin|phenylbutazone|human_LE1 pharmacologic_LE1 study_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY may_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylphenidate|P|ritalin|primidone|human_LE1 pharmacologic_LE1 study_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY may_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylphenidate|P|ritalin|anticonvulsant|human_LE1 pharmacologic_LE1 study_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY may_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylphenidate|P|ritalin|coumarin anticoagulant|human_LE1 pharmacologic_LE1 study_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY may_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylprednisolone|P|cyclosporin|methylprednisolone|mutual_LE1 inhibition_LE1 of_LE1 metabolism_LE1 occur_LE1 with_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY 
Methylprednisolone|P|methylprednisolone|cyclosporin|convulsion_LE1 have_LE1 be_LE1 report_LE1 with_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY 
Methylprednisolone|P|phenytoin|methylprednisolone|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 may_BE12 require_BE12 increase_BE12 in_BE12 BIOENTITY dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Methylprednisolone|P|phenytoin|methylprednisolone|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 may_BE12 require_BE12 increase_BE12 in_BE12 BIOENTITY dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Methylprednisolone|P|phenytoin|methylprednisolone|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 may_BE12 require_BE12 increase_BE12 in_BE12 BIOENTITY dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Methylprednisolone|P|phenytoin|methylprednisolone|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 may_BE12 require_BE12 increase_BE12 in_BE12 BIOENTITY dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Methylprednisolone|P|phenytoin|methylprednisolone|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY and_RE2 may_RE2 require_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Methylprednisolone|P|phenytoin|methylprednisolone|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY and_RE2 may_RE2 require_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Methylprednisolone|P|rifampin|methylprednisolone|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 may_BE12 require_BE12 increase_BE12 in_BE12 BIOENTITY dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Methylprednisolone|P|rifampin|methylprednisolone|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 may_BE12 require_BE12 increase_BE12 in_BE12 BIOENTITY dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Methylprednisolone|P|rifampin|methylprednisolone|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 may_BE12 require_BE12 increase_BE12 in_BE12 BIOENTITY dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Methylprednisolone|P|rifampin|methylprednisolone|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 may_BE12 require_BE12 increase_BE12 in_BE12 BIOENTITY dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Methylprednisolone|P|rifampin|methylprednisolone|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY and_RE2 may_RE2 require_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Methylprednisolone|P|rifampin|methylprednisolone|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY and_RE2 may_RE2 require_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Methylprednisolone|P|phenobarbital|methylprednisolone|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY and_RE2 may_RE2 require_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Methylprednisolone|P|phenobarbital|methylprednisolone|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY and_RE2 may_RE2 require_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Methylprednisolone|P|phenobarbital|methylprednisolone|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 may_BE12 require_BE12 increase_BE12 in_BE12 BIOENTITY dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Methylprednisolone|P|phenobarbital|methylprednisolone|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 may_BE12 require_BE12 increase_BE12 in_BE12 BIOENTITY dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Methylprednisolone|P|phenobarbital|methylprednisolone|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 may_BE12 require_BE12 increase_BE12 in_BE12 BIOENTITY dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Methylprednisolone|P|phenobarbital|methylprednisolone|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 may_BE12 require_BE12 increase_BE12 in_BE12 BIOENTITY dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Methylprednisolone|P|ketoconazole|methylprednisolone|drug_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY and_RE2 thus_RE2 decrease_RE2 its_RE2 clearance_RE2 
Methylprednisolone|P|troleandomycin|methylprednisolone|drug_LE1 such_LE1 as_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY and_RE2 thus_RE2 decrease_RE2 its_RE2 clearance_RE2 
Methylprednisolone|P|methylprednisolone|aspirin|BIOENTITY may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 chronic_BE12 high_BE12 dose_BE12 BIOENTITY 
Methylprednisolone|P|salicylate|methylprednisolone|this_LE1 can_LE1 lead_LE1 to_LE1 decrease_LE1 BIOGENERAL_LE1 serum_LE1 level_LE1 or_LE1 increase_LE1 the_LE1 risk_LE1 of_LE1 BIOENTITY toxicity_BE12 when_BE12 BIOENTITY be_RE2 withdraw_RE2 
Methylprednisolone|P|aspirin|corticosteroid|BIOENTITY shall_BE12 be_BE12 use_BE12 cautious_BE12 in_BE12 conjunction_BE12 with_BE12 BIOENTITY in_RE2 patient_RE2 suffer_RE2 from_RE2 hypoprothrombinemia_RE2 
Methylprednisolone|P|anticoagulant|corticosteroid|there_LE1 be_LE1 report_LE1 of_LE1 enhance_LE1 as_LE1 well_LE1 as_LE1 diminish_LE1 effect_LE1 of_LE1 BIOENTITY when_BE12 give_BE12 concurrent_BE12 with_BE12 BIOENTITY 
Methylscopolamine|P|methscopolamine|chlorpromazine|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 type_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 supplement_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 rrb._RE2 
Methylscopolamine|P|methscopolamine|promethazine|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 type_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 supplement_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY rrb._RE2 
Methylscopolamine|P|methscopolamine|isocarboxazid|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 type_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 supplement_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylscopolamine|P|methscopolamine|tranylcypromine|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 type_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 supplement_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylscopolamine|P|methscopolamine|furazolidone|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 type_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 supplement_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylscopolamine|P|methscopolamine|selegiline|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 type_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 supplement_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylscopolamine|P|methscopolamine|quinidine|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 type_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 supplement_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylscopolamine|P|methscopolamine|mao inhibitor|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 type_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 supplement_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylscopolamine|P|methscopolamine|tricyclic|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY type_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 supplement_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylscopolamine|P|methscopolamine|linezolid|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 type_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 supplement_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylscopolamine|P|methscopolamine|phenelzine|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 type_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 supplement_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylscopolamine|P|methscopolamine|kaolin|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 type_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 supplement_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylscopolamine|P|methscopolamine|phenothiazine|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 type_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 supplement_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylscopolamine|P|methscopolamine|absorbent-type anti-diarrhea medicine|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 type_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 supplement_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylscopolamine|P|methscopolamine|kaolin|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 type_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 supplement_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylscopolamine|P|methscopolamine|potassium chloride|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 type_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 other_BE12 BIOGENERAL_BE12 BIOENTITY supplement_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylscopolamine|P|methscopolamine|antacid|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 type_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 supplement_BE12 BIOENTITY BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylscopolamine|P|methscopolamine|anticholinergic|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 type_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 other_BE12 BIOENTITY BIOGENERAL_RE2 supplement_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylscopolamine|P|methscopolamine|diphenhydramine|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 type_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY -RRB-_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 supplement_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylscopolamine|P|methscopolamine|antihistamine|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 type_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 supplement_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methylscopolamine|P|methscopolamine|amantadine|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 type_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 supplement_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Methyprylon|P|cns depression-producing drug|methyprylon|concurrent_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 cns_BE12 depressant_BE12 effect_BE12 of_BE12 BIOENTITY or_RE2 these_RE2 other_RE2 medication_RE2 
Methyprylon|P|alcohol|methyprylon|concurrent_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 other_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 cns_BE12 depressant_BE12 effect_BE12 of_BE12 BIOENTITY or_RE2 these_RE2 other_RE2 medication_RE2 
Methysergide|P|methysergide|narcotic analgesic|BIOENTITY may_BE12 reverse_BE12 the_BE12 analgesic_BE12 activity_BE12 of_BE12 BIOENTITY 
Metoclopramide|P|metoclopramide|narcotic analgesic|the_LE1 effect_LE1 of_LE1 BIOENTITY on_BE12 gastrointestinal_BE12 motility_BE12 be_BE12 antagonize_BE12 by_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Metoclopramide|P|metoclopramide|anticholinergic drug|the_LE1 effect_LE1 of_LE1 BIOENTITY on_BE12 gastrointestinal_BE12 motility_BE12 be_BE12 antagonize_BE12 by_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Metoclopramide|P|metoclopramide|narcotic|additive_LE1 sedative_LE1 effect_LE1 can_LE1 occur_LE1 when_LE1 BIOENTITY be_BE12 give_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Metoclopramide|P|metoclopramide|tranquilizer|additive_LE1 sedative_LE1 effect_LE1 can_LE1 occur_LE1 when_LE1 BIOENTITY be_BE12 give_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Metoclopramide|P|metoclopramide|sedative|additive_LE1 sedative_LE1 effect_LE1 can_LE1 occur_LE1 when_LE1 BIOENTITY be_BE12 give_BE12 with_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Metoclopramide|P|metoclopramide|hypnotic|additive_LE1 sedative_LE1 effect_LE1 can_LE1 occur_LE1 when_LE1 BIOENTITY be_BE12 give_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Metoclopramide|P|metoclopramide|alcohol|additive_LE1 sedative_LE1 effect_LE1 can_LE1 occur_LE1 when_LE1 BIOENTITY be_BE12 give_BE12 with_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Metoclopramide|P|metoclopramide|monoamine oxi-dase inhibitor|the_LE1 finding_LE1 that_LE1 BIOENTITY release_BE12 catecholamine_BE12 in_BE12 patient_BE12 with_BE12 essential_BE12 hypertension_BE12 suggest_BE12 that_BE12 it_BE12 shall_BE12 be_BE12 use_BE12 cautious_BE12 if_BE12 at_BE12 all_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Metoclopramide|P|digoxin|metoclopramide|absorption_LE1 of_LE1 drug_LE1 from_LE1 the_LE1 stomach_LE1 may_LE1 be_LE1 diminish_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY -RRB-_BE12 by_BE12 BIOENTITY whereas_RE2 the_RE2 rate_RE2 and_RE2 extent_RE2 of_RE2 absorption_RE2 of_RE2 drug_RE2 from_RE2 the_RE2 small_RE2 bowel_RE2 may_RE2 be_RE2 increase_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Metoclopramide|P|metoclopramide|acetaminophen|absorption_LE1 of_LE1 drug_LE1 from_LE1 the_LE1 stomach_LE1 may_LE1 be_LE1 diminish_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 -RRB-_LE1 by_LE1 BIOENTITY whereas_BE12 the_BE12 rate_BE12 and_BE12 extent_BE12 of_BE12 absorption_BE12 of_BE12 drug_BE12 from_BE12 the_BE12 small_BE12 bowel_BE12 may_BE12 be_BE12 increase_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Metoclopramide|P|metoclopramide|insulin|because_LE1 the_LE1 action_LE1 of_LE1 BIOENTITY will_BE12 influence_BE12 the_BE12 delivery_BE12 of_BE12 food_BE12 to_BE12 the_BE12 intestine_BE12 and_BE12 thus_BE12 the_BE12 rate_BE12 of_BE12 absorption_BE12 BIOENTITY dosage_RE2 or_RE2 timing_RE2 of_RE2 dosage_RE2 may_RE2 require_RE2 adjustment_RE2 
Metolazone|P|furosemide|metolazone|BIOGENERAL_LE1 :_LE1 BIOENTITY and_BE12 probable_BE12 other_BE12 BIOGENERAL_BE12 give_BE12 concomitant_BE12 with_BE12 BIOENTITY can_RE2 cause_RE2 unusual_RE2 large_RE2 or_RE2 prolonged_RE2 loss_RE2 of_RE2 fluid_RE2 and_RE2 electrolyte_RE2 
Metolazone|P|loop diuretic|metolazone|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 and_LE1 probable_LE1 other_LE1 BIOENTITY give_BE12 concomitant_BE12 with_BE12 BIOENTITY can_RE2 cause_RE2 unusual_RE2 large_RE2 or_RE2 prolonged_RE2 loss_RE2 of_RE2 fluid_RE2 and_RE2 electrolyte_RE2 
Metolazone|P|mykrox|antihypertensive drug|other_LE1 BIOGENERAL_LE1 :_LE1 when_LE1 BIOENTITY tablet_BE12 be_BE12 use_BE12 with_BE12 other_BE12 BIOENTITY care_RE2 must_RE2 be_RE2 take_RE2 especial_RE2 during_RE2 initial_RE2 therapy_RE2 
Metolazone|P|diuretic|digitali|BIOGENERAL_LE1 :_LE1 BIOENTITY hypokalemia_BE12 can_BE12 increase_BE12 the_BE12 sensitivity_BE12 of_BE12 the_BE12 myocardium_BE12 to_BE12 BIOENTITY 
Metolazone|P|diuretic|tubocurarine|BIOGENERAL_LE1 :_LE1 BIOENTITY hypokalemia_BE12 may_BE12 enhance_BE12 neuromuscular_BE12 blocking_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOENTITY -RRB-_RE2 the_RE2 much_RE2 serious_RE2 effect_RE2 will_RE2 be_RE2 respiratory_RE2 depression_RE2 which_RE2 can_RE2 proceed_RE2 to_RE2 apnea_RE2 
Metolazone|P|diuretic|curariform drug|BIOGENERAL_LE1 :_LE1 BIOENTITY hypokalemia_BE12 may_BE12 enhance_BE12 neuromuscular_BE12 blocking_BE12 effect_BE12 of_BE12 BIOENTITY -LRB-_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 -RRB-_RE2 the_RE2 much_RE2 serious_RE2 effect_RE2 will_RE2 be_RE2 respiratory_RE2 depression_RE2 which_RE2 can_RE2 proceed_RE2 to_RE2 apnea_RE2 
Metolazone|P|non-steroidal anti-inflammatory drug|mykrox|BIOGENERAL_LE1 and_LE1 other_LE1 BIOENTITY :_BE12 may_BE12 decrease_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOENTITY tablet_RE2 
Metolazone|P|salicylate|mykrox|BIOENTITY and_BE12 other_BE12 BIOGENERAL_BE12 :_BE12 may_BE12 decrease_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOENTITY tablet_RE2 
Metolazone|P|metolazone|norepinephrine|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 decrease_BE12 arterial_BE12 responsiveness_BE12 to_BE12 BIOENTITY but_RE2 this_RE2 diminution_RE2 be_RE2 not_RE2 sufficient_RE2 to_RE2 preclude_RE2 effectiveness_RE2 of_RE2 the_RE2 pressor_RE2 agent_RE2 for_RE2 therapeutic_RE2 use_RE2 
Metolazone|P|methenamine|metolazone|BIOENTITY :_BE12 efficacy_BE12 may_BE12 be_BE12 decrease_BE12 due_BE12 to_BE12 urinary_BE12 alkalizing_BE12 effect_BE12 of_BE12 BIOENTITY 
Metolazone|P|metolazone|anticoagulant|BIOGENERAL_LE1 :_LE1 BIOENTITY as_BE12 well_BE12 as_BE12 other_BE12 BIOGENERAL_BE12 may_BE12 affect_BE12 the_BE12 hypoprothrombinemic_BE12 response_BE12 to_BE12 BIOENTITY 
Metoprolol|P|reserpine|beta-blocking agent|catecholaminedepleting_LE1 drug_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY -RRB-_BE12 may_BE12 have_BE12 additive_BE12 effect_BE12 when_BE12 give_BE12 with_BE12 BIOENTITY 
Metronidazole|P|metronidazole|coumarin|oral_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 potentiate_BE12 the_BE12 anticoagulant_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 prolongation_RE2 of_RE2 prothrombin_RE2 time_RE2 
Metronidazole|P|metronidazole|warfarin|oral_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 potentiate_BE12 the_BE12 anticoagulant_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY result_RE2 in_RE2 prolongation_RE2 of_RE2 prothrombin_RE2 time_RE2 
Metyrapone|P|metopirone|phenytoin|the_LE1 metabolism_LE1 of_LE1 BIOENTITY be_BE12 accelerate_BE12 by_BE12 BIOENTITY 
Metyrapone|P|metopirone|acetaminophen|BIOENTITY inhibit_BE12 the_BE12 glucuronidation_BE12 of_BE12 BIOENTITY and_RE2 can_RE2 possible_RE2 potentiate_RE2 BIOGENERAL_RE2 toxicity_RE2 
Metyrapone|P|metopirone|acetaminophen|BIOENTITY inhibit_BE12 the_BE12 glucuronidation_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 can_BE12 possible_BE12 potentiate_BE12 BIOENTITY toxicity_RE2 
Metyrosine|P|demser|haloperidol|caution_LE1 shall_LE1 be_LE1 observe_LE1 in_LE1 administer_LE1 BIOENTITY to_BE12 patient_BE12 receive_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY because_RE2 the_RE2 extrapyramidal_RE2 effect_RE2 of_RE2 these_RE2 drug_RE2 can_RE2 be_RE2 expect_RE2 to_RE2 be_RE2 potentiate_RE2 by_RE2 inhibition_RE2 of_RE2 catecholamine_RE2 synthesis_RE2 
Metyrosine|P|demser|phenothiazine|caution_LE1 shall_LE1 be_LE1 observe_LE1 in_LE1 administer_LE1 BIOENTITY to_BE12 patient_BE12 receive_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 because_RE2 the_RE2 extrapyramidal_RE2 effect_RE2 of_RE2 these_RE2 drug_RE2 can_RE2 be_RE2 expect_RE2 to_RE2 be_RE2 potentiate_RE2 by_RE2 inhibition_RE2 of_RE2 catecholamine_RE2 synthesis_RE2 
Metyrosine|P|demser|cns depressant|concurrent_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 BIOENTITY can_RE2 increase_RE2 their_RE2 sedative_RE2 effect_RE2 
Metyrosine|P|demser|alcohol|concurrent_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY or_RE2 other_RE2 BIOGENERAL_RE2 can_RE2 increase_RE2 their_RE2 sedative_RE2 effect_RE2 
Mexiletine|P|mexiletine|fluvoxamine|In_LE1 formal_LE1 singledose_LE1 interaction_LE1 study_LE1 -LRB-_LE1 NUM_LE1 male_LE1 -RRB-_LE1 the_LE1 clearance_LE1 of_LE1 BIOENTITY be_BE12 decrease_BE12 by_BE12 NUM_BE12 following_BE12 the_BE12 coadministration_BE12 of_BE12 BIOENTITY inhibitor_RE2 of_RE2 cypa_RE2 
Mexiletine|P|phenobarbital|mexitil|when_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 hepatic_LE1 enzyme_LE1 inducer_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY have_BE12 be_BE12 take_BE12 concurrent_BE12 with_BE12 BIOENTITY lowered_RE2 BIOGENERAL_RE2 plasma_RE2 level_RE2 have_RE2 be_RE2 report_RE2 
Mexiletine|P|phenytoin|mexitil|when_LE1 BIOENTITY or_BE12 other_BE12 hepatic_BE12 enzyme_BE12 inducer_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 have_BE12 be_BE12 take_BE12 concurrent_BE12 with_BE12 BIOENTITY lowered_RE2 BIOGENERAL_RE2 plasma_RE2 level_RE2 have_RE2 be_RE2 report_RE2 
Mexiletine|P|rifampin|mexitil|when_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 hepatic_LE1 enzyme_LE1 inducer_LE1 such_LE1 as_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 have_BE12 be_BE12 take_BE12 concurrent_BE12 with_BE12 BIOENTITY lowered_RE2 BIOGENERAL_RE2 plasma_RE2 level_RE2 have_RE2 be_RE2 report_RE2 
Mexiletine|P|cimetidine|mexitil|concurrent_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY have_RE2 be_RE2 report_RE2 to_RE2 increase_RE2 decrease_RE2 or_RE2 leave_RE2 unchanged_RE2 BIOGENERAL_RE2 plasma_RE2 level_RE2 
Mexiletine|P|magnesium-aluminum hydroxide|digoxin|BIOGENERAL_LE1 do_LE1 not_LE1 alter_LE1 serum_LE1 BIOGENERAL_LE1 level_LE1 but_LE1 BIOENTITY when_BE12 use_BE12 to_BE12 treat_BE12 gastrointestinal_BE12 symptom_BE12 due_BE12 to_BE12 BIOGENERAL_BE12 have_BE12 be_BE12 report_BE12 to_BE12 low_BE12 serum_BE12 BIOENTITY level_RE2 
Mexiletine|P|mexitil|theophylline|concurrent_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 lead_RE2 to_RE2 increase_RE2 plasma_RE2 BIOGENERAL_RE2 level_RE2 
Mexiletine|P|mexitil|theophylline|this_LE1 increase_LE1 be_LE1 observe_LE1 at_LE1 the_LE1 first_LE1 test_LE1 point_LE1 which_LE1 be_LE1 the_LE1 second_LE1 day_LE1 after_LE1 start_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 plasma_LE1 level_LE1 return_LE1 to_LE1 BIOGENERAL_LE1 value_LE1 within_LE1 NUM_LE1 hour_LE1 after_LE1 discontinuing_LE1 BIOGENERAL_LE1 if_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 to_RE2 be_RE2 use_RE2 concurrent_RE2 BIOGENERAL_RE2 blood_RE2 level_RE2 shall_RE2 be_RE2 monitor_RE2 particular_RE2 when_RE2 the_RE2 BIOGENERAL_RE2 dose_RE2 be_RE2 change_RE2 
Mexiletine|P|theophylline|mexitil|this_LE1 increase_LE1 be_LE1 observe_LE1 at_LE1 the_LE1 first_LE1 test_LE1 point_LE1 which_LE1 be_LE1 the_LE1 second_LE1 day_LE1 after_LE1 start_LE1 BIOGENERAL_LE1 BIOENTITY plasma_BE12 level_BE12 return_BE12 to_BE12 BIOGENERAL_BE12 value_BE12 within_BE12 NUM_BE12 hour_BE12 after_BE12 discontinuing_BE12 BIOENTITY if_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 be_RE2 to_RE2 be_RE2 use_RE2 concurrent_RE2 BIOGENERAL_RE2 blood_RE2 level_RE2 shall_RE2 be_RE2 monitor_RE2 particular_RE2 when_RE2 the_RE2 BIOGENERAL_RE2 dose_RE2 be_RE2 change_RE2 
Mexiletine|P|caffeine|mexitil|additional_LE1 in_LE1 one_LE1 controlled_LE1 study_LE1 in_LE1 five_LE1 normal_LE1 subject_LE1 and_LE1 seven_LE1 patient_LE1 the_LE1 clearance_LE1 of_LE1 BIOENTITY be_BE12 decrease_BE12 NUM_BE12 following_BE12 the_BE12 administration_BE12 of_BE12 BIOENTITY 
Mibefradil|P|posicor|cyclosporine|BIOENTITY inhibit_BE12 some_BE12 of_BE12 the_BE12 liver_BE12 's_BE12 ability_BE12 to_BE12 metabolize_BE12 some_BE12 other_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Mibefradil|P|posicor|tricyclic antidepressant|BIOENTITY inhibit_BE12 some_BE12 of_BE12 the_BE12 liver_BE12 's_BE12 ability_BE12 to_BE12 metabolize_BE12 some_BE12 other_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Mibefradil|P|posicor|astemizole|BIOENTITY inhibit_BE12 some_BE12 of_BE12 the_BE12 liver_BE12 's_BE12 ability_BE12 to_BE12 metabolize_BE12 some_BE12 other_BE12 drug_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mibefradil|P|posicor|cisapride|BIOENTITY inhibit_BE12 some_BE12 of_BE12 the_BE12 liver_BE12 's_BE12 ability_BE12 to_BE12 metabolize_BE12 some_BE12 other_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mibefradil|P|posicor|terfenadine|BIOENTITY inhibit_BE12 some_BE12 of_BE12 the_BE12 liver_BE12 's_BE12 ability_BE12 to_BE12 metabolize_BE12 some_BE12 other_BE12 drug_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Micafungin|P|sirolimu|mycamine|BIOENTITY auc_BE12 be_BE12 increase_BE12 by_BE12 NUM_BE12 with_BE12 no_BE12 effect_BE12 on_BE12 cmax_BE12 in_BE12 the_BE12 presence_BE12 of_BE12 steadystate_BE12 BIOENTITY compared_RE2 with_RE2 BIOGENERAL_RE2 alone_RE2 
Micafungin|P|nifedipine|mycamine|BIOENTITY auc_BE12 and_BE12 cmax_BE12 be_BE12 increase_BE12 by_BE12 NUM_BE12 and_BE12 NUM_BE12 respective_BE12 in_BE12 the_BE12 presence_BE12 of_BE12 steadystate_BE12 BIOENTITY compared_RE2 with_RE2 BIOGENERAL_RE2 alone_RE2 
Micafungin|P|nifedipine|mycamine|patient_LE1 receive_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY in_BE12 combination_BE12 with_BE12 BIOENTITY shall_RE2 be_RE2 monitor_RE2 for_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 toxicity_RE2 and_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 dosage_RE2 shall_RE2 be_RE2 reduce_RE2 if_RE2 necessary_RE2 
Micafungin|P|sirolimu|mycamine|patient_LE1 receive_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY shall_RE2 be_RE2 monitor_RE2 for_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 toxicity_RE2 and_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 dosage_RE2 shall_RE2 be_RE2 reduce_RE2 if_RE2 necessary_RE2 
Midazolam|P|midazolam|macrolide antibiotic|drug_LE1 interaction_LE1 :_LE1 inhibitor_LE1 of_LE1 cypa_LE1 isozyme_LE1 :_LE1 caution_LE1 be_LE1 advised_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 be_BE12 know_BE12 to_BE12 inhibit_BE12 the_BE12 cytochrome_BE12 enzyme_BE12 system_BE12 -LRB-_BE12 ie_BE12 some_BE12 drug_BE12 in_BE12 the_BE12 drug_BE12 class_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY rrb._RE2 
Midazolam|P|midazolam|macrolide antibiotic|drug_LE1 interaction_LE1 :_LE1 inhibitor_LE1 of_LE1 cypa_LE1 isozyme_LE1 :_LE1 caution_LE1 be_LE1 advised_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 be_BE12 know_BE12 to_BE12 inhibit_BE12 the_BE12 cytochrome_BE12 enzyme_BE12 system_BE12 -LRB-_BE12 ie_BE12 some_BE12 drug_BE12 in_BE12 the_BE12 drug_BE12 class_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY rrb._RE2 
Midazolam|P|midazolam|protease inhibitor|drug_LE1 interaction_LE1 :_LE1 inhibitor_LE1 of_LE1 cypa_LE1 isozyme_LE1 :_LE1 caution_LE1 be_LE1 advised_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 be_BE12 know_BE12 to_BE12 inhibit_BE12 the_BE12 cytochrome_BE12 enzyme_BE12 system_BE12 -LRB-_BE12 ie_BE12 some_BE12 drug_BE12 in_BE12 the_BE12 drug_BE12 class_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 rrb._RE2 
Midazolam|P|midazolam|protease inhibitor|drug_LE1 interaction_LE1 :_LE1 inhibitor_LE1 of_LE1 cypa_LE1 isozyme_LE1 :_LE1 caution_LE1 be_LE1 advised_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 be_BE12 know_BE12 to_BE12 inhibit_BE12 the_BE12 cytochrome_BE12 enzyme_BE12 system_BE12 -LRB-_BE12 ie_BE12 some_BE12 drug_BE12 in_BE12 the_BE12 drug_BE12 class_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 rrb._RE2 
Midazolam|P|midazolam|calcium channel antagonist|drug_LE1 interaction_LE1 :_LE1 inhibitor_LE1 of_LE1 cypa_LE1 isozyme_LE1 :_LE1 caution_LE1 be_LE1 advised_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 be_BE12 know_BE12 to_BE12 inhibit_BE12 the_BE12 cytochrome_BE12 enzyme_BE12 system_BE12 -LRB-_BE12 ie_BE12 some_BE12 drug_BE12 in_BE12 the_BE12 drug_BE12 class_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 rrb._RE2 
Midazolam|P|midazolam|calcium channel antagonist|drug_LE1 interaction_LE1 :_LE1 inhibitor_LE1 of_LE1 cypa_LE1 isozyme_LE1 :_LE1 caution_LE1 be_LE1 advised_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 be_BE12 know_BE12 to_BE12 inhibit_BE12 the_BE12 cytochrome_BE12 enzyme_BE12 system_BE12 -LRB-_BE12 ie_BE12 some_BE12 drug_BE12 in_BE12 the_BE12 drug_BE12 class_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 rrb._RE2 
Midazolam|P|midazolam|azole antimycotic|drug_LE1 interaction_LE1 :_LE1 inhibitor_LE1 of_LE1 cypa_LE1 isozyme_LE1 :_LE1 caution_LE1 be_LE1 advised_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 be_BE12 know_BE12 to_BE12 inhibit_BE12 the_BE12 cytochrome_BE12 enzyme_BE12 system_BE12 -LRB-_BE12 ie_BE12 some_BE12 drug_BE12 in_BE12 the_BE12 drug_BE12 class_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 rrb._RE2 
Midazolam|P|midazolam|azole antimycotic|drug_LE1 interaction_LE1 :_LE1 inhibitor_LE1 of_LE1 cypa_LE1 isozyme_LE1 :_LE1 caution_LE1 be_LE1 advised_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 be_BE12 know_BE12 to_BE12 inhibit_BE12 the_BE12 cytochrome_BE12 enzyme_BE12 system_BE12 -LRB-_BE12 ie_BE12 some_BE12 drug_BE12 in_BE12 the_BE12 drug_BE12 class_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 rrb._RE2 
Midazolam|P|fluconazole|midazolam|drug_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 be_BE12 show_BE12 to_BE12 significant_BE12 increase_BE12 the_BE12 max_BE12 and_BE12 auc_BE12 of_BE12 oral_BE12 administer_BE12 BIOENTITY 
Midazolam|P|ketoconazole|midazolam|drug_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 be_BE12 show_BE12 to_BE12 significant_BE12 increase_BE12 the_BE12 max_BE12 and_BE12 auc_BE12 of_BE12 oral_BE12 administer_BE12 BIOENTITY 
Midazolam|P|itraconazole|midazolam|drug_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY be_BE12 show_BE12 to_BE12 significant_BE12 increase_BE12 the_BE12 max_BE12 and_BE12 auc_BE12 of_BE12 oral_BE12 administer_BE12 BIOENTITY 
Midazolam|P|verapamil|midazolam|drug_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 be_BE12 show_BE12 to_BE12 significant_BE12 increase_BE12 the_BE12 max_BE12 and_BE12 auc_BE12 of_BE12 oral_BE12 administer_BE12 BIOENTITY 
Midazolam|P|diltiazem|midazolam|drug_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 be_BE12 show_BE12 to_BE12 significant_BE12 increase_BE12 the_BE12 max_BE12 and_BE12 auc_BE12 of_BE12 oral_BE12 administer_BE12 BIOENTITY 
Midazolam|P|erythromycin|midazolam|drug_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 be_BE12 show_BE12 to_BE12 significant_BE12 increase_BE12 the_BE12 max_BE12 and_BE12 auc_BE12 of_BE12 oral_BE12 administer_BE12 BIOENTITY 
Midazolam|P|ritonavir|midazolam|although_LE1 not_LE1 study_LE1 the_LE1 potent_LE1 cytochrome_LE1 inhibitor_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 cause_BE12 intense_BE12 and_BE12 prolonged_BE12 sedation_BE12 and_BE12 respiratory_BE12 depression_BE12 due_BE12 to_BE12 decrease_BE12 in_BE12 plasma_BE12 clearance_BE12 of_BE12 BIOENTITY 
Midazolam|P|nelfinavir|midazolam|although_LE1 not_LE1 study_LE1 the_LE1 potent_LE1 cytochrome_LE1 inhibitor_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 cause_BE12 intense_BE12 and_BE12 prolonged_BE12 sedation_BE12 and_BE12 respiratory_BE12 depression_BE12 due_BE12 to_BE12 decrease_BE12 in_BE12 plasma_BE12 clearance_BE12 of_BE12 BIOENTITY 
Midazolam|P|carbamazepine|midazolam|inducer_LE1 of_LE1 cypa_LE1 isozyme_LE1 :_LE1 cytochrome_LE1 inducer_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 induce_BE12 metabolism_BE12 and_BE12 cause_BE12 marked_BE12 decrease_BE12 max_BE12 and_BE12 auc_BE12 of_BE12 oral_BE12 BIOENTITY in_RE2 adult_RE2 study_RE2 
Midazolam|P|rifampin|midazolam|inducer_LE1 of_LE1 cypa_LE1 isozyme_LE1 :_LE1 cytochrome_LE1 inducer_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 induce_BE12 metabolism_BE12 and_BE12 cause_BE12 marked_BE12 decrease_BE12 max_BE12 and_BE12 auc_BE12 of_BE12 oral_BE12 BIOENTITY in_RE2 adult_RE2 study_RE2 
Midazolam|P|phenytoin|midazolam|inducer_LE1 of_LE1 cypa_LE1 isozyme_LE1 :_LE1 cytochrome_LE1 inducer_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY induce_BE12 metabolism_BE12 and_BE12 cause_BE12 marked_BE12 decrease_BE12 max_BE12 and_BE12 auc_BE12 of_BE12 oral_BE12 BIOENTITY in_RE2 adult_RE2 study_RE2 
Midazolam|P|versed syrup|propofol|the_LE1 sedative_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 accentuate_BE12 by_BE12 any_BE12 concomitant_BE12 administer_BE12 medication_BE12 which_BE12 depress_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 particular_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Midazolam|P|versed syrup|propofol|the_LE1 sedative_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 accentuate_BE12 by_BE12 any_BE12 concomitant_BE12 administer_BE12 medication_BE12 which_BE12 depress_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 particular_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Midazolam|P|versed syrup|ketamine|the_LE1 sedative_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 accentuate_BE12 by_BE12 any_BE12 concomitant_BE12 administer_BE12 medication_BE12 which_BE12 depress_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 particular_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Midazolam|P|versed syrup|ketamine|the_LE1 sedative_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 accentuate_BE12 by_BE12 any_BE12 concomitant_BE12 administer_BE12 medication_BE12 which_BE12 depress_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 particular_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Midazolam|P|versed syrup|nitrous oxide|the_LE1 sedative_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 accentuate_BE12 by_BE12 any_BE12 concomitant_BE12 administer_BE12 medication_BE12 which_BE12 depress_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 particular_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Midazolam|P|versed syrup|nitrous oxide|the_LE1 sedative_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 accentuate_BE12 by_BE12 any_BE12 concomitant_BE12 administer_BE12 medication_BE12 which_BE12 depress_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 particular_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Midazolam|P|versed syrup|secobarbital|the_LE1 sedative_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 accentuate_BE12 by_BE12 any_BE12 concomitant_BE12 administer_BE12 medication_BE12 which_BE12 depress_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 particular_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Midazolam|P|versed syrup|secobarbital|the_LE1 sedative_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 accentuate_BE12 by_BE12 any_BE12 concomitant_BE12 administer_BE12 medication_BE12 which_BE12 depress_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 particular_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Midazolam|P|versed syrup|droperidol|the_LE1 sedative_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 accentuate_BE12 by_BE12 any_BE12 concomitant_BE12 administer_BE12 medication_BE12 which_BE12 depress_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 particular_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Midazolam|P|versed syrup|droperidol|the_LE1 sedative_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 accentuate_BE12 by_BE12 any_BE12 concomitant_BE12 administer_BE12 medication_BE12 which_BE12 depress_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 particular_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Midazolam|P|versed syrup|morphine|the_LE1 sedative_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 accentuate_BE12 by_BE12 any_BE12 concomitant_BE12 administer_BE12 medication_BE12 which_BE12 depress_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 particular_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Midazolam|P|versed syrup|morphine|the_LE1 sedative_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 accentuate_BE12 by_BE12 any_BE12 concomitant_BE12 administer_BE12 medication_BE12 which_BE12 depress_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 particular_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Midazolam|P|versed syrup|narcotic|the_LE1 sedative_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 accentuate_BE12 by_BE12 any_BE12 concomitant_BE12 administer_BE12 medication_BE12 which_BE12 depress_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 particular_BE12 BIOENTITY -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Midazolam|P|versed syrup|narcotic|the_LE1 sedative_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 accentuate_BE12 by_BE12 any_BE12 concomitant_BE12 administer_BE12 medication_BE12 which_BE12 depress_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 particular_BE12 BIOENTITY -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Midazolam|P|versed syrup|fentanyl|the_LE1 sedative_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 accentuate_BE12 by_BE12 any_BE12 concomitant_BE12 administer_BE12 medication_BE12 which_BE12 depress_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 particular_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Midazolam|P|versed syrup|fentanyl|the_LE1 sedative_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 accentuate_BE12 by_BE12 any_BE12 concomitant_BE12 administer_BE12 medication_BE12 which_BE12 depress_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 particular_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Midazolam|P|versed syrup|meperidine|the_LE1 sedative_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 accentuate_BE12 by_BE12 any_BE12 concomitant_BE12 administer_BE12 medication_BE12 which_BE12 depress_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 particular_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Midazolam|P|versed syrup|meperidine|the_LE1 sedative_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 accentuate_BE12 by_BE12 any_BE12 concomitant_BE12 administer_BE12 medication_BE12 which_BE12 depress_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 particular_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Midodrine|P|proamatine|cardiac glycoside|when_LE1 administer_LE1 concomitant_LE1 with_LE1 BIOENTITY BIOENTITY may_RE2 enhance_RE2 or_RE2 precipitate_RE2 bradycardia_RE2 a.v._RE2 
Midodrine|P|ephedrine|proamatine|the_LE1 use_LE1 of_LE1 drug_LE1 that_LE1 stimulate_LE1 alphaadrenergic_LE1 receptor_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 enhance_BE12 or_BE12 potentiate_BE12 the_BE12 pressor_BE12 effect_BE12 of_BE12 BIOENTITY therefore_RE2 caution_RE2 shall_RE2 be_RE2 use_RE2 when_RE2 BIOGENERAL_RE2 be_RE2 administer_RE2 concomitant_RE2 with_RE2 agent_RE2 that_RE2 cause_RE2 vasoconstriction_RE2 
Midodrine|P|ephedrine|proamatine|the_LE1 use_LE1 of_LE1 drug_LE1 that_LE1 stimulate_LE1 alphaadrenergic_LE1 receptor_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 enhance_BE12 or_BE12 potentiate_BE12 the_BE12 pressor_BE12 effect_BE12 of_BE12 BIOENTITY therefore_RE2 caution_RE2 shall_RE2 be_RE2 use_RE2 when_RE2 BIOGENERAL_RE2 be_RE2 administer_RE2 concomitant_RE2 with_RE2 agent_RE2 that_RE2 cause_RE2 vasoconstriction_RE2 
Midodrine|P|pseudoephedrine|proamatine|the_LE1 use_LE1 of_LE1 drug_LE1 that_LE1 stimulate_LE1 alphaadrenergic_LE1 receptor_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 enhance_BE12 or_BE12 potentiate_BE12 the_BE12 pressor_BE12 effect_BE12 of_BE12 BIOENTITY therefore_RE2 caution_RE2 shall_RE2 be_RE2 use_RE2 when_RE2 BIOGENERAL_RE2 be_RE2 administer_RE2 concomitant_RE2 with_RE2 agent_RE2 that_RE2 cause_RE2 vasoconstriction_RE2 
Midodrine|P|pseudoephedrine|proamatine|the_LE1 use_LE1 of_LE1 drug_LE1 that_LE1 stimulate_LE1 alphaadrenergic_LE1 receptor_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 enhance_BE12 or_BE12 potentiate_BE12 the_BE12 pressor_BE12 effect_BE12 of_BE12 BIOENTITY therefore_RE2 caution_RE2 shall_RE2 be_RE2 use_RE2 when_RE2 BIOGENERAL_RE2 be_RE2 administer_RE2 concomitant_RE2 with_RE2 agent_RE2 that_RE2 cause_RE2 vasoconstriction_RE2 
Midodrine|P|phenylephrine|proamatine|the_LE1 use_LE1 of_LE1 drug_LE1 that_LE1 stimulate_LE1 alphaadrenergic_LE1 receptor_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 enhance_BE12 or_BE12 potentiate_BE12 the_BE12 pressor_BE12 effect_BE12 of_BE12 BIOENTITY therefore_RE2 caution_RE2 shall_RE2 be_RE2 use_RE2 when_RE2 BIOGENERAL_RE2 be_RE2 administer_RE2 concomitant_RE2 with_RE2 agent_RE2 that_RE2 cause_RE2 vasoconstriction_RE2 
Midodrine|P|phenylephrine|proamatine|the_LE1 use_LE1 of_LE1 drug_LE1 that_LE1 stimulate_LE1 alphaadrenergic_LE1 receptor_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 enhance_BE12 or_BE12 potentiate_BE12 the_BE12 pressor_BE12 effect_BE12 of_BE12 BIOENTITY therefore_RE2 caution_RE2 shall_RE2 be_RE2 use_RE2 when_RE2 BIOGENERAL_RE2 be_RE2 administer_RE2 concomitant_RE2 with_RE2 agent_RE2 that_RE2 cause_RE2 vasoconstriction_RE2 
Midodrine|P|phenylpropanolamine|proamatine|the_LE1 use_LE1 of_LE1 drug_LE1 that_LE1 stimulate_LE1 alphaadrenergic_LE1 receptor_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 enhance_BE12 or_BE12 potentiate_BE12 the_BE12 pressor_BE12 effect_BE12 of_BE12 BIOENTITY therefore_RE2 caution_RE2 shall_RE2 be_RE2 use_RE2 when_RE2 BIOGENERAL_RE2 be_RE2 administer_RE2 concomitant_RE2 with_RE2 agent_RE2 that_RE2 cause_RE2 vasoconstriction_RE2 
Midodrine|P|phenylpropanolamine|proamatine|the_LE1 use_LE1 of_LE1 drug_LE1 that_LE1 stimulate_LE1 alphaadrenergic_LE1 receptor_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 enhance_BE12 or_BE12 potentiate_BE12 the_BE12 pressor_BE12 effect_BE12 of_BE12 BIOENTITY therefore_RE2 caution_RE2 shall_RE2 be_RE2 use_RE2 when_RE2 BIOGENERAL_RE2 be_RE2 administer_RE2 concomitant_RE2 with_RE2 agent_RE2 that_RE2 cause_RE2 vasoconstriction_RE2 
Midodrine|P|dihydroergotamine|proamatine|the_LE1 use_LE1 of_LE1 drug_LE1 that_LE1 stimulate_LE1 alphaadrenergic_LE1 receptor_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY -RRB-_BE12 may_BE12 enhance_BE12 or_BE12 potentiate_BE12 the_BE12 pressor_BE12 effect_BE12 of_BE12 BIOENTITY therefore_RE2 caution_RE2 shall_RE2 be_RE2 use_RE2 when_RE2 BIOGENERAL_RE2 be_RE2 administer_RE2 concomitant_RE2 with_RE2 agent_RE2 that_RE2 cause_RE2 vasoconstriction_RE2 
Midodrine|P|dihydroergotamine|proamatine|the_LE1 use_LE1 of_LE1 drug_LE1 that_LE1 stimulate_LE1 alphaadrenergic_LE1 receptor_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY -RRB-_BE12 may_BE12 enhance_BE12 or_BE12 potentiate_BE12 the_BE12 pressor_BE12 effect_BE12 of_BE12 BIOENTITY therefore_RE2 caution_RE2 shall_RE2 be_RE2 use_RE2 when_RE2 BIOGENERAL_RE2 be_RE2 administer_RE2 concomitant_RE2 with_RE2 agent_RE2 that_RE2 cause_RE2 vasoconstriction_RE2 
Midodrine|P|desglymidodrine|quinidine|BIOGENERAL_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 can_LE1 antagonize_LE1 the_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 potential_LE1 for_LE1 drug_LE1 interaction_LE1 :_LE1 it_LE1 appear_LE1 possible_LE1 although_LE1 there_LE1 be_LE1 no_LE1 support_LE1 experimental_LE1 evidence_LE1 that_LE1 the_LE1 high_LE1 renal_LE1 clearance_LE1 of_LE1 BIOENTITY -LRB-_BE12 base_BE12 -RRB-_BE12 be_BE12 due_BE12 to_BE12 active_BE12 tubular_BE12 secretion_BE12 by_BE12 the_BE12 basesecreting_BE12 system_BE12 also_BE12 responsible_BE12 for_BE12 the_BE12 secretion_BE12 of_BE12 such_BE12 drug_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Midodrine|P|desglymidodrine|flecainide|BIOGENERAL_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 can_LE1 antagonize_LE1 the_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 potential_LE1 for_LE1 drug_LE1 interaction_LE1 :_LE1 it_LE1 appear_LE1 possible_LE1 although_LE1 there_LE1 be_LE1 no_LE1 support_LE1 experimental_LE1 evidence_LE1 that_LE1 the_LE1 high_LE1 renal_LE1 clearance_LE1 of_LE1 BIOENTITY -LRB-_BE12 base_BE12 -RRB-_BE12 be_BE12 due_BE12 to_BE12 active_BE12 tubular_BE12 secretion_BE12 by_BE12 the_BE12 basesecreting_BE12 system_BE12 also_BE12 responsible_BE12 for_BE12 the_BE12 secretion_BE12 of_BE12 such_BE12 drug_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Midodrine|P|desglymidodrine|triamterene|BIOGENERAL_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 can_LE1 antagonize_LE1 the_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 potential_LE1 for_LE1 drug_LE1 interaction_LE1 :_LE1 it_LE1 appear_LE1 possible_LE1 although_LE1 there_LE1 be_LE1 no_LE1 support_LE1 experimental_LE1 evidence_LE1 that_LE1 the_LE1 high_LE1 renal_LE1 clearance_LE1 of_LE1 BIOENTITY -LRB-_BE12 base_BE12 -RRB-_BE12 be_BE12 due_BE12 to_BE12 active_BE12 tubular_BE12 secretion_BE12 by_BE12 the_BE12 basesecreting_BE12 system_BE12 also_BE12 responsible_BE12 for_BE12 the_BE12 secretion_BE12 of_BE12 such_BE12 drug_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Midodrine|P|desglymidodrine|ranitidine|BIOGENERAL_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 can_LE1 antagonize_LE1 the_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 potential_LE1 for_LE1 drug_LE1 interaction_LE1 :_LE1 it_LE1 appear_LE1 possible_LE1 although_LE1 there_LE1 be_LE1 no_LE1 support_LE1 experimental_LE1 evidence_LE1 that_LE1 the_LE1 high_LE1 renal_LE1 clearance_LE1 of_LE1 BIOENTITY -LRB-_BE12 base_BE12 -RRB-_BE12 be_BE12 due_BE12 to_BE12 active_BE12 tubular_BE12 secretion_BE12 by_BE12 the_BE12 basesecreting_BE12 system_BE12 also_BE12 responsible_BE12 for_BE12 the_BE12 secretion_BE12 of_BE12 such_BE12 drug_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Midodrine|P|desglymidodrine|procainamide|BIOGENERAL_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 can_LE1 antagonize_LE1 the_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 potential_LE1 for_LE1 drug_LE1 interaction_LE1 :_LE1 it_LE1 appear_LE1 possible_LE1 although_LE1 there_LE1 be_LE1 no_LE1 support_LE1 experimental_LE1 evidence_LE1 that_LE1 the_LE1 high_LE1 renal_LE1 clearance_LE1 of_LE1 BIOENTITY -LRB-_BE12 base_BE12 -RRB-_BE12 be_BE12 due_BE12 to_BE12 active_BE12 tubular_BE12 secretion_BE12 by_BE12 the_BE12 basesecreting_BE12 system_BE12 also_BE12 responsible_BE12 for_BE12 the_BE12 secretion_BE12 of_BE12 such_BE12 drug_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Midodrine|P|terazosin|proamatine|BIOGENERAL_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 can_BE12 antagonize_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY potential_RE2 for_RE2 drug_RE2 interaction_RE2 :_RE2 it_RE2 appear_RE2 possible_RE2 although_RE2 there_RE2 be_RE2 no_RE2 support_RE2 experimental_RE2 evidence_RE2 that_RE2 the_RE2 high_RE2 renal_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 -LRB-_RE2 base_RE2 -RRB-_RE2 be_RE2 due_RE2 to_RE2 active_RE2 tubular_RE2 secretion_RE2 by_RE2 the_RE2 basesecreting_RE2 system_RE2 also_RE2 responsible_RE2 for_RE2 the_RE2 secretion_RE2 of_RE2 such_RE2 drug_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Midodrine|P|desglymidodrine|metformin|BIOGENERAL_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 can_LE1 antagonize_LE1 the_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 potential_LE1 for_LE1 drug_LE1 interaction_LE1 :_LE1 it_LE1 appear_LE1 possible_LE1 although_LE1 there_LE1 be_LE1 no_LE1 support_LE1 experimental_LE1 evidence_LE1 that_LE1 the_LE1 high_LE1 renal_LE1 clearance_LE1 of_LE1 BIOENTITY -LRB-_BE12 base_BE12 -RRB-_BE12 be_BE12 due_BE12 to_BE12 active_BE12 tubular_BE12 secretion_BE12 by_BE12 the_BE12 basesecreting_BE12 system_BE12 also_BE12 responsible_BE12 for_BE12 the_BE12 secretion_BE12 of_BE12 such_BE12 drug_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Midodrine|P|desglymidodrine|cimetidine|BIOGENERAL_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 can_LE1 antagonize_LE1 the_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 potential_LE1 for_LE1 drug_LE1 interaction_LE1 :_LE1 it_LE1 appear_LE1 possible_LE1 although_LE1 there_LE1 be_LE1 no_LE1 support_LE1 experimental_LE1 evidence_LE1 that_LE1 the_LE1 high_LE1 renal_LE1 clearance_LE1 of_LE1 BIOENTITY -LRB-_BE12 base_BE12 -RRB-_BE12 be_BE12 due_BE12 to_BE12 active_BE12 tubular_BE12 secretion_BE12 by_BE12 the_BE12 basesecreting_BE12 system_BE12 also_BE12 responsible_BE12 for_BE12 the_BE12 secretion_BE12 of_BE12 such_BE12 drug_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Midodrine|P|prazosin|proamatine|BIOGENERAL_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 can_BE12 antagonize_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY potential_RE2 for_RE2 drug_RE2 interaction_RE2 :_RE2 it_RE2 appear_RE2 possible_RE2 although_RE2 there_RE2 be_RE2 no_RE2 support_RE2 experimental_RE2 evidence_RE2 that_RE2 the_RE2 high_RE2 renal_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 -LRB-_RE2 base_RE2 -RRB-_RE2 be_RE2 due_RE2 to_RE2 active_RE2 tubular_RE2 secretion_RE2 by_RE2 the_RE2 basesecreting_RE2 system_RE2 also_RE2 responsible_RE2 for_RE2 the_RE2 secretion_RE2 of_RE2 such_RE2 drug_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Midodrine|P|doxazosin|proamatine|BIOGENERAL_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY can_BE12 antagonize_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY potential_RE2 for_RE2 drug_RE2 interaction_RE2 :_RE2 it_RE2 appear_RE2 possible_RE2 although_RE2 there_RE2 be_RE2 no_RE2 support_RE2 experimental_RE2 evidence_RE2 that_RE2 the_RE2 high_RE2 renal_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 -LRB-_RE2 base_RE2 -RRB-_RE2 be_RE2 due_RE2 to_RE2 active_RE2 tubular_RE2 secretion_RE2 by_RE2 the_RE2 basesecreting_RE2 system_RE2 also_RE2 responsible_RE2 for_RE2 the_RE2 secretion_RE2 of_RE2 such_RE2 drug_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Midodrine|P|alpha-adrenergic blocking agent|proamatine|BIOGENERAL_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 can_BE12 antagonize_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY potential_RE2 for_RE2 drug_RE2 interaction_RE2 :_RE2 it_RE2 appear_RE2 possible_RE2 although_RE2 there_RE2 be_RE2 no_RE2 support_RE2 experimental_RE2 evidence_RE2 that_RE2 the_RE2 high_RE2 renal_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 -LRB-_RE2 base_RE2 -RRB-_RE2 be_RE2 due_RE2 to_RE2 active_RE2 tubular_RE2 secretion_RE2 by_RE2 the_RE2 basesecreting_RE2 system_RE2 also_RE2 responsible_RE2 for_RE2 the_RE2 secretion_RE2 of_RE2 such_RE2 drug_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mifepristone|P|itraconazole|mifepristone|although_LE1 specific_LE1 drug_LE1 or_LE1 food_LE1 interaction_LE1 with_LE1 BIOGENERAL_LE1 have_LE1 not_LE1 be_LE1 study_LE1 on_LE1 the_LE1 basis_LE1 of_LE1 this_LE1 drug_LE1 metabolism_LE1 by_LE1 cyp_LE1 it_LE1 be_LE1 possible_LE1 that_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 grapefruit_BE12 juice_BE12 may_BE12 inhibit_BE12 its_BE12 metabolism_BE12 -LRB-_BE12 increase_BE12 serum_BE12 level_BE12 of_BE12 BIOENTITY rrb._RE2 
Mifepristone|P|erythromycin|mifepristone|although_LE1 specific_LE1 drug_LE1 or_LE1 food_LE1 interaction_LE1 with_LE1 BIOGENERAL_LE1 have_LE1 not_LE1 be_LE1 study_LE1 on_LE1 the_LE1 basis_LE1 of_LE1 this_LE1 drug_LE1 metabolism_LE1 by_LE1 cyp_LE1 it_LE1 be_LE1 possible_LE1 that_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 grapefruit_BE12 juice_BE12 may_BE12 inhibit_BE12 its_BE12 metabolism_BE12 -LRB-_BE12 increase_BE12 serum_BE12 level_BE12 of_BE12 BIOENTITY rrb._RE2 
Mifepristone|P|ketoconazole|mifepristone|although_LE1 specific_LE1 drug_LE1 or_LE1 food_LE1 interaction_LE1 with_LE1 BIOGENERAL_LE1 have_LE1 not_LE1 be_LE1 study_LE1 on_LE1 the_LE1 basis_LE1 of_LE1 this_LE1 drug_LE1 metabolism_LE1 by_LE1 cyp_LE1 it_LE1 be_LE1 possible_LE1 that_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 grapefruit_BE12 juice_BE12 may_BE12 inhibit_BE12 its_BE12 metabolism_BE12 -LRB-_BE12 increase_BE12 serum_BE12 level_BE12 of_BE12 BIOENTITY rrb._RE2 
Mifepristone|P|phenytoin|mifepristone|john_LE1 wort_LE1 and_LE1 certain_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 induce_BE12 BIOENTITY metabolism_RE2 -LRB-_RE2 lower_RE2 serum_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 rrb._RE2 
Mifepristone|P|anticonvulsant|mifepristone|john_LE1 wort_LE1 and_LE1 certain_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 induce_BE12 BIOENTITY metabolism_RE2 -LRB-_RE2 lower_RE2 serum_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 rrb._RE2 
Mifepristone|P|phenobarbital|mifepristone|john_LE1 wort_LE1 and_LE1 certain_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 may_BE12 induce_BE12 BIOENTITY metabolism_RE2 -LRB-_RE2 lower_RE2 serum_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 rrb._RE2 
Mifepristone|P|carbamazepine|mifepristone|john_LE1 wort_LE1 and_LE1 certain_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 may_BE12 induce_BE12 BIOENTITY metabolism_RE2 -LRB-_RE2 lower_RE2 serum_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 rrb._RE2 
Miglustat|P|zavesca|cerezyme|while_LE1 coadministration_LE1 of_LE1 BIOENTITY appear_BE12 to_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY by_RE2 NUM_RE2 these_RE2 result_RE2 be_RE2 not_RE2 conclusive_RE2 because_RE2 of_RE2 the_RE2 small_RE2 number_RE2 of_RE2 subject_RE2 study_RE2 and_RE2 because_RE2 patient_RE2 take_RE2 variable_RE2 dose_RE2 of_RE2 BIOGENERAL_RE2 
Miglustat|P|imiglucerase|zavesca|combination_LE1 therapy_LE1 with_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 and_BE12 BIOENTITY be_RE2 not_RE2 indicate_RE2 
Miglustat|P|cerezyme|zavesca|combination_LE1 therapy_LE1 with_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY be_RE2 not_RE2 indicate_RE2 
Minocycline|P|tetracycline|anticoagulant|because_LE1 BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 depress_BE12 plasma_BE12 prothrombin_BE12 activity_BE12 patient_BE12 who_BE12 be_BE12 on_BE12 BIOENTITY therapy_RE2 may_RE2 require_RE2 downward_RE2 adjustment_RE2 of_RE2 their_RE2 BIOGENERAL_RE2 dosage_RE2 
Minocycline|P|tetracycline|anticoagulant|because_LE1 BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 depress_BE12 plasma_BE12 prothrombin_BE12 activity_BE12 patient_BE12 who_BE12 be_BE12 on_BE12 BIOENTITY therapy_RE2 may_RE2 require_RE2 downward_RE2 adjustment_RE2 of_RE2 their_RE2 BIOGENERAL_RE2 dosage_RE2 
Minocycline|P|tetracycline class drug|penicillin|since_LE1 bacteriostatic_LE1 drug_LE1 may_LE1 interfere_LE1 with_LE1 the_LE1 bactericidal_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 it_LE1 be_LE1 advisable_LE1 to_LE1 avoid_LE1 giving_LE1 BIOENTITY in_BE12 conjunction_BE12 with_BE12 BIOENTITY 
Minocycline|P|tetracycline|aluminum|absorption_LE1 of_LE1 BIOENTITY be_BE12 impair_BE12 by_BE12 BIOGENERAL_BE12 contain_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 preparation_RE2 
Minocycline|P|tetracycline|magnesium|absorption_LE1 of_LE1 BIOENTITY be_BE12 impair_BE12 by_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 preparation_RE2 
Minocycline|P|tetracycline|magnesium|absorption_LE1 of_LE1 BIOENTITY be_BE12 impair_BE12 by_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 preparation_RE2 
Minocycline|P|tetracycline|calcium|absorption_LE1 of_LE1 BIOENTITY be_BE12 impair_BE12 by_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 preparation_RE2 
Minocycline|P|tetracycline|iron|absorption_LE1 of_LE1 BIOENTITY be_BE12 impair_BE12 by_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY preparation_RE2 
Minocycline|P|tetracycline|methoxyflurane|the_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY have_RE2 be_RE2 report_RE2 to_RE2 result_RE2 in_RE2 fatal_RE2 renal_RE2 toxicity_RE2 
Minocycline|P|tetracycline|contraceptive|concurrent_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 oral_BE12 BIOENTITY may_RE2 render_RE2 oral_RE2 BIOGENERAL_RE2 little_RE2 effective_RE2 
Minoxidil|P|minoxidil|guanethidine|interaction_LE1 with_LE1 BIOGENERAL_LE1 :_LE1 although_LE1 BIOENTITY do_BE12 not_BE12 itself_BE12 cause_BE12 orthostatic_BE12 hypotension_BE12 its_BE12 administration_BE12 to_BE12 patient_BE12 already_BE12 receive_BE12 BIOENTITY can_RE2 result_RE2 in_RE2 profound_RE2 orthostatic_RE2 effect_RE2 
Minoxidil|P|guanethidine|minoxidil|if_LE1 at_LE1 all_LE1 possible_LE1 BIOENTITY shall_BE12 be_BE12 discontinue_BE12 well_BE12 before_BE12 BIOENTITY be_RE2 begin_RE2 
Mirtazapine|P|alcohol|mirtazapine|BIOGENERAL_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY -LRB-_BE12 equivalent_BE12 to_BE12 NUM_BE12 -RRB-_BE12 have_BE12 minimal_BE12 effect_BE12 on_BE12 plasma_BE12 level_BE12 of_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 -RRB-_RE2 in_RE2 NUM_RE2 healthy_RE2 male_RE2 subject_RE2 
Mirtazapine|P|remeron|alcohol|however_LE1 the_LE1 impairment_LE1 of_LE1 cognitive_LE1 and_LE1 motor_LE1 skill_LE1 produce_LE1 by_LE1 BIOENTITY be_BE12 show_BE12 to_BE12 be_BE12 additive_BE12 with_BE12 those_BE12 produce_BE12 by_BE12 BIOENTITY 
Mirtazapine|P|diazepam|mirtazapine|according_LE1 patient_LE1 shall_LE1 be_LE1 advise_LE1 to_LE1 avoid_LE1 BIOGENERAL_LE1 while_LE1 take_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 -RRB-_BE12 have_BE12 minimal_BE12 effect_BE12 on_BE12 plasma_BE12 level_BE12 of_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 -RRB-_RE2 in_RE2 NUM_RE2 healthy_RE2 subject_RE2 
Mirtazapine|P|alcohol|remeron soltab|according_LE1 patient_LE1 shall_LE1 be_LE1 advise_LE1 to_LE1 avoid_LE1 BIOENTITY while_BE12 take_BE12 BIOENTITY BIOGENERAL_RE2 :_RE2 concomitant_RE2 administration_RE2 of_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 mg_RE2 -RRB-_RE2 have_RE2 minimal_RE2 effect_RE2 on_RE2 plasma_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 mg_RE2 -RRB-_RE2 in_RE2 NUM_RE2 healthy_RE2 subject_RE2 
Mirtazapine|P|remeron|diazepam|however_LE1 the_LE1 impairment_LE1 of_LE1 motor_LE1 skill_LE1 produce_LE1 by_LE1 BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 be_BE12 additive_BE12 with_BE12 those_BE12 cause_BE12 by_BE12 BIOENTITY 
Mirtazapine|P|diazepam|remeron soltab|according_LE1 patient_LE1 shall_LE1 be_LE1 advise_LE1 to_LE1 avoid_LE1 BIOENTITY and_BE12 other_BE12 similar_BE12 drug_BE12 while_BE12 take_BE12 BIOENTITY 
Mitotane|P|mitotane|warfarin|BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 accelerate_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY by_RE2 the_RE2 mechanism_RE2 of_RE2 hepatic_RE2 microsomal_RE2 enzyme_RE2 induction_RE2 lead_RE2 to_RE2 increase_RE2 in_RE2 dosage_RE2 requirement_RE2 for_RE2 BIOGENERAL_RE2 
Mitotane|P|mitotane|coumarin-type anticoagulant|therefore_LE1 physician_LE1 shall_LE1 close_LE1 monitor_LE1 patient_LE1 for_LE1 change_LE1 in_LE1 BIOGENERAL_LE1 dosage_LE1 requirement_LE1 when_LE1 administer_LE1 BIOENTITY to_BE12 patient_BE12 on_BE12 BIOENTITY 
Mivacurium|P|succinylcholine|nondepolarizing agent|prior_LE1 administration_LE1 of_LE1 BIOENTITY can_BE12 potentiate_BE12 the_BE12 neuromuscular_BE12 blocking_BE12 effect_BE12 of_BE12 BIOENTITY 
Mivacurium|P|succinylcholine|mivacron|evidence_LE1 of_LE1 spontaneous_LE1 recovery_LE1 from_LE1 BIOENTITY shall_BE12 be_BE12 observe_BE12 before_BE12 the_BE12 administration_BE12 of_BE12 BIOENTITY 
Mivacurium|P|mivacron|aminoglycoside|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|aminoglycoside|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|tetracycline|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|tetracycline|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|quinidine|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOGENERAL_BE12 local_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Mivacurium|P|nondepolarizing agent|quinidine|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOGENERAL_BE12 local_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Mivacurium|P|mivacron|antibiotic|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|antibiotic|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|bacitracin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|bacitracin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|polymyxin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|polymyxin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|anesthetic|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOGENERAL_BE12 local_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|anesthetic|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOGENERAL_BE12 local_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|procainamide|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOGENERAL_BE12 local_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|procainamide|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOGENERAL_BE12 local_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|magnesium|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|magnesium|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|lithium|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOENTITY local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|lithium|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOENTITY local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|lithium|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOENTITY local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|lithium|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOENTITY local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|anesthetic|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOGENERAL_BE12 local_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|anesthetic|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOGENERAL_BE12 local_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|procainamide|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOGENERAL_BE12 local_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|procainamide|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOGENERAL_BE12 local_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|quinidine|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOGENERAL_BE12 local_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Mivacurium|P|mivacron|quinidine|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOGENERAL_BE12 local_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Mivacurium|P|nondepolarizing agent|sodium colistimethate|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|sodium colistimethate|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|lincomycin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|lincomycin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|colistin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|colistin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|clindamycin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|clindamycin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|clindamycin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|clindamycin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|colistin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|colistin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|lincomycin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|lincomycin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|sodium colistimethate|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|sodium colistimethate|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|polymyxin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|polymyxin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|magnesium|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|magnesium|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|tetracycline|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|tetracycline|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|bacitracin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|bacitracin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|antibiotic|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|antibiotic|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|aminoglycoside|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|nondepolarizing agent|aminoglycoside|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|glucocorticoid|the_LE1 neuromuscular_LE1 blocking_LE1 effect_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 enhance_BE12 by_BE12 drug_BE12 that_BE12 reduce_BE12 plasma_BE12 cholinesterase_BE12 activity_BE12 -LRB-_BE12 e.g._BE12 chronic_BE12 administer_BE12 oral_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 certain_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 by_RE2 drug_RE2 that_RE2 irreversible_RE2 inhibit_RE2 plasma_RE2 cholinesterase_RE2 resistance_RE2 to_RE2 the_RE2 neuromuscular_RE2 block_RE2 action_RE2 of_RE2 nondepolarizing_RE2 BIOGENERAL_RE2 have_RE2 be_RE2 demonstrate_RE2 in_RE2 patient_RE2 chronic_RE2 administer_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|glucocorticoid|the_LE1 neuromuscular_LE1 blocking_LE1 effect_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 enhance_BE12 by_BE12 drug_BE12 that_BE12 reduce_BE12 plasma_BE12 cholinesterase_BE12 activity_BE12 -LRB-_BE12 e.g._BE12 chronic_BE12 administer_BE12 oral_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 certain_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 by_RE2 drug_RE2 that_RE2 irreversible_RE2 inhibit_RE2 plasma_RE2 cholinesterase_RE2 resistance_RE2 to_RE2 the_RE2 neuromuscular_RE2 block_RE2 action_RE2 of_RE2 nondepolarizing_RE2 BIOGENERAL_RE2 have_RE2 be_RE2 demonstrate_RE2 in_RE2 patient_RE2 chronic_RE2 administer_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|contraceptive|the_LE1 neuromuscular_LE1 blocking_LE1 effect_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 enhance_BE12 by_BE12 drug_BE12 that_BE12 reduce_BE12 plasma_BE12 cholinesterase_BE12 activity_BE12 -LRB-_BE12 e.g._BE12 chronic_BE12 administer_BE12 oral_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 certain_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 by_RE2 drug_RE2 that_RE2 irreversible_RE2 inhibit_RE2 plasma_RE2 cholinesterase_RE2 resistance_RE2 to_RE2 the_RE2 neuromuscular_RE2 block_RE2 action_RE2 of_RE2 nondepolarizing_RE2 BIOGENERAL_RE2 have_RE2 be_RE2 demonstrate_RE2 in_RE2 patient_RE2 chronic_RE2 administer_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|contraceptive|the_LE1 neuromuscular_LE1 blocking_LE1 effect_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 enhance_BE12 by_BE12 drug_BE12 that_BE12 reduce_BE12 plasma_BE12 cholinesterase_BE12 activity_BE12 -LRB-_BE12 e.g._BE12 chronic_BE12 administer_BE12 oral_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 certain_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 by_RE2 drug_RE2 that_RE2 irreversible_RE2 inhibit_RE2 plasma_RE2 cholinesterase_RE2 resistance_RE2 to_RE2 the_RE2 neuromuscular_RE2 block_RE2 action_RE2 of_RE2 nondepolarizing_RE2 BIOGENERAL_RE2 have_RE2 be_RE2 demonstrate_RE2 in_RE2 patient_RE2 chronic_RE2 administer_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|monoamine oxidase inhibitor|the_LE1 neuromuscular_LE1 blocking_LE1 effect_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 enhance_BE12 by_BE12 drug_BE12 that_BE12 reduce_BE12 plasma_BE12 cholinesterase_BE12 activity_BE12 -LRB-_BE12 e.g._BE12 chronic_BE12 administer_BE12 oral_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 certain_BE12 BIOENTITY -RRB-_RE2 or_RE2 by_RE2 drug_RE2 that_RE2 irreversible_RE2 inhibit_RE2 plasma_RE2 cholinesterase_RE2 resistance_RE2 to_RE2 the_RE2 neuromuscular_RE2 block_RE2 action_RE2 of_RE2 nondepolarizing_RE2 BIOGENERAL_RE2 have_RE2 be_RE2 demonstrate_RE2 in_RE2 patient_RE2 chronic_RE2 administer_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Mivacurium|P|mivacron|monoamine oxidase inhibitor|the_LE1 neuromuscular_LE1 blocking_LE1 effect_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 enhance_BE12 by_BE12 drug_BE12 that_BE12 reduce_BE12 plasma_BE12 cholinesterase_BE12 activity_BE12 -LRB-_BE12 e.g._BE12 chronic_BE12 administer_BE12 oral_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 certain_BE12 BIOENTITY -RRB-_RE2 or_RE2 by_RE2 drug_RE2 that_RE2 irreversible_RE2 inhibit_RE2 plasma_RE2 cholinesterase_RE2 resistance_RE2 to_RE2 the_RE2 neuromuscular_RE2 block_RE2 action_RE2 of_RE2 nondepolarizing_RE2 BIOGENERAL_RE2 have_RE2 be_RE2 demonstrate_RE2 in_RE2 patient_RE2 chronic_RE2 administer_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Mivacurium|P|neuromuscular blocking agent|carbamazepine|the_LE1 neuromuscular_LE1 blocking_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 may_LE1 be_LE1 enhance_LE1 by_LE1 drug_LE1 that_LE1 reduce_LE1 plasma_LE1 cholinesterase_LE1 activity_LE1 -LRB-_LE1 e.g._LE1 chronic_LE1 administer_LE1 oral_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 or_LE1 certain_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 by_LE1 drug_LE1 that_LE1 irreversible_LE1 inhibit_LE1 plasma_LE1 cholinesterase_LE1 resistance_LE1 to_LE1 the_LE1 neuromuscular_LE1 block_LE1 action_LE1 of_LE1 nondepolarizing_LE1 BIOENTITY have_BE12 be_BE12 demonstrate_BE12 in_BE12 patient_BE12 chronic_BE12 administer_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Mivacurium|P|neuromuscular blocking agent|phenytoin|the_LE1 neuromuscular_LE1 blocking_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 may_LE1 be_LE1 enhance_LE1 by_LE1 drug_LE1 that_LE1 reduce_LE1 plasma_LE1 cholinesterase_LE1 activity_LE1 -LRB-_LE1 e.g._LE1 chronic_LE1 administer_LE1 oral_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 or_LE1 certain_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 by_LE1 drug_LE1 that_LE1 irreversible_LE1 inhibit_LE1 plasma_LE1 cholinesterase_LE1 resistance_LE1 to_LE1 the_LE1 neuromuscular_LE1 block_LE1 action_LE1 of_LE1 nondepolarizing_LE1 BIOENTITY have_BE12 be_BE12 demonstrate_BE12 in_BE12 patient_BE12 chronic_BE12 administer_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Mivacurium|P|carbamazepine|mivacron|while_LE1 the_LE1 effect_LE1 of_LE1 chronic_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY therapy_BE12 on_BE12 the_BE12 action_BE12 of_BE12 BIOENTITY be_RE2 unknown_RE2 slight_RE2 short_RE2 duration_RE2 of_RE2 neuromuscular_RE2 block_RE2 may_RE2 be_RE2 anticipate_RE2 and_RE2 infusion_RE2 rate_RE2 requirement_RE2 may_RE2 be_RE2 high_RE2 
Mivacurium|P|phenytoin|mivacron|while_LE1 the_LE1 effect_LE1 of_LE1 chronic_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 therapy_BE12 on_BE12 the_BE12 action_BE12 of_BE12 BIOENTITY be_RE2 unknown_RE2 slight_RE2 short_RE2 duration_RE2 of_RE2 neuromuscular_RE2 block_RE2 may_RE2 be_RE2 anticipate_RE2 and_RE2 infusion_RE2 rate_RE2 requirement_RE2 may_RE2 be_RE2 high_RE2 
Moexipril|P|spironolactone|ace inhibitor|use_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 supplement_BE12 concomitant_BE12 with_BE12 BIOENTITY can_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 hyperkalemia_RE2 
Moexipril|P|potassium-sparing diuretic|ace inhibitor|use_LE1 of_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 supplement_BE12 concomitant_BE12 with_BE12 BIOENTITY can_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 hyperkalemia_RE2 
Moexipril|P|triamterene|ace inhibitor|use_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 supplement_BE12 concomitant_BE12 with_BE12 BIOENTITY can_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 hyperkalemia_RE2 
Moexipril|P|potassium|ace inhibitor|use_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 BIOENTITY supplement_BE12 concomitant_BE12 with_BE12 BIOENTITY can_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 hyperkalemia_RE2 
Moexipril|P|amiloride|ace inhibitor|use_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 or_BE12 BIOGENERAL_BE12 supplement_BE12 concomitant_BE12 with_BE12 BIOENTITY can_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 hyperkalemia_RE2 
Moexipril|P|ace inhibitor|lithium|BIOGENERAL_LE1 :_LE1 increase_LE1 serum_LE1 BIOGENERAL_LE1 level_LE1 and_LE1 symptom_LE1 of_LE1 BIOGENERAL_LE1 toxicity_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY during_BE12 therapy_BE12 with_BE12 BIOENTITY 
Moexipril|P|diuretic|lithium|if_LE1 BIOENTITY be_BE12 also_BE12 use_BE12 the_BE12 risk_BE12 of_BE12 BIOENTITY toxicity_RE2 may_RE2 be_RE2 increase_RE2 
Mometasone|P|ketoconazole|mometasone furoate|however_LE1 BIOENTITY potent_BE12 inhibitor_BE12 of_BE12 cytochrome_BE12 may_BE12 increase_BE12 plasma_BE12 level_BE12 of_BE12 BIOENTITY during_RE2 concomitant_RE2 dosing_RE2 
Montelukast|P|rifampin|montelukast|it_LE1 be_LE1 reasonable_LE1 to_LE1 employ_LE1 appropriate_LE1 clinical_LE1 monitoring_LE1 when_LE1 potent_LE1 cytochrome_LE1 enzyme_LE1 inducer_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Montelukast|P|phenobarbital|montelukast|it_LE1 be_LE1 reasonable_LE1 to_LE1 employ_LE1 appropriate_LE1 clinical_LE1 monitoring_LE1 when_LE1 potent_LE1 cytochrome_LE1 enzyme_LE1 inducer_LE1 such_LE1 as_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 be_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Montelukast|P|rifampin|montelukast|it_LE1 be_LE1 reasonable_LE1 to_LE1 employ_LE1 appropriate_LE1 clinical_LE1 monitoring_LE1 when_LE1 potent_LE1 cytochrome_LE1 enzyme_LE1 inducer_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Montelukast|P|phenobarbital|montelukast|it_LE1 be_LE1 reasonable_LE1 to_LE1 employ_LE1 appropriate_LE1 clinical_LE1 monitoring_LE1 when_LE1 potent_LE1 cytochrome_LE1 enzyme_LE1 inducer_LE1 such_LE1 as_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 be_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Morphine|P|morphine|psychotropic drug|use_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 :_LE1 the_LE1 depressant_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 potentiate_BE12 by_BE12 the_BE12 presence_BE12 of_BE12 other_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Morphine|P|morphine|cns depressant|use_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 :_LE1 the_LE1 depressant_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 potentiate_BE12 by_BE12 the_BE12 presence_BE12 of_BE12 other_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Morphine|P|morphine|sedative|use_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 :_LE1 the_LE1 depressant_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 potentiate_BE12 by_BE12 the_BE12 presence_BE12 of_BE12 other_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Morphine|P|morphine|alcohol|use_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 :_LE1 the_LE1 depressant_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 potentiate_BE12 by_BE12 the_BE12 presence_BE12 of_BE12 other_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Morphine|P|morphine|antihistaminic|use_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 :_LE1 the_LE1 depressant_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 potentiate_BE12 by_BE12 the_BE12 presence_BE12 of_BE12 other_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Morphine|P|neuroleptic|morphine|use_LE1 of_LE1 BIOENTITY in_BE12 conjunction_BE12 with_BE12 oral_BE12 BIOENTITY may_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 respiratory_RE2 depression_RE2 hypotension_RE2 and_RE2 profound_RE2 sedation_RE2 or_RE2 coma_RE2 
Morphine|P|agonist/antagonist analgesic|opioid agonist analgesic|interaction_LE1 with_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY -LRB-_BE12 i.e._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 to_BE12 patient_BE12 who_BE12 have_BE12 receive_BE12 or_BE12 be_BE12 receive_BE12 course_BE12 of_BE12 therapy_BE12 with_BE12 proof_BE12 BIOENTITY 
Morphine|P|agonist/antagonist analgesic|opioid agonist analgesic|interaction_LE1 with_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY -LRB-_BE12 i.e._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 to_BE12 patient_BE12 who_BE12 have_BE12 receive_BE12 or_BE12 be_BE12 receive_BE12 course_BE12 of_BE12 therapy_BE12 with_BE12 proof_BE12 BIOENTITY 
Morphine|P|buprenorphine|opioid agonist analgesic|interaction_LE1 with_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 -LRB-_LE1 i.e._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY -RRB-_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 to_BE12 patient_BE12 who_BE12 have_BE12 receive_BE12 or_BE12 be_BE12 receive_BE12 course_BE12 of_BE12 therapy_BE12 with_BE12 proof_BE12 BIOENTITY 
Morphine|P|buprenorphine|opioid agonist analgesic|interaction_LE1 with_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 -LRB-_LE1 i.e._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY -RRB-_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 to_BE12 patient_BE12 who_BE12 have_BE12 receive_BE12 or_BE12 be_BE12 receive_BE12 course_BE12 of_BE12 therapy_BE12 with_BE12 proof_BE12 BIOENTITY 
Morphine|P|pentazocine|opioid agonist analgesic|interaction_LE1 with_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 -LRB-_LE1 i.e._LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 to_BE12 patient_BE12 who_BE12 have_BE12 receive_BE12 or_BE12 be_BE12 receive_BE12 course_BE12 of_BE12 therapy_BE12 with_BE12 proof_BE12 BIOENTITY 
Morphine|P|pentazocine|opioid agonist analgesic|interaction_LE1 with_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 -LRB-_LE1 i.e._LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 to_BE12 patient_BE12 who_BE12 have_BE12 receive_BE12 or_BE12 be_BE12 receive_BE12 course_BE12 of_BE12 therapy_BE12 with_BE12 proof_BE12 BIOENTITY 
Morphine|P|nalbuphine|opioid agonist analgesic|interaction_LE1 with_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 -LRB-_LE1 i.e._LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 to_BE12 patient_BE12 who_BE12 have_BE12 receive_BE12 or_BE12 be_BE12 receive_BE12 course_BE12 of_BE12 therapy_BE12 with_BE12 proof_BE12 BIOENTITY 
Morphine|P|nalbuphine|opioid agonist analgesic|interaction_LE1 with_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 -LRB-_LE1 i.e._LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 to_BE12 patient_BE12 who_BE12 have_BE12 receive_BE12 or_BE12 be_BE12 receive_BE12 course_BE12 of_BE12 therapy_BE12 with_BE12 proof_BE12 BIOENTITY 
Morphine|P|butorphanol|opioid agonist analgesic|interaction_LE1 with_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 -LRB-_LE1 i.e._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 to_BE12 patient_BE12 who_BE12 have_BE12 receive_BE12 or_BE12 be_BE12 receive_BE12 course_BE12 of_BE12 therapy_BE12 with_BE12 proof_BE12 BIOENTITY 
Morphine|P|butorphanol|opioid agonist analgesic|interaction_LE1 with_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 -LRB-_LE1 i.e._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 to_BE12 patient_BE12 who_BE12 have_BE12 receive_BE12 or_BE12 be_BE12 receive_BE12 course_BE12 of_BE12 therapy_BE12 with_BE12 proof_BE12 BIOENTITY 
Mycophenolic acid|P|myfortic|magnesium|BIOGENERAL_LE1 :_LE1 absorption_LE1 of_LE1 single_LE1 dose_LE1 of_LE1 BIOENTITY be_BE12 decrease_BE12 when_BE12 administer_BE12 to_BE12 NUM_BE12 stable_BE12 renal_BE12 transplant_BE12 patient_BE12 also_BE12 take_BE12 BIOENTITY contain_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 ml_RE2 -RRB-_RE2 :_RE2 the_RE2 mean_RE2 cmax_RE2 and_RE2 auc_RE2 -LRB-_RE2 -RRB-_RE2 value_RE2 for_RE2 mpa_RE2 be_RE2 NUM_RE2 and_RE2 NUM_RE2 low_RE2 respective_RE2 than_RE2 when_RE2 BIOGENERAL_RE2 be_RE2 administer_RE2 alone_RE2 under_RE2 fast_RE2 condition_RE2 
Mycophenolic acid|P|myfortic|magnesium|BIOGENERAL_LE1 :_LE1 absorption_LE1 of_LE1 single_LE1 dose_LE1 of_LE1 BIOENTITY be_BE12 decrease_BE12 when_BE12 administer_BE12 to_BE12 NUM_BE12 stable_BE12 renal_BE12 transplant_BE12 patient_BE12 also_BE12 take_BE12 BIOENTITY contain_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 ml_RE2 -RRB-_RE2 :_RE2 the_RE2 mean_RE2 cmax_RE2 and_RE2 auc_RE2 -LRB-_RE2 -RRB-_RE2 value_RE2 for_RE2 mpa_RE2 be_RE2 NUM_RE2 and_RE2 NUM_RE2 low_RE2 respective_RE2 than_RE2 when_RE2 BIOGENERAL_RE2 be_RE2 administer_RE2 alone_RE2 under_RE2 fast_RE2 condition_RE2 
Mycophenolic acid|P|myfortic|antacid|it_LE1 be_LE1 recommend_LE1 that_LE1 BIOENTITY and_BE12 BIOENTITY not_RE2 be_RE2 administer_RE2 simultaneous_RE2 
Mycophenolic acid|P|myfortic|azathioprine|BIOGENERAL_LE1 BIOGENERAL_LE1 :_LE1 given_LE1 that_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 inhibit_LE1 purine_LE1 metabolism_LE1 it_LE1 be_LE1 recommend_LE1 that_LE1 BIOENTITY not_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Mycophenolic acid|P|myfortic|mycophenolate mofetil|BIOGENERAL_LE1 BIOGENERAL_LE1 :_LE1 given_LE1 that_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 inhibit_LE1 purine_LE1 metabolism_LE1 it_LE1 be_LE1 recommend_LE1 that_LE1 BIOENTITY not_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Mycophenolic acid|P|myfortic|cholestyramine|therefore_LE1 do_LE1 not_LE1 administer_LE1 BIOENTITY with_BE12 BIOENTITY or_RE2 other_RE2 agent_RE2 that_RE2 may_RE2 interfere_RE2 with_RE2 enterohepatic_RE2 recirculation_RE2 or_RE2 drug_RE2 that_RE2 may_RE2 bind_RE2 bile_RE2 acid_RE2 for_RE2 example_RE2 bile_RE2 acid_RE2 sequestrate_RE2 or_RE2 oral_RE2 BIOGENERAL_RE2 because_RE2 of_RE2 the_RE2 potential_RE2 to_RE2 reduce_RE2 the_RE2 efficacy_RE2 of_RE2 BIOGENERAL_RE2 
Mycophenolic acid|P|myfortic|activated charcoal|therefore_LE1 do_LE1 not_LE1 administer_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 agent_BE12 that_BE12 may_BE12 interfere_BE12 with_BE12 enterohepatic_BE12 recirculation_BE12 or_BE12 drug_BE12 that_BE12 may_BE12 bind_BE12 bile_BE12 acid_BE12 for_BE12 example_BE12 bile_BE12 acid_BE12 sequestrate_BE12 or_BE12 oral_BE12 BIOENTITY because_RE2 of_RE2 the_RE2 potential_RE2 to_RE2 reduce_RE2 the_RE2 efficacy_RE2 of_RE2 BIOGENERAL_RE2 
Mycophenolic acid|P|myfortic|activated charcoal|therefore_LE1 do_LE1 not_LE1 administer_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 agent_BE12 that_BE12 may_BE12 interfere_BE12 with_BE12 enterohepatic_BE12 recirculation_BE12 or_BE12 drug_BE12 that_BE12 may_BE12 bind_BE12 bile_BE12 acid_BE12 for_BE12 example_BE12 bile_BE12 acid_BE12 sequestrate_BE12 or_BE12 oral_BE12 BIOENTITY because_RE2 of_RE2 the_RE2 potential_RE2 to_RE2 reduce_RE2 the_RE2 efficacy_RE2 of_RE2 BIOGENERAL_RE2 
Mycophenolic acid|P|levonorgesterol|mycophenolate mofetil|however_LE1 in_LE1 drugdrug_LE1 interaction_LE1 study_LE1 mean_LE1 BIOENTITY auc_BE12 be_BE12 decrease_BE12 by_BE12 NUM_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Mycophenolic acid|P|contraceptive|myfortic|therefore_LE1 it_LE1 be_LE1 recommend_LE1 that_LE1 oral_LE1 BIOENTITY be_BE12 co_BE12 administer_BE12 with_BE12 BIOENTITY with_RE2 caution_RE2 and_RE2 additional_RE2 birth_RE2 control_RE2 method_RE2 be_RE2 consider_RE2 
Mycophenolic acid|P|myfortic|live attenuated vaccine|BIOGENERAL_LE1 :_LE1 During_LE1 treatment_LE1 with_LE1 BIOENTITY the_BE12 use_BE12 of_BE12 BIOENTITY shall_RE2 be_RE2 avoid_RE2 and_RE2 patient_RE2 shall_RE2 be_RE2 advise_RE2 that_RE2 vaccinations_RE2 may_RE2 be_RE2 little_RE2 effective_RE2 
Ondansetron|P|carbamazepine|ondansetron|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 In_LE1 patient_LE1 treat_LE1 with_LE1 potent_LE1 inducer_LE1 of_LE1 cypa_LE1 -LRB-_LE1 i.e._LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -RRB-_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 be_BE12 significant_BE12 increase_BE12 and_BE12 BIOENTITY blood_RE2 concentration_RE2 be_RE2 decrease_RE2 
Ondansetron|P|rifampicin|ondansetron|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 In_LE1 patient_LE1 treat_LE1 with_LE1 potent_LE1 inducer_LE1 of_LE1 cypa_LE1 -LRB-_LE1 i.e._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY -RRB-_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY be_RE2 significant_RE2 increase_RE2 and_RE2 BIOGENERAL_RE2 blood_RE2 concentration_RE2 be_RE2 decrease_RE2 
Ondansetron|P|rifampicin|ondansetron|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 In_LE1 patient_LE1 treat_LE1 with_LE1 potent_LE1 inducer_LE1 of_LE1 cypa_LE1 -LRB-_LE1 i.e._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY -RRB-_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 be_BE12 significant_BE12 increase_BE12 and_BE12 BIOENTITY blood_RE2 concentration_RE2 be_RE2 decrease_RE2 
Ondansetron|P|phenytoin|ondansetron|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 In_LE1 patient_LE1 treat_LE1 with_LE1 potent_LE1 inducer_LE1 of_LE1 cypa_LE1 -LRB-_LE1 i.e._LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY be_RE2 significant_RE2 increase_RE2 and_RE2 BIOGENERAL_RE2 blood_RE2 concentration_RE2 be_RE2 decrease_RE2 
Ondansetron|P|phenytoin|ondansetron|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 In_LE1 patient_LE1 treat_LE1 with_LE1 potent_LE1 inducer_LE1 of_LE1 cypa_LE1 -LRB-_LE1 i.e._LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 be_BE12 significant_BE12 increase_BE12 and_BE12 BIOENTITY blood_RE2 concentration_RE2 be_RE2 decrease_RE2 
Ondansetron|P|carbamazepine|ondansetron|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 In_LE1 patient_LE1 treat_LE1 with_LE1 potent_LE1 inducer_LE1 of_LE1 cypa_LE1 -LRB-_LE1 i.e._LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -RRB-_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY be_RE2 significant_RE2 increase_RE2 and_RE2 BIOGENERAL_RE2 blood_RE2 concentration_RE2 be_RE2 decrease_RE2 
Ondansetron|P|ondansetron|tramadol|however_LE1 on_LE1 the_LE1 basis_LE1 of_LE1 available_LE1 datum_LE1 no_LE1 dosage_LE1 adjustment_LE1 for_LE1 BIOGENERAL_LE1 be_LE1 recommend_LE1 for_LE1 patient_LE1 on_LE1 these_LE1 drugs.,_LE1 BIOGENERAL_LE1 :_LE1 although_LE1 no_LE1 pharmacokinetic_LE1 drug_LE1 interaction_LE1 between_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 have_LE1 be_LE1 observe_LE1 datum_LE1 from_LE1 NUM_LE1 small_LE1 study_LE1 indicate_LE1 that_LE1 BIOENTITY may_BE12 be_BE12 associate_BE12 with_BE12 increase_BE12 in_BE12 patient_BE12 controlled_BE12 administration_BE12 of_BE12 BIOENTITY chemotherapy_RE2 :_RE2 tumor_RE2 response_RE2 to_RE2 chemotherapy_RE2 in_RE2 the_RE2 NUM_RE2 mouse_RE2 leukemia_RE2 model_RE2 be_RE2 not_RE2 affect_RE2 by_RE2 BIOGENERAL_RE2 
Orciprenaline|P|beta adrenergic aerosol bronchodilator|alupent|other_LE1 BIOENTITY shall_BE12 not_BE12 be_BE12 use_BE12 concomitant_BE12 with_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 usp_RE2 -RRB-_RE2 because_RE2 they_RE2 may_RE2 have_RE2 additive_RE2 effect_RE2 
Orciprenaline|P|beta adrenergic aerosol bronchodilator|metaproterenol sulfate|other_LE1 BIOENTITY shall_BE12 not_BE12 be_BE12 use_BE12 concomitant_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY usp_RE2 -RRB-_RE2 because_RE2 they_RE2 may_RE2 have_RE2 additive_RE2 effect_RE2 
Orciprenaline|P|beta adrenergic agonist|monoamine oxidase inhibitor|BIOENTITY shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 to_BE12 patient_BE12 be_BE12 treat_BE12 with_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 since_RE2 the_RE2 action_RE2 of_RE2 BIOGENERAL_RE2 on_RE2 the_RE2 vascular_RE2 system_RE2 may_RE2 be_RE2 potentiate_RE2 
Orciprenaline|P|beta adrenergic agonist|tricyclic antidepressant|BIOENTITY shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 to_BE12 patient_BE12 be_BE12 treat_BE12 with_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY since_RE2 the_RE2 action_RE2 of_RE2 BIOGENERAL_RE2 on_RE2 the_RE2 vascular_RE2 system_RE2 may_RE2 be_RE2 potentiate_RE2 
Orlistat|P|xenical|cyclosporine|BIOGENERAL_LE1 :_LE1 preliminary_LE1 datum_LE1 from_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 drug_LE1 interaction_LE1 study_LE1 indicate_LE1 reduction_LE1 in_LE1 BIOGENERAL_LE1 plasma_LE1 level_LE1 when_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Orlistat|P|beta-carotene|xenical|BIOGENERAL_LE1 and_LE1 analogue_LE1 :_LE1 pharmacokinetic_LE1 interaction_LE1 study_LE1 show_LE1 NUM_LE1 reduction_LE1 in_LE1 BIOENTITY supplement_BE12 absorption_BE12 when_BE12 concomitant_BE12 administer_BE12 with_BE12 BIOENTITY 
Orlistat|P|xenical|vitamin e acetate|BIOENTITY inhibited_BE12 absorption_BE12 of_BE12 BIOENTITY supplement_RE2 by_RE2 approximate_RE2 NUM_RE2 %._RE2 
Orlistat|P|vitamin k|xenical|therefore_LE1 as_LE1 BIOENTITY absorption_BE12 may_BE12 be_BE12 decrease_BE12 with_BE12 BIOENTITY patient_RE2 on_RE2 chronic_RE2 stable_RE2 dose_RE2 of_RE2 BIOGENERAL_RE2 who_RE2 be_RE2 prescribe_RE2 BIOGENERAL_RE2 shall_RE2 be_RE2 monitor_RE2 close_RE2 for_RE2 change_RE2 in_RE2 coagulation_RE2 parameter_RE2 
Orlistat|P|warfarin|xenical|therefore_LE1 as_LE1 BIOGENERAL_LE1 absorption_LE1 may_LE1 be_LE1 decrease_LE1 with_LE1 BIOGENERAL_LE1 patient_LE1 on_LE1 chronic_LE1 stable_LE1 dose_LE1 of_LE1 BIOENTITY who_BE12 be_BE12 prescribe_BE12 BIOENTITY shall_RE2 be_RE2 monitor_RE2 close_RE2 for_RE2 change_RE2 in_RE2 coagulation_RE2 parameter_RE2 
Orlistat|P|warfarin|xenical|therefore_LE1 as_LE1 BIOGENERAL_LE1 absorption_LE1 may_LE1 be_LE1 decrease_LE1 with_LE1 BIOGENERAL_LE1 patient_LE1 on_LE1 chronic_LE1 stable_LE1 dose_LE1 of_LE1 BIOENTITY who_BE12 be_BE12 prescribe_BE12 BIOENTITY shall_RE2 be_RE2 monitor_RE2 close_RE2 for_RE2 change_RE2 in_RE2 coagulation_RE2 parameter_RE2 
Oxacillin|P|tetracycline|penicillin|BIOENTITY bacteriostatic_BE12 BIOGENERAL_BE12 may_BE12 antagonize_BE12 the_BE12 bactericidal_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 concurrent_RE2 use_RE2 of_RE2 these_RE2 drug_RE2 shall_RE2 be_RE2 avoid_RE2 
Oxaliplatin|P|5-fu|eloxatin|increase_LE1 of_LE1 BIOENTITY plasma_BE12 concentration_BE12 by_BE12 approximate_BE12 NUM_BE12 have_BE12 be_BE12 observe_BE12 with_BE12 dose_BE12 of_BE12 NUM_BE12 mg_BE12 BIOENTITY dose_RE2 every_RE2 NUM_RE2 week_RE2 
Oxandrolone|P|anabolic steroid|anticoagulant|BIOGENERAL_LE1 BIOENTITY may_BE12 increase_BE12 sensitivity_BE12 to_BE12 oral_BE12 BIOENTITY 
Oxandrolone|P|oxandrolone|warfarin|BIOGENERAL_LE1 :_LE1 multidose_LE1 study_LE1 of_LE1 BIOENTITY give_BE12 as_BE12 NUM_BE12 or_BE12 NUM_BE12 mg_BE12 bid_BE12 in_BE12 NUM_BE12 healthy_BE12 subject_BE12 concurrent_BE12 treat_BE12 with_BE12 BIOENTITY result_RE2 in_RE2 mean_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 halflife_RE2 from_RE2 NUM_RE2 to_RE2 NUM_RE2 hour_RE2 and_RE2 auc_RE2 from_RE2 to_RE2 ng_RE2 hr_RE2 :_RE2 similar_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 halflife_RE2 and_RE2 auc_RE2 be_RE2 also_RE2 detect_RE2 
Oxandrolone|P|oxandrolone|warfarin|when_LE1 BIOENTITY therapy_BE12 be_BE12 initiate_BE12 in_BE12 patient_BE12 already_BE12 receive_BE12 treatment_BE12 with_BE12 BIOENTITY the_RE2 inr_RE2 or_RE2 prothrombin_RE2 time_RE2 -LRB-_RE2 pt_RE2 -RRB-_RE2 shall_RE2 be_RE2 monitor_RE2 close_RE2 and_RE2 the_RE2 dose_RE2 of_RE2 BIOGENERAL_RE2 adjust_RE2 as_RE2 necessary_RE2 until_RE2 stable_RE2 target_RE2 inr_RE2 or_RE2 pt_RE2 have_RE2 be_RE2 achieve_RE2 
Oxandrolone|P|warfarin|oxandrolone|furthermore_LE1 in_LE1 patient_LE1 receive_LE1 both_LE1 drug_LE1 careful_LE1 monitoring_LE1 of_LE1 the_LE1 inr_LE1 or_LE1 pt_LE1 and_LE1 adjustment_LE1 of_LE1 the_LE1 BIOENTITY dosage_BE12 if_BE12 indicate_BE12 be_BE12 recommend_BE12 when_BE12 the_BE12 BIOENTITY dose_RE2 be_RE2 change_RE2 or_RE2 discontinue_RE2 
Oxandrolone|P|warfarin|oxandrolone|furthermore_LE1 in_LE1 patient_LE1 receive_LE1 both_LE1 drug_LE1 careful_LE1 monitoring_LE1 of_LE1 the_LE1 inr_LE1 or_LE1 pt_LE1 and_LE1 adjustment_LE1 of_LE1 the_LE1 BIOENTITY dosage_BE12 if_BE12 indicate_BE12 be_BE12 recommend_BE12 when_BE12 the_BE12 BIOENTITY dose_RE2 be_RE2 change_RE2 or_RE2 discontinue_RE2 
Oxandrolone|P|oxandrolone|hypoglycemic agent|oral_LE1 BIOGENERAL_LE1 BIOENTITY may_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 oral_BE12 BIOENTITY 
Oxybutynin|P|oxybutynin|anticholinergic drug|the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 BIOENTITY or_RE2 with_RE2 other_RE2 agent_RE2 which_RE2 produce_RE2 dry_RE2 mouth_RE2 constipation_RE2 somnolence_RE2 -LRB-_RE2 drowsiness_RE2 -RRB-_RE2 and_RE2 other_RE2 anticholinergiclike_RE2 effect_RE2 may_RE2 increase_RE2 the_RE2 frequency_RE2 and_RE2 severity_RE2 of_RE2 such_RE2 effect_RE2 
Oxybutynin|P|ditropan xl|ketoconazole|mean_LE1 BIOGENERAL_LE1 plasma_LE1 concentration_LE1 be_LE1 approximate_LE1 NUM_LE1 fold_LE1 high_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 with_BE12 BIOENTITY potent_RE2 cypa_RE2 inhibitor_RE2 
Oxybutynin|P|erythromycin|oxybutynin|other_LE1 inhibitor_LE1 of_LE1 the_LE1 cytochrome_LE1 enzyme_LE1 system_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 alter_BE12 BIOENTITY mean_RE2 pharmacokinetic_RE2 parameter_RE2 -LRB-_RE2 i.e._RE2 cmax_RE2 and_RE2 auc_RE2 rrb._RE2 
Oxybutynin|P|macrolide antibiotic|oxybutynin|other_LE1 inhibitor_LE1 of_LE1 the_LE1 cytochrome_LE1 enzyme_LE1 system_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 BIOENTITY -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 alter_BE12 BIOENTITY mean_RE2 pharmacokinetic_RE2 parameter_RE2 -LRB-_RE2 i.e._RE2 cmax_RE2 and_RE2 auc_RE2 rrb._RE2 
Oxybutynin|P|miconazole|oxybutynin|other_LE1 inhibitor_LE1 of_LE1 the_LE1 cytochrome_LE1 enzyme_LE1 system_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY -RRB-_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 alter_BE12 BIOENTITY mean_RE2 pharmacokinetic_RE2 parameter_RE2 -LRB-_RE2 i.e._RE2 cmax_RE2 and_RE2 auc_RE2 rrb._RE2 
Oxybutynin|P|antimycotic agent|oxybutynin|other_LE1 inhibitor_LE1 of_LE1 the_LE1 cytochrome_LE1 enzyme_LE1 system_LE1 such_LE1 as_LE1 BIOENTITY -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 alter_BE12 BIOENTITY mean_RE2 pharmacokinetic_RE2 parameter_RE2 -LRB-_RE2 i.e._RE2 cmax_RE2 and_RE2 auc_RE2 rrb._RE2 
Oxybutynin|P|clarithromycin|oxybutynin|other_LE1 inhibitor_LE1 of_LE1 the_LE1 cytochrome_LE1 enzyme_LE1 system_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY -RRB-_BE12 may_BE12 alter_BE12 BIOENTITY mean_RE2 pharmacokinetic_RE2 parameter_RE2 -LRB-_RE2 i.e._RE2 cmax_RE2 and_RE2 auc_RE2 rrb._RE2 
Oxybutynin|P|itraconazole|oxybutynin|other_LE1 inhibitor_LE1 of_LE1 the_LE1 cytochrome_LE1 enzyme_LE1 system_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 alter_BE12 BIOENTITY mean_RE2 pharmacokinetic_RE2 parameter_RE2 -LRB-_RE2 i.e._RE2 cmax_RE2 and_RE2 auc_RE2 rrb._RE2 
Oxycodone|P|oxycodone hydrochloride|cns depressant|the_LE1 cns_LE1 depressant_LE1 effect_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 additive_BE12 with_BE12 that_BE12 of_BE12 other_BE12 BIOENTITY .._RE2 
Oxymorphone|P|anticholinergic|opioid analgesic|BIOENTITY or_BE12 other_BE12 medication_BE12 with_BE12 anticholinergic_BE12 activity_BE12 when_BE12 use_BE12 concurrent_BE12 with_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 increase_RE2 risk_RE2 of_RE2 urinary_RE2 retention_RE2 and_RE2 severe_RE2 constipation_RE2 which_RE2 may_RE2 lead_RE2 to_RE2 paralytic_RE2 ileu_RE2 
Oxymorphone|P|oxymorphone|propofol|it_LE1 have_LE1 be_LE1 report_LE1 that_LE1 the_LE1 incidence_LE1 of_LE1 bradycardia_LE1 be_LE1 increase_LE1 when_LE1 BIOENTITY be_BE12 combine_BE12 with_BE12 BIOENTITY for_RE2 induction_RE2 of_RE2 anesthesia_RE2 
Oxymorphone|P|cimetidine|opioid analgesic|In_LE1 addition_LE1 cns_LE1 toxicity_LE1 have_LE1 be_LE1 report_LE1 -LRB-_LE1 confusion_LE1 disorientation_LE1 respiratory_LE1 depression_LE1 apnea_LE1 seizure_LE1 -RRB-_LE1 follow_LE1 coadministration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY 
Paliperidone|P|paliperidone|centrally acting drug|given_LE1 the_LE1 primary_LE1 cns_LE1 effect_LE1 of_LE1 BIOENTITY BIOGENERAL_BE12 shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 in_BE12 combination_BE12 with_BE12 other_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Paliperidone|P|invega|alcohol|given_LE1 the_LE1 primary_LE1 cns_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 in_BE12 combination_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Paliperidone|P|invega|centrally acting drug|given_LE1 the_LE1 primary_LE1 cns_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 in_BE12 combination_BE12 with_BE12 other_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Paliperidone|P|paliperidone|alcohol|given_LE1 the_LE1 primary_LE1 cns_LE1 effect_LE1 of_LE1 BIOENTITY BIOGENERAL_BE12 shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 in_BE12 combination_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Paliperidone|P|paliperidone|dopamine agonist|BIOENTITY may_BE12 antagonize_BE12 the_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOENTITY 
Paliperidone|P|paliperidone|levodopa|BIOENTITY may_BE12 antagonize_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 other_RE2 BIOGENERAL_RE2 
Pantoprazole|P|pantoprazole|warfarin|there_LE1 have_LE1 be_LE1 postmarketing_LE1 report_LE1 of_LE1 increase_LE1 inr_LE1 and_LE1 prothrombin_LE1 time_LE1 in_LE1 patient_LE1 receive_LE1 BIOGENERAL_LE1 including_LE1 BIOENTITY and_BE12 BIOENTITY concomitant_RE2 
Pantoprazole|P|proton pump inhibitor|warfarin|there_LE1 have_LE1 be_LE1 postmarketing_LE1 report_LE1 of_LE1 increase_LE1 inr_LE1 and_LE1 prothrombin_LE1 time_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY including_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY concomitant_RE2 
Pantoprazole|P|proton pump inhibitor|warfarin|patient_LE1 treat_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY concomitant_RE2 shall_RE2 be_RE2 monitor_RE2 for_RE2 increase_RE2 in_RE2 inr_RE2 and_RE2 prothrombin_RE2 time_RE2 
Pantoprazole|P|pantoprazole|ketoconazole|Because_LE1 of_LE1 profound_LE1 and_LE1 long_LE1 lasting_LE1 inhibition_LE1 of_LE1 gastric_LE1 acid_LE1 secretion_LE1 BIOENTITY may_BE12 interfere_BE12 with_BE12 absorption_BE12 of_BE12 drug_BE12 where_BE12 gastric_BE12 ph_BE12 be_BE12 important_BE12 determinant_BE12 of_BE12 their_BE12 bioavailability_BE12 -LRB-_BE12 eg_BE12 BIOENTITY BIOGENERAL_RE2 ester_RE2 and_RE2 BIOGENERAL_RE2 salt_RE2 rrb._RE2 
Pantoprazole|P|pantoprazole|iron|Because_LE1 of_LE1 profound_LE1 and_LE1 long_LE1 lasting_LE1 inhibition_LE1 of_LE1 gastric_LE1 acid_LE1 secretion_LE1 BIOENTITY may_BE12 interfere_BE12 with_BE12 absorption_BE12 of_BE12 drug_BE12 where_BE12 gastric_BE12 ph_BE12 be_BE12 important_BE12 determinant_BE12 of_BE12 their_BE12 bioavailability_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 ester_BE12 and_BE12 BIOENTITY salt_RE2 rrb._RE2 
Pantoprazole|P|pantoprazole|ampicillin|Because_LE1 of_LE1 profound_LE1 and_LE1 long_LE1 lasting_LE1 inhibition_LE1 of_LE1 gastric_LE1 acid_LE1 secretion_LE1 BIOENTITY may_BE12 interfere_BE12 with_BE12 absorption_BE12 of_BE12 drug_BE12 where_BE12 gastric_BE12 ph_BE12 be_BE12 important_BE12 determinant_BE12 of_BE12 their_BE12 bioavailability_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOENTITY ester_RE2 and_RE2 BIOGENERAL_RE2 salt_RE2 rrb._RE2 
Paricalcitol|P|paricalcitol|nelfinavir|multiple_LE1 dose_LE1 drugdrug_LE1 interaction_LE1 study_LE1 demonstrate_LE1 that_LE1 BIOGENERAL_LE1 approximate_LE1 double_LE1 BIOGENERAL_LE1 auc_LE1 since_LE1 BIOGENERAL_LE1 be_LE1 partial_LE1 metabolize_LE1 by_LE1 cypa_LE1 and_LE1 BIOGENERAL_LE1 le_LE1 be_LE1 know_LE1 to_LE1 be_LE1 strong_LE1 inhibitor_LE1 of_LE1 cytochrome_LE1 enzyme_LE1 care_LE1 shall_LE1 be_LE1 take_LE1 while_LE1 dosing_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 strong_BE12 inhibitor_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Paricalcitol|P|paricalcitol|ritonavir|multiple_LE1 dose_LE1 drugdrug_LE1 interaction_LE1 study_LE1 demonstrate_LE1 that_LE1 BIOGENERAL_LE1 approximate_LE1 double_LE1 BIOGENERAL_LE1 auc_LE1 since_LE1 BIOGENERAL_LE1 be_LE1 partial_LE1 metabolize_LE1 by_LE1 cypa_LE1 and_LE1 BIOGENERAL_LE1 le_LE1 be_LE1 know_LE1 to_LE1 be_LE1 strong_LE1 inhibitor_LE1 of_LE1 cytochrome_LE1 enzyme_LE1 care_LE1 shall_LE1 be_LE1 take_LE1 while_LE1 dosing_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 strong_BE12 inhibitor_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Paricalcitol|P|paricalcitol|saquinavir|multiple_LE1 dose_LE1 drugdrug_LE1 interaction_LE1 study_LE1 demonstrate_LE1 that_LE1 BIOGENERAL_LE1 approximate_LE1 double_LE1 BIOGENERAL_LE1 auc_LE1 since_LE1 BIOGENERAL_LE1 be_LE1 partial_LE1 metabolize_LE1 by_LE1 cypa_LE1 and_LE1 BIOGENERAL_LE1 le_LE1 be_LE1 know_LE1 to_LE1 be_LE1 strong_LE1 inhibitor_LE1 of_LE1 cytochrome_LE1 enzyme_LE1 care_LE1 shall_LE1 be_LE1 take_LE1 while_LE1 dosing_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 strong_BE12 inhibitor_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Paricalcitol|P|paricalcitol|telithromycin|multiple_LE1 dose_LE1 drugdrug_LE1 interaction_LE1 study_LE1 demonstrate_LE1 that_LE1 BIOGENERAL_LE1 approximate_LE1 double_LE1 BIOGENERAL_LE1 auc_LE1 since_LE1 BIOGENERAL_LE1 be_LE1 partial_LE1 metabolize_LE1 by_LE1 cypa_LE1 and_LE1 BIOGENERAL_LE1 le_LE1 be_LE1 know_LE1 to_LE1 be_LE1 strong_LE1 inhibitor_LE1 of_LE1 cytochrome_LE1 enzyme_LE1 care_LE1 shall_LE1 be_LE1 take_LE1 while_LE1 dosing_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 strong_BE12 inhibitor_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Paricalcitol|P|paricalcitol|voriconazole|multiple_LE1 dose_LE1 drugdrug_LE1 interaction_LE1 study_LE1 demonstrate_LE1 that_LE1 BIOGENERAL_LE1 approximate_LE1 double_LE1 BIOGENERAL_LE1 auc_LE1 since_LE1 BIOGENERAL_LE1 be_LE1 partial_LE1 metabolize_LE1 by_LE1 cypa_LE1 and_LE1 BIOGENERAL_LE1 le_LE1 be_LE1 know_LE1 to_LE1 be_LE1 strong_LE1 inhibitor_LE1 of_LE1 cytochrome_LE1 enzyme_LE1 care_LE1 shall_LE1 be_LE1 take_LE1 while_LE1 dosing_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 strong_BE12 inhibitor_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Paricalcitol|P|paricalcitol|atazanavir|multiple_LE1 dose_LE1 drugdrug_LE1 interaction_LE1 study_LE1 demonstrate_LE1 that_LE1 BIOGENERAL_LE1 approximate_LE1 double_LE1 BIOGENERAL_LE1 auc_LE1 since_LE1 BIOGENERAL_LE1 be_LE1 partial_LE1 metabolize_LE1 by_LE1 cypa_LE1 and_LE1 BIOGENERAL_LE1 le_LE1 be_LE1 know_LE1 to_LE1 be_LE1 strong_LE1 inhibitor_LE1 of_LE1 cytochrome_LE1 enzyme_LE1 care_LE1 shall_LE1 be_LE1 take_LE1 while_LE1 dosing_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 strong_BE12 inhibitor_BE12 including_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Paricalcitol|P|paricalcitol|ketoconazole|multiple_LE1 dose_LE1 drugdrug_LE1 interaction_LE1 study_LE1 demonstrate_LE1 that_LE1 BIOGENERAL_LE1 approximate_LE1 double_LE1 BIOGENERAL_LE1 auc_LE1 since_LE1 BIOGENERAL_LE1 be_LE1 partial_LE1 metabolize_LE1 by_LE1 cypa_LE1 and_LE1 BIOGENERAL_LE1 le_LE1 be_LE1 know_LE1 to_LE1 be_LE1 strong_LE1 inhibitor_LE1 of_LE1 cytochrome_LE1 enzyme_LE1 care_LE1 shall_LE1 be_LE1 take_LE1 while_LE1 dosing_LE1 BIOENTITY with_BE12 BIOENTITY and_RE2 other_RE2 strong_RE2 inhibitor_RE2 including_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Paricalcitol|P|paricalcitol|indinavir|multiple_LE1 dose_LE1 drugdrug_LE1 interaction_LE1 study_LE1 demonstrate_LE1 that_LE1 BIOGENERAL_LE1 approximate_LE1 double_LE1 BIOGENERAL_LE1 auc_LE1 since_LE1 BIOGENERAL_LE1 be_LE1 partial_LE1 metabolize_LE1 by_LE1 cypa_LE1 and_LE1 BIOGENERAL_LE1 le_LE1 be_LE1 know_LE1 to_LE1 be_LE1 strong_LE1 inhibitor_LE1 of_LE1 cytochrome_LE1 enzyme_LE1 care_LE1 shall_LE1 be_LE1 take_LE1 while_LE1 dosing_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 strong_BE12 inhibitor_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Paricalcitol|P|ketoconazole|paricalcitol|multiple_LE1 dose_LE1 drugdrug_LE1 interaction_LE1 study_LE1 demonstrate_LE1 that_LE1 BIOENTITY approximate_BE12 double_BE12 BIOENTITY auc_RE2 since_RE2 BIOGENERAL_RE2 be_RE2 partial_RE2 metabolize_RE2 by_RE2 cypa_RE2 and_RE2 BIOGENERAL_RE2 le_RE2 be_RE2 know_RE2 to_RE2 be_RE2 strong_RE2 inhibitor_RE2 of_RE2 cytochrome_RE2 enzyme_RE2 care_RE2 shall_RE2 be_RE2 take_RE2 while_RE2 dosing_RE2 BIOGENERAL_RE2 with_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 strong_RE2 inhibitor_RE2 including_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Paricalcitol|P|paricalcitol|clarithromycin|multiple_LE1 dose_LE1 drugdrug_LE1 interaction_LE1 study_LE1 demonstrate_LE1 that_LE1 BIOGENERAL_LE1 approximate_LE1 double_LE1 BIOGENERAL_LE1 auc_LE1 since_LE1 BIOGENERAL_LE1 be_LE1 partial_LE1 metabolize_LE1 by_LE1 cypa_LE1 and_LE1 BIOGENERAL_LE1 le_LE1 be_LE1 know_LE1 to_LE1 be_LE1 strong_LE1 inhibitor_LE1 of_LE1 cytochrome_LE1 enzyme_LE1 care_LE1 shall_LE1 be_LE1 take_LE1 while_LE1 dosing_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 strong_BE12 inhibitor_BE12 including_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Paricalcitol|P|paricalcitol|nefazodone|multiple_LE1 dose_LE1 drugdrug_LE1 interaction_LE1 study_LE1 demonstrate_LE1 that_LE1 BIOGENERAL_LE1 approximate_LE1 double_LE1 BIOGENERAL_LE1 auc_LE1 since_LE1 BIOGENERAL_LE1 be_LE1 partial_LE1 metabolize_LE1 by_LE1 cypa_LE1 and_LE1 BIOGENERAL_LE1 le_LE1 be_LE1 know_LE1 to_LE1 be_LE1 strong_LE1 inhibitor_LE1 of_LE1 cytochrome_LE1 enzyme_LE1 care_LE1 shall_LE1 be_LE1 take_LE1 while_LE1 dosing_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 strong_BE12 inhibitor_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Paricalcitol|P|paricalcitol|itraconazole|multiple_LE1 dose_LE1 drugdrug_LE1 interaction_LE1 study_LE1 demonstrate_LE1 that_LE1 BIOGENERAL_LE1 approximate_LE1 double_LE1 BIOGENERAL_LE1 auc_LE1 since_LE1 BIOGENERAL_LE1 be_LE1 partial_LE1 metabolize_LE1 by_LE1 cypa_LE1 and_LE1 BIOGENERAL_LE1 le_LE1 be_LE1 know_LE1 to_LE1 be_LE1 strong_LE1 inhibitor_LE1 of_LE1 cytochrome_LE1 enzyme_LE1 care_LE1 shall_LE1 be_LE1 take_LE1 while_LE1 dosing_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 strong_BE12 inhibitor_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Paricalcitol|P|zemplar|ketoconazole|dose_LE1 adjustment_LE1 of_LE1 BIOENTITY capsule_BE12 may_BE12 be_BE12 require_BE12 and_BE12 ipth_BE12 and_BE12 serum_BE12 calcium_BE12 concentration_BE12 shall_BE12 be_BE12 close_BE12 monitor_BE12 if_BE12 patient_BE12 initiate_BE12 or_BE12 discontinues_BE12 therapy_BE12 with_BE12 strong_BE12 cypa_BE12 inhibitor_BE12 such_BE12 as_BE12 BIOENTITY 
Paricalcitol|P|fat-soluble vitamin|cholestyramine|drug_LE1 that_LE1 impair_LE1 intestinal_LE1 absorption_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOENTITY may_RE2 interfere_RE2 with_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 capsule_RE2 
Paricalcitol|P|fat-soluble vitamin|cholestyramine|drug_LE1 that_LE1 impair_LE1 intestinal_LE1 absorption_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOENTITY may_RE2 interfere_RE2 with_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 capsule_RE2 
Paricalcitol|P|cholestyramine|zemplar|drug_LE1 that_LE1 impair_LE1 intestinal_LE1 absorption_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY may_BE12 interfere_BE12 with_BE12 the_BE12 absorption_BE12 of_BE12 BIOENTITY capsule_RE2 
Pegfilgrastim|P|lithium|neulasta|patient_LE1 receive_LE1 BIOENTITY and_BE12 BIOENTITY shall_RE2 have_RE2 much_RE2 frequent_RE2 monitoring_RE2 of_RE2 neutrophil_RE2 count_RE2 
Peginterferon alfa-2b|P|methadone|peg-intron|In_LE1 pharmacokinetic_LE1 study_LE1 of_LE1 NUM_LE1 chronic_LE1 hepatitis_LE1 patient_LE1 concomitant_LE1 receive_LE1 BIOENTITY treatment_BE12 with_BE12 BIOENTITY once_RE2 weekly_RE2 for_RE2 NUM_RE2 week_RE2 be_RE2 associate_RE2 with_RE2 mean_RE2 increase_RE2 of_RE2 NUM_RE2 in_RE2 BIOGENERAL_RE2 auc_RE2 
Pegvisomant|P|hypoglycemic|somavert|acromegalic_LE1 patient_LE1 with_LE1 diabetes_LE1 mellitus_LE1 be_LE1 treat_LE1 with_LE1 BIOGENERAL_LE1 and_LE1 oral_LE1 BIOENTITY agent_BE12 may_BE12 require_BE12 dose_BE12 reduction_BE12 of_BE12 these_BE12 therapeutic_BE12 agent_BE12 after_BE12 the_BE12 initiation_BE12 of_BE12 therapy_BE12 with_BE12 BIOENTITY 
Pegvisomant|P|insulin|somavert|acromegalic_LE1 patient_LE1 with_LE1 diabetes_LE1 mellitus_LE1 be_LE1 treat_LE1 with_LE1 BIOENTITY and_BE12 oral_BE12 BIOGENERAL_BE12 agent_BE12 may_BE12 require_BE12 dose_BE12 reduction_BE12 of_BE12 these_BE12 therapeutic_BE12 agent_BE12 after_BE12 the_BE12 initiation_BE12 of_BE12 therapy_BE12 with_BE12 BIOENTITY 
Pegvisomant|P|opioid|pegvisomant|In_LE1 clinical_LE1 study_LE1 patient_LE1 on_LE1 BIOENTITY often_BE12 need_BE12 high_BE12 serum_BE12 BIOENTITY concentration_RE2 to_RE2 achieve_RE2 appropriate_RE2 igfi_RE2 suppression_RE2 compared_RE2 with_RE2 patient_RE2 not_RE2 receive_RE2 BIOGENERAL_RE2 
Pemetrexed|P|probenecid|alimta|concomitant_LE1 administration_LE1 of_LE1 substance_LE1 that_LE1 be_LE1 also_LE1 tubular_LE1 secrete_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY -RRB-_BE12 can_BE12 potential_BE12 result_BE12 in_BE12 delay_BE12 clearance_BE12 of_BE12 BIOENTITY 
Pemetrexed|P|ibuprofen|alimta|although_LE1 BIOGENERAL_LE1 -LRB-_LE1 NUM_LE1 mg_LE1 qid_LE1 -RRB-_LE1 can_LE1 be_LE1 administer_LE1 with_LE1 BIOGENERAL_LE1 in_LE1 patient_LE1 with_LE1 normal_LE1 renal_LE1 function_LE1 -LRB-_LE1 creatinine_LE1 clearance_LE1 NUM_LE1 ml_LE1 -RRB-_LE1 caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 administer_LE1 BIOENTITY concurrent_BE12 with_BE12 BIOENTITY to_RE2 patient_RE2 with_RE2 mild_RE2 to_RE2 moderate_RE2 renal_RE2 insufficiency_RE2 -LRB-_RE2 creatinine_RE2 clearance_RE2 from_RE2 NUM_RE2 to_RE2 NUM_RE2 ml_RE2 rrb._RE2 
Pemetrexed|P|nsaid|alimta|patient_LE1 with_LE1 mild_LE1 to_LE1 moderate_LE1 renal_LE1 insufficiency_LE1 shall_LE1 avoid_LE1 take_LE1 BIOENTITY with_BE12 short_BE12 elimination_BE12 halflive_BE12 for_BE12 period_BE12 of_BE12 NUM_BE12 day_BE12 before_BE12 the_BE12 day_BE12 of_BE12 and_BE12 NUM_BE12 day_BE12 follow_BE12 administration_BE12 of_BE12 BIOENTITY 
Pemetrexed|P|nsaid|alimta|In_LE1 the_LE1 absence_LE1 of_LE1 datum_LE1 regarding_LE1 potential_LE1 interaction_LE1 between_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 with_LE1 long_LE1 halflive_LE1 all_LE1 patient_LE1 take_LE1 these_LE1 BIOENTITY shall_BE12 interrupt_BE12 dosing_BE12 for_BE12 at_BE12 little_BE12 NUM_BE12 day_BE12 before_BE12 the_BE12 day_BE12 of_BE12 and_BE12 NUM_BE12 day_BE12 follow_BE12 BIOENTITY administration_RE2 
Pemoline|P|cylert|antiepileptic medication|decrease_LE1 seizure_LE1 threshold_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOENTITY 
Penicillin G|P|bacteriostatic antibiotic|penicillin|concurrent_LE1 administration_LE1 of_LE1 BIOENTITY -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 diminish_BE12 the_BE12 bactericidal_BE12 effect_BE12 of_BE12 BIOENTITY by_RE2 slow_RE2 the_RE2 rate_RE2 of_RE2 bacterial_RE2 growth_RE2 
Penicillin G|P|erythromycin|penicillin|concurrent_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 may_BE12 diminish_BE12 the_BE12 bactericidal_BE12 effect_BE12 of_BE12 BIOENTITY by_RE2 slow_RE2 the_RE2 rate_RE2 of_RE2 bacterial_RE2 growth_RE2 
Penicillin G|P|tetracycline|penicillin|concurrent_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 may_BE12 diminish_BE12 the_BE12 bactericidal_BE12 effect_BE12 of_BE12 BIOENTITY by_RE2 slow_RE2 the_RE2 rate_RE2 of_RE2 bacterial_RE2 growth_RE2 
Penicillin G|P|penicillin|probenecid|BIOENTITY blood_BE12 level_BE12 may_BE12 be_BE12 prolong_BE12 by_BE12 concurrent_BE12 administration_BE12 of_BE12 BIOENTITY which_RE2 block_RE2 the_RE2 renal_RE2 tubular_RE2 secretion_RE2 of_RE2 BIOGENERAL_RE2 
Pentazocine|P|alcohol|pentazocine|usage_LE1 with_LE1 BIOGENERAL_LE1 :_LE1 Due_LE1 to_LE1 the_LE1 potential_LE1 for_LE1 increase_LE1 cns_LE1 depressants_LE1 effect_LE1 BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 who_BE12 be_BE12 current_BE12 receive_BE12 BIOENTITY 
Pentazocine|P|alcohol|pentazocine|usage_LE1 with_LE1 BIOGENERAL_LE1 :_LE1 Due_LE1 to_LE1 the_LE1 potential_LE1 for_LE1 increase_LE1 cns_LE1 depressants_LE1 effect_LE1 BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 who_BE12 be_BE12 current_BE12 receive_BE12 BIOENTITY 
Pentoxifylline|P|trental|platelet aggregation inhibitor|although_LE1 causal_LE1 relationship_LE1 have_LE1 not_LE1 be_LE1 establish_LE1 there_LE1 have_LE1 be_LE1 report_LE1 of_LE1 bleeding_LE1 and_LE1 prolonged_LE1 prothrombin_LE1 time_LE1 in_LE1 patient_LE1 treat_LE1 with_LE1 BIOENTITY with_BE12 and_BE12 without_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Pentoxifylline|P|trental|anticoagulant|although_LE1 causal_LE1 relationship_LE1 have_LE1 not_LE1 be_LE1 establish_LE1 there_LE1 have_LE1 be_LE1 report_LE1 of_LE1 bleeding_LE1 and_LE1 prolonged_LE1 prothrombin_LE1 time_LE1 in_LE1 patient_LE1 treat_LE1 with_LE1 BIOENTITY with_BE12 and_BE12 without_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Pentoxifylline|P|trental|theophylline|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY drug_RE2 lead_RE2 to_RE2 increase_RE2 BIOGENERAL_RE2 level_RE2 and_RE2 BIOGENERAL_RE2 toxicity_RE2 in_RE2 some_RE2 individual_RE2 
Pergolide|P|neuroleptic|permax|BIOGENERAL_LE1 such_LE1 as_LE1 the_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 ordinary_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 concurrent_BE12 with_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 rrb;_RE2 
Pergolide|P|phenothiazine|permax|BIOGENERAL_LE1 such_LE1 as_LE1 the_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 ordinary_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 concurrent_BE12 with_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 rrb;_RE2 
Pergolide|P|thioxanthine|permax|BIOGENERAL_LE1 such_LE1 as_LE1 the_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 or_BE12 BIOGENERAL_BE12 ordinary_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 concurrent_BE12 with_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 rrb;_RE2 
Pergolide|P|butyrophenone|permax|BIOGENERAL_LE1 such_LE1 as_LE1 the_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 ordinary_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 concurrent_BE12 with_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 rrb;_RE2 
Pergolide|P|metoclopramide|permax|BIOGENERAL_LE1 such_LE1 as_LE1 the_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 BIOENTITY ordinary_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 concurrent_BE12 with_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 rrb;_RE2 
Pergolide|P|dopamine antagonist|permax|BIOENTITY such_BE12 as_BE12 the_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 ordinary_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 concurrent_BE12 with_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 rrb;_RE2 
Perindopril|P|diuretic|aceon|BIOGENERAL_LE1 :_LE1 patient_LE1 on_LE1 BIOENTITY and_BE12 especial_BE12 those_BE12 start_BE12 recent_BE12 may_BE12 occasional_BE12 experience_BE12 excessive_BE12 reduction_BE12 of_BE12 blood_BE12 pressure_BE12 after_BE12 initiation_BE12 of_BE12 BIOENTITY tablet_RE2 therapy_RE2 
Perindopril|P|diuretic|perindopril|the_LE1 possibility_LE1 of_LE1 hypotensive_LE1 effect_LE1 can_LE1 be_LE1 minimize_LE1 by_LE1 either_LE1 discontinue_LE1 the_LE1 BIOENTITY or_BE12 increase_BE12 the_BE12 salt_BE12 intake_BE12 prior_BE12 to_BE12 initiation_BE12 of_BE12 treatment_BE12 with_BE12 BIOENTITY 
Perindopril|P|diuretic|aceon|if_LE1 BIOENTITY can_BE12 be_BE12 interrupt_BE12 close_BE12 medical_BE12 supervision_BE12 shall_BE12 be_BE12 provide_BE12 with_BE12 the_BE12 first_BE12 dose_BE12 of_BE12 BIOENTITY tablet_RE2 for_RE2 at_RE2 little_RE2 two_RE2 hour_RE2 and_RE2 until_RE2 blood_RE2 pressure_RE2 have_RE2 stabilise_RE2 for_RE2 another_RE2 hour_RE2 
Perindopril|P|digoxin|perindopril|BIOGENERAL_LE1 :_LE1 controlled_LE1 pharmacokinetic_LE1 study_LE1 have_LE1 show_LE1 no_LE1 effect_LE1 on_LE1 plasma_LE1 BIOGENERAL_LE1 concentration_LE1 when_LE1 coadminister_LE1 with_LE1 BIOGENERAL_LE1 tablet_LE1 but_LE1 effect_LE1 of_LE1 BIOENTITY on_BE12 the_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY have_RE2 not_RE2 be_RE2 exclude_RE2 
Perindopril|P|digoxin|perindopril|BIOGENERAL_LE1 :_LE1 controlled_LE1 pharmacokinetic_LE1 study_LE1 have_LE1 show_LE1 no_LE1 effect_LE1 on_LE1 plasma_LE1 BIOGENERAL_LE1 concentration_LE1 when_LE1 coadminister_LE1 with_LE1 BIOGENERAL_LE1 tablet_LE1 but_LE1 effect_LE1 of_LE1 BIOENTITY on_BE12 the_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY have_RE2 not_RE2 be_RE2 exclude_RE2 
Perindopril|P|perindopril|gentamicin|BIOGENERAL_LE1 :_LE1 animal_LE1 datum_LE1 have_LE1 suggest_LE1 the_LE1 possibility_LE1 of_LE1 interaction_LE1 between_LE1 BIOENTITY and_BE12 BIOENTITY 
Phentermine|P|alcohol|phentermine hydrochloride|concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 adverse_RE2 drug_RE2 interaction_RE2 
Phenylephrine|P|vasopressor|halothane|BIOENTITY particular_BE12 BIOGENERAL_BE12 may_BE12 cause_BE12 serious_BE12 cardiac_BE12 arrhythmia_BE12 during_BE12 BIOENTITY anesthesia_RE2 and_RE2 therefore_RE2 shall_RE2 be_RE2 use_RE2 only_RE2 with_RE2 great_RE2 caution_RE2 or_RE2 not_RE2 at_RE2 all_RE2 
Phenylephrine|P|metaraminol|halothane|BIOGENERAL_LE1 particular_LE1 BIOENTITY may_BE12 cause_BE12 serious_BE12 cardiac_BE12 arrhythmia_BE12 during_BE12 BIOENTITY anesthesia_RE2 and_RE2 therefore_RE2 shall_RE2 be_RE2 use_RE2 only_RE2 with_RE2 great_RE2 caution_RE2 or_RE2 not_RE2 at_RE2 all_RE2 
Phenylephrine|P|sympathomimetic pressor amine|maoi|BIOGENERAL_LE1 :_LE1 the_LE1 pressor_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 marked_BE12 potentiate_BE12 in_BE12 patient_BE12 receive_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY 
Phenylephrine|P|sympathomimetic pressor amine|monoamine oxidase inhibitor|BIOGENERAL_LE1 :_LE1 the_LE1 pressor_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 marked_BE12 potentiate_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 
Phenylephrine|P|adrenergic agent|tricyclic antidepressant|the_LE1 pressor_LE1 response_LE1 of_LE1 BIOENTITY may_BE12 also_BE12 be_BE12 potentiate_BE12 by_BE12 BIOENTITY 
Phenylpropanolamine|P|vasopressor|halothane|BIOENTITY particular_BE12 BIOGENERAL_BE12 may_BE12 cause_BE12 serious_BE12 cardiac_BE12 arrhythmia_BE12 during_BE12 BIOENTITY anesthesia_RE2 and_RE2 therefore_RE2 shall_RE2 be_RE2 use_RE2 only_RE2 with_RE2 great_RE2 caution_RE2 or_RE2 not_RE2 at_RE2 all_RE2 
Phenylpropanolamine|P|metaraminol|halothane|BIOGENERAL_LE1 particular_LE1 BIOENTITY may_BE12 cause_BE12 serious_BE12 cardiac_BE12 arrhythmia_BE12 during_BE12 BIOENTITY anesthesia_RE2 and_RE2 therefore_RE2 shall_RE2 be_RE2 use_RE2 only_RE2 with_RE2 great_RE2 caution_RE2 or_RE2 not_RE2 at_RE2 all_RE2 
Phenylpropanolamine|P|sympathomimetic pressor amine|monoamine oxidase inhibitor|BIOGENERAL_LE1 the_LE1 pressor_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 marked_BE12 potentiate_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 
Phenylpropanolamine|P|sympathomimetic pressor amine|maoi|BIOGENERAL_LE1 the_LE1 pressor_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 marked_BE12 potentiate_BE12 in_BE12 patient_BE12 receive_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY 
Phenylpropanolamine|P|adrenergic agent|tricyclic antidepressant|the_LE1 pressor_LE1 response_LE1 of_LE1 BIOENTITY may_BE12 also_BE12 be_BE12 potentiate_BE12 by_BE12 BIOENTITY 
Pilocarpine|P|pilocarpine|beta adrenergic antagonist|BIOENTITY shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 to_BE12 patient_BE12 take_BE12 BIOENTITY because_RE2 of_RE2 the_RE2 possibility_RE2 of_RE2 conduction_RE2 disturbance_RE2 
Pindolol|P|reserpine|beta-blocking agent|catecholaminedepleting_LE1 drug_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY -RRB-_BE12 may_BE12 have_BE12 additive_BE12 effect_BE12 when_BE12 give_BE12 with_BE12 BIOENTITY 
Pindolol|P|pindolol|thioridazine|BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 increase_BE12 serum_BE12 BIOENTITY level_RE2 when_RE2 both_RE2 drug_RE2 be_RE2 coadministered_RE2 
Pirbuterol|P|short-acting beta adrenergic aerosol bronchodilator|maxair autohaler|other_LE1 BIOENTITY shall_BE12 not_BE12 be_BE12 use_BE12 concomitant_BE12 with_BE12 BIOENTITY because_RE2 they_RE2 may_RE2 have_RE2 additive_RE2 effect_RE2 
Piroxicam|P|feldene|coumarin-type anticoagulant|although_LE1 this_LE1 have_LE1 not_LE1 occur_LE1 in_LE1 in_LE1 vitro_LE1 study_LE1 with_LE1 BIOGENERAL_LE1 interaction_LE1 with_LE1 BIOGENERAL_LE1 have_LE1 be_LE1 report_LE1 with_LE1 BIOGENERAL_LE1 since_LE1 marketing_LE1 therefore_LE1 physician_LE1 shall_LE1 close_LE1 monitor_LE1 patient_LE1 for_LE1 change_LE1 in_LE1 dosage_LE1 requirement_LE1 when_LE1 administer_LE1 BIOENTITY to_BE12 patient_BE12 on_BE12 BIOENTITY and_RE2 other_RE2 high_RE2 proteinbound_RE2 drug_RE2 
Piroxicam|P|coumarin-type anticoagulant|feldene|although_LE1 this_LE1 have_LE1 not_LE1 occur_LE1 in_LE1 in_LE1 vitro_LE1 study_LE1 with_LE1 BIOGENERAL_LE1 interaction_LE1 with_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 with_BE12 BIOENTITY since_RE2 marketing_RE2 therefore_RE2 physician_RE2 shall_RE2 close_RE2 monitor_RE2 patient_RE2 for_RE2 change_RE2 in_RE2 dosage_RE2 requirement_RE2 when_RE2 administer_RE2 BIOGENERAL_RE2 to_RE2 patient_RE2 on_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 high_RE2 proteinbound_RE2 drug_RE2 
Piroxicam|P|nonsteroidal anti-inflammatory agent|lithium|plasma_LE1 level_LE1 of_LE1 BIOGENERAL_LE1 be_LE1 depress_LE1 to_LE1 approximate_LE1 NUM_LE1 of_LE1 their_LE1 normal_LE1 value_LE1 when_LE1 BIOGENERAL_LE1 be_LE1 administer_LE1 in_LE1 conjunction_LE1 with_LE1 BIOGENERAL_LE1 -LRB-_LE1 NUM_LE1 mg_LE1 -RRB-_LE1 but_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 have_LE1 no_LE1 effect_LE1 on_LE1 BIOGENERAL_LE1 plasma_LE1 level_LE1 BIOENTITY including_BE12 BIOGENERAL_BE12 have_BE12 be_BE12 report_BE12 to_BE12 increase_BE12 steady_BE12 state_BE12 plasma_BE12 BIOENTITY level_RE2 
Piroxicam|P|feldene|lithium|plasma_LE1 level_LE1 of_LE1 BIOGENERAL_LE1 be_LE1 depress_LE1 to_LE1 approximate_LE1 NUM_LE1 of_LE1 their_LE1 normal_LE1 value_LE1 when_LE1 BIOGENERAL_LE1 be_LE1 administer_LE1 in_LE1 conjunction_LE1 with_LE1 BIOGENERAL_LE1 -LRB-_LE1 NUM_LE1 mg_LE1 -RRB-_LE1 but_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 have_LE1 no_LE1 effect_LE1 on_LE1 BIOGENERAL_LE1 plasma_LE1 level_LE1 BIOGENERAL_LE1 including_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 increase_BE12 steady_BE12 state_BE12 plasma_BE12 BIOENTITY level_RE2 
Piroxicam|P|feldene|aspirin|plasma_LE1 level_LE1 of_LE1 BIOGENERAL_LE1 be_LE1 depress_LE1 to_LE1 approximate_LE1 NUM_LE1 of_LE1 their_LE1 normal_LE1 value_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 in_BE12 conjunction_BE12 with_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 -RRB-_RE2 but_RE2 concomitant_RE2 administration_RE2 of_RE2 BIOGENERAL_RE2 have_RE2 no_RE2 effect_RE2 on_RE2 BIOGENERAL_RE2 plasma_RE2 level_RE2 BIOGENERAL_RE2 including_RE2 BIOGENERAL_RE2 have_RE2 be_RE2 report_RE2 to_RE2 increase_RE2 steady_RE2 state_RE2 plasma_RE2 BIOGENERAL_RE2 level_RE2 
Piroxicam|P|lithium|feldene|it_LE1 be_LE1 recommend_LE1 that_LE1 plasma_LE1 BIOENTITY level_BE12 be_BE12 monitor_BE12 when_BE12 initiate_BE12 adjust_BE12 and_BE12 discontinue_BE12 BIOENTITY 
Pralidoxime|P|atropine|pralidoxime|when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 use_RE2 together_RE2 the_RE2 sign_RE2 of_RE2 atropinization_RE2 -LRB-_RE2 flush_RE2 mydriasis_RE2 tachycardia_RE2 dryness_RE2 of_RE2 the_RE2 mouth_RE2 and_RE2 nose_RE2 -RRB-_RE2 may_RE2 occur_RE2 early_RE2 than_RE2 may_RE2 be_RE2 expect_RE2 when_RE2 BIOGENERAL_RE2 be_RE2 use_RE2 alone_RE2 
Pralidoxime|P|barbiturate|anticholinesterase|NUM_LE1 NUM_LE1 the_LE1 follow_LE1 precaution_LE1 shall_LE1 be_LE1 keep_LE1 in_LE1 mind_LE1 in_LE1 the_LE1 treatment_LE1 of_LE1 anticholinesterase_LE1 poisoning_LE1 although_LE1 they_LE1 do_LE1 not_LE1 bear_LE1 direct_LE1 on_LE1 the_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 :_LE1 since_LE1 BIOENTITY be_BE12 potentiate_BE12 by_BE12 the_BE12 BIOENTITY they_RE2 shall_RE2 be_RE2 use_RE2 cautious_RE2 in_RE2 the_RE2 treatment_RE2 of_RE2 convulsion_RE2 
Pramipexole|P|cimetidine|pramipexole|BIOGENERAL_LE1 :_LE1 BIOENTITY known_BE12 inhibitor_BE12 of_BE12 renal_BE12 tubular_BE12 secretion_BE12 of_BE12 organic_BE12 base_BE12 via_BE12 the_BE12 cationic_BE12 transport_BE12 system_BE12 cause_BE12 NUM_BE12 increase_BE12 in_BE12 BIOENTITY auc_RE2 and_RE2 NUM_RE2 increase_RE2 in_RE2 halflife_RE2 -LRB-_RE2 n=_RE2 NUM_RE2 rrb._RE2 
Pramipexole|P|quinine|pramipexole|other_LE1 drug_LE1 eliminate_LE1 via_LE1 renal_LE1 secretion_LE1 :_LE1 population_LE1 pharmacokinetic_LE1 analysis_LE1 suggest_LE1 that_LE1 coadministration_LE1 of_LE1 drug_LE1 that_LE1 be_LE1 secrete_LE1 by_LE1 the_LE1 cationic_LE1 transport_LE1 system_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY -RRB-_BE12 decrease_BE12 the_BE12 oral_BE12 clearance_BE12 of_BE12 BIOENTITY by_RE2 about_RE2 NUM_RE2 while_RE2 those_RE2 secrete_RE2 by_RE2 the_RE2 anionic_RE2 transport_RE2 system_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 likely_RE2 to_RE2 have_RE2 little_RE2 effect_RE2 on_RE2 the_RE2 oral_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 
Pramipexole|P|quinine|pramipexole|other_LE1 drug_LE1 eliminate_LE1 via_LE1 renal_LE1 secretion_LE1 :_LE1 population_LE1 pharmacokinetic_LE1 analysis_LE1 suggest_LE1 that_LE1 coadministration_LE1 of_LE1 drug_LE1 that_LE1 be_LE1 secrete_LE1 by_LE1 the_LE1 cationic_LE1 transport_LE1 system_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY -RRB-_BE12 decrease_BE12 the_BE12 oral_BE12 clearance_BE12 of_BE12 BIOENTITY by_RE2 about_RE2 NUM_RE2 while_RE2 those_RE2 secrete_RE2 by_RE2 the_RE2 anionic_RE2 transport_RE2 system_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 likely_RE2 to_RE2 have_RE2 little_RE2 effect_RE2 on_RE2 the_RE2 oral_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 
Pramipexole|P|diltiazem|pramipexole|other_LE1 drug_LE1 eliminate_LE1 via_LE1 renal_LE1 secretion_LE1 :_LE1 population_LE1 pharmacokinetic_LE1 analysis_LE1 suggest_LE1 that_LE1 coadministration_LE1 of_LE1 drug_LE1 that_LE1 be_LE1 secrete_LE1 by_LE1 the_LE1 cationic_LE1 transport_LE1 system_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 decrease_BE12 the_BE12 oral_BE12 clearance_BE12 of_BE12 BIOENTITY by_RE2 about_RE2 NUM_RE2 while_RE2 those_RE2 secrete_RE2 by_RE2 the_RE2 anionic_RE2 transport_RE2 system_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 likely_RE2 to_RE2 have_RE2 little_RE2 effect_RE2 on_RE2 the_RE2 oral_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 
Pramipexole|P|diltiazem|pramipexole|other_LE1 drug_LE1 eliminate_LE1 via_LE1 renal_LE1 secretion_LE1 :_LE1 population_LE1 pharmacokinetic_LE1 analysis_LE1 suggest_LE1 that_LE1 coadministration_LE1 of_LE1 drug_LE1 that_LE1 be_LE1 secrete_LE1 by_LE1 the_LE1 cationic_LE1 transport_LE1 system_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 decrease_BE12 the_BE12 oral_BE12 clearance_BE12 of_BE12 BIOENTITY by_RE2 about_RE2 NUM_RE2 while_RE2 those_RE2 secrete_RE2 by_RE2 the_RE2 anionic_RE2 transport_RE2 system_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 likely_RE2 to_RE2 have_RE2 little_RE2 effect_RE2 on_RE2 the_RE2 oral_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 
Pramipexole|P|cimetidine|pramipexole|other_LE1 drug_LE1 eliminate_LE1 via_LE1 renal_LE1 secretion_LE1 :_LE1 population_LE1 pharmacokinetic_LE1 analysis_LE1 suggest_LE1 that_LE1 coadministration_LE1 of_LE1 drug_LE1 that_LE1 be_LE1 secrete_LE1 by_LE1 the_LE1 cationic_LE1 transport_LE1 system_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 decrease_BE12 the_BE12 oral_BE12 clearance_BE12 of_BE12 BIOENTITY by_RE2 about_RE2 NUM_RE2 while_RE2 those_RE2 secrete_RE2 by_RE2 the_RE2 anionic_RE2 transport_RE2 system_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 likely_RE2 to_RE2 have_RE2 little_RE2 effect_RE2 on_RE2 the_RE2 oral_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 
Pramipexole|P|cimetidine|pramipexole|other_LE1 drug_LE1 eliminate_LE1 via_LE1 renal_LE1 secretion_LE1 :_LE1 population_LE1 pharmacokinetic_LE1 analysis_LE1 suggest_LE1 that_LE1 coadministration_LE1 of_LE1 drug_LE1 that_LE1 be_LE1 secrete_LE1 by_LE1 the_LE1 cationic_LE1 transport_LE1 system_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 decrease_BE12 the_BE12 oral_BE12 clearance_BE12 of_BE12 BIOENTITY by_RE2 about_RE2 NUM_RE2 while_RE2 those_RE2 secrete_RE2 by_RE2 the_RE2 anionic_RE2 transport_RE2 system_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 likely_RE2 to_RE2 have_RE2 little_RE2 effect_RE2 on_RE2 the_RE2 oral_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 
Pramipexole|P|quinidine|pramipexole|other_LE1 drug_LE1 eliminate_LE1 via_LE1 renal_LE1 secretion_LE1 :_LE1 population_LE1 pharmacokinetic_LE1 analysis_LE1 suggest_LE1 that_LE1 coadministration_LE1 of_LE1 drug_LE1 that_LE1 be_LE1 secrete_LE1 by_LE1 the_LE1 cationic_LE1 transport_LE1 system_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -RRB-_BE12 decrease_BE12 the_BE12 oral_BE12 clearance_BE12 of_BE12 BIOENTITY by_RE2 about_RE2 NUM_RE2 while_RE2 those_RE2 secrete_RE2 by_RE2 the_RE2 anionic_RE2 transport_RE2 system_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 likely_RE2 to_RE2 have_RE2 little_RE2 effect_RE2 on_RE2 the_RE2 oral_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 
Pramipexole|P|quinidine|pramipexole|other_LE1 drug_LE1 eliminate_LE1 via_LE1 renal_LE1 secretion_LE1 :_LE1 population_LE1 pharmacokinetic_LE1 analysis_LE1 suggest_LE1 that_LE1 coadministration_LE1 of_LE1 drug_LE1 that_LE1 be_LE1 secrete_LE1 by_LE1 the_LE1 cationic_LE1 transport_LE1 system_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -RRB-_BE12 decrease_BE12 the_BE12 oral_BE12 clearance_BE12 of_BE12 BIOENTITY by_RE2 about_RE2 NUM_RE2 while_RE2 those_RE2 secrete_RE2 by_RE2 the_RE2 anionic_RE2 transport_RE2 system_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 likely_RE2 to_RE2 have_RE2 little_RE2 effect_RE2 on_RE2 the_RE2 oral_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 
Pramipexole|P|ranitidine|pramipexole|other_LE1 drug_LE1 eliminate_LE1 via_LE1 renal_LE1 secretion_LE1 :_LE1 population_LE1 pharmacokinetic_LE1 analysis_LE1 suggest_LE1 that_LE1 coadministration_LE1 of_LE1 drug_LE1 that_LE1 be_LE1 secrete_LE1 by_LE1 the_LE1 cationic_LE1 transport_LE1 system_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 decrease_BE12 the_BE12 oral_BE12 clearance_BE12 of_BE12 BIOENTITY by_RE2 about_RE2 NUM_RE2 while_RE2 those_RE2 secrete_RE2 by_RE2 the_RE2 anionic_RE2 transport_RE2 system_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 likely_RE2 to_RE2 have_RE2 little_RE2 effect_RE2 on_RE2 the_RE2 oral_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 
Pramipexole|P|ranitidine|pramipexole|other_LE1 drug_LE1 eliminate_LE1 via_LE1 renal_LE1 secretion_LE1 :_LE1 population_LE1 pharmacokinetic_LE1 analysis_LE1 suggest_LE1 that_LE1 coadministration_LE1 of_LE1 drug_LE1 that_LE1 be_LE1 secrete_LE1 by_LE1 the_LE1 cationic_LE1 transport_LE1 system_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 decrease_BE12 the_BE12 oral_BE12 clearance_BE12 of_BE12 BIOENTITY by_RE2 about_RE2 NUM_RE2 while_RE2 those_RE2 secrete_RE2 by_RE2 the_RE2 anionic_RE2 transport_RE2 system_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 likely_RE2 to_RE2 have_RE2 little_RE2 effect_RE2 on_RE2 the_RE2 oral_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 
Pramipexole|P|chlorpropamide|pramipexole|other_LE1 drug_LE1 eliminate_LE1 via_LE1 renal_LE1 secretion_LE1 :_LE1 population_LE1 pharmacokinetic_LE1 analysis_LE1 suggest_LE1 that_LE1 coadministration_LE1 of_LE1 drug_LE1 that_LE1 be_LE1 secrete_LE1 by_LE1 the_LE1 cationic_LE1 transport_LE1 system_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -RRB-_LE1 decrease_LE1 the_LE1 oral_LE1 clearance_LE1 of_LE1 BIOGENERAL_LE1 by_LE1 about_LE1 NUM_LE1 while_LE1 those_LE1 secrete_LE1 by_LE1 the_LE1 anionic_LE1 transport_LE1 system_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY -RRB-_BE12 be_BE12 likely_BE12 to_BE12 have_BE12 little_BE12 effect_BE12 on_BE12 the_BE12 oral_BE12 clearance_BE12 of_BE12 BIOENTITY 
Pramipexole|P|verapamil|pramipexole|other_LE1 drug_LE1 eliminate_LE1 via_LE1 renal_LE1 secretion_LE1 :_LE1 population_LE1 pharmacokinetic_LE1 analysis_LE1 suggest_LE1 that_LE1 coadministration_LE1 of_LE1 drug_LE1 that_LE1 be_LE1 secrete_LE1 by_LE1 the_LE1 cationic_LE1 transport_LE1 system_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 decrease_BE12 the_BE12 oral_BE12 clearance_BE12 of_BE12 BIOENTITY by_RE2 about_RE2 NUM_RE2 while_RE2 those_RE2 secrete_RE2 by_RE2 the_RE2 anionic_RE2 transport_RE2 system_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 likely_RE2 to_RE2 have_RE2 little_RE2 effect_RE2 on_RE2 the_RE2 oral_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 
Pramipexole|P|verapamil|pramipexole|other_LE1 drug_LE1 eliminate_LE1 via_LE1 renal_LE1 secretion_LE1 :_LE1 population_LE1 pharmacokinetic_LE1 analysis_LE1 suggest_LE1 that_LE1 coadministration_LE1 of_LE1 drug_LE1 that_LE1 be_LE1 secrete_LE1 by_LE1 the_LE1 cationic_LE1 transport_LE1 system_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 decrease_BE12 the_BE12 oral_BE12 clearance_BE12 of_BE12 BIOENTITY by_RE2 about_RE2 NUM_RE2 while_RE2 those_RE2 secrete_RE2 by_RE2 the_RE2 anionic_RE2 transport_RE2 system_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 likely_RE2 to_RE2 have_RE2 little_RE2 effect_RE2 on_RE2 the_RE2 oral_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 
Pramipexole|P|cephalosporin|pramipexole|other_LE1 drug_LE1 eliminate_LE1 via_LE1 renal_LE1 secretion_LE1 :_LE1 population_LE1 pharmacokinetic_LE1 analysis_LE1 suggest_LE1 that_LE1 coadministration_LE1 of_LE1 drug_LE1 that_LE1 be_LE1 secrete_LE1 by_LE1 the_LE1 cationic_LE1 transport_LE1 system_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -RRB-_LE1 decrease_LE1 the_LE1 oral_LE1 clearance_LE1 of_LE1 BIOGENERAL_LE1 by_LE1 about_LE1 NUM_LE1 while_LE1 those_LE1 secrete_LE1 by_LE1 the_LE1 anionic_LE1 transport_LE1 system_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 be_BE12 likely_BE12 to_BE12 have_BE12 little_BE12 effect_BE12 on_BE12 the_BE12 oral_BE12 clearance_BE12 of_BE12 BIOENTITY 
Pramipexole|P|indomethacin|pramipexole|other_LE1 drug_LE1 eliminate_LE1 via_LE1 renal_LE1 secretion_LE1 :_LE1 population_LE1 pharmacokinetic_LE1 analysis_LE1 suggest_LE1 that_LE1 coadministration_LE1 of_LE1 drug_LE1 that_LE1 be_LE1 secrete_LE1 by_LE1 the_LE1 cationic_LE1 transport_LE1 system_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -RRB-_LE1 decrease_LE1 the_LE1 oral_LE1 clearance_LE1 of_LE1 BIOGENERAL_LE1 by_LE1 about_LE1 NUM_LE1 while_LE1 those_LE1 secrete_LE1 by_LE1 the_LE1 anionic_LE1 transport_LE1 system_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 be_BE12 likely_BE12 to_BE12 have_BE12 little_BE12 effect_BE12 on_BE12 the_BE12 oral_BE12 clearance_BE12 of_BE12 BIOENTITY 
Pramipexole|P|hydrochlorothiazide|pramipexole|other_LE1 drug_LE1 eliminate_LE1 via_LE1 renal_LE1 secretion_LE1 :_LE1 population_LE1 pharmacokinetic_LE1 analysis_LE1 suggest_LE1 that_LE1 coadministration_LE1 of_LE1 drug_LE1 that_LE1 be_LE1 secrete_LE1 by_LE1 the_LE1 cationic_LE1 transport_LE1 system_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -RRB-_LE1 decrease_LE1 the_LE1 oral_LE1 clearance_LE1 of_LE1 BIOGENERAL_LE1 by_LE1 about_LE1 NUM_LE1 while_LE1 those_LE1 secrete_LE1 by_LE1 the_LE1 anionic_LE1 transport_LE1 system_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -RRB-_BE12 be_BE12 likely_BE12 to_BE12 have_BE12 little_BE12 effect_BE12 on_BE12 the_BE12 oral_BE12 clearance_BE12 of_BE12 BIOENTITY 
Pramipexole|P|penicillin|pramipexole|other_LE1 drug_LE1 eliminate_LE1 via_LE1 renal_LE1 secretion_LE1 :_LE1 population_LE1 pharmacokinetic_LE1 analysis_LE1 suggest_LE1 that_LE1 coadministration_LE1 of_LE1 drug_LE1 that_LE1 be_LE1 secrete_LE1 by_LE1 the_LE1 cationic_LE1 transport_LE1 system_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -RRB-_LE1 decrease_LE1 the_LE1 oral_LE1 clearance_LE1 of_LE1 BIOGENERAL_LE1 by_LE1 about_LE1 NUM_LE1 while_LE1 those_LE1 secrete_LE1 by_LE1 the_LE1 anionic_LE1 transport_LE1 system_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 be_BE12 likely_BE12 to_BE12 have_BE12 little_BE12 effect_BE12 on_BE12 the_BE12 oral_BE12 clearance_BE12 of_BE12 BIOENTITY 
Pramipexole|P|triamterene|pramipexole|other_LE1 drug_LE1 eliminate_LE1 via_LE1 renal_LE1 secretion_LE1 :_LE1 population_LE1 pharmacokinetic_LE1 analysis_LE1 suggest_LE1 that_LE1 coadministration_LE1 of_LE1 drug_LE1 that_LE1 be_LE1 secrete_LE1 by_LE1 the_LE1 cationic_LE1 transport_LE1 system_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 decrease_BE12 the_BE12 oral_BE12 clearance_BE12 of_BE12 BIOENTITY by_RE2 about_RE2 NUM_RE2 while_RE2 those_RE2 secrete_RE2 by_RE2 the_RE2 anionic_RE2 transport_RE2 system_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 likely_RE2 to_RE2 have_RE2 little_RE2 effect_RE2 on_RE2 the_RE2 oral_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 
Pramipexole|P|triamterene|pramipexole|other_LE1 drug_LE1 eliminate_LE1 via_LE1 renal_LE1 secretion_LE1 :_LE1 population_LE1 pharmacokinetic_LE1 analysis_LE1 suggest_LE1 that_LE1 coadministration_LE1 of_LE1 drug_LE1 that_LE1 be_LE1 secrete_LE1 by_LE1 the_LE1 cationic_LE1 transport_LE1 system_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 decrease_BE12 the_BE12 oral_BE12 clearance_BE12 of_BE12 BIOENTITY by_RE2 about_RE2 NUM_RE2 while_RE2 those_RE2 secrete_RE2 by_RE2 the_RE2 anionic_RE2 transport_RE2 system_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 likely_RE2 to_RE2 have_RE2 little_RE2 effect_RE2 on_RE2 the_RE2 oral_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 
Pramipexole|P|dopamine antagonist|mirapex|BIOGENERAL_LE1 :_LE1 since_LE1 BIOGENERAL_LE1 be_LE1 BIOGENERAL_LE1 it_LE1 be_LE1 possible_LE1 that_LE1 BIOENTITY such_BE12 as_BE12 the_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 may_BE12 diminish_BE12 the_BE12 effectiveness_BE12 of_BE12 BIOENTITY 
Pramipexole|P|thioxanthene|mirapex|BIOGENERAL_LE1 :_LE1 since_LE1 BIOGENERAL_LE1 be_LE1 BIOGENERAL_LE1 it_LE1 be_LE1 possible_LE1 that_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 the_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 or_BE12 BIOGENERAL_BE12 may_BE12 diminish_BE12 the_BE12 effectiveness_BE12 of_BE12 BIOENTITY 
Pramipexole|P|metoclopramide|mirapex|BIOGENERAL_LE1 :_LE1 since_LE1 BIOGENERAL_LE1 be_LE1 BIOGENERAL_LE1 it_LE1 be_LE1 possible_LE1 that_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 the_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 BIOENTITY may_BE12 diminish_BE12 the_BE12 effectiveness_BE12 of_BE12 BIOENTITY 
Pramipexole|P|butyrophenone|mirapex|BIOGENERAL_LE1 :_LE1 since_LE1 BIOGENERAL_LE1 be_LE1 BIOGENERAL_LE1 it_LE1 be_LE1 possible_LE1 that_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 the_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 may_BE12 diminish_BE12 the_BE12 effectiveness_BE12 of_BE12 BIOENTITY 
Pramipexole|P|phenothiazine|mirapex|BIOGENERAL_LE1 :_LE1 since_LE1 BIOGENERAL_LE1 be_LE1 BIOGENERAL_LE1 it_LE1 be_LE1 possible_LE1 that_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 the_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 may_BE12 diminish_BE12 the_BE12 effectiveness_BE12 of_BE12 BIOENTITY 
Pramipexole|P|neuroleptic|mirapex|BIOGENERAL_LE1 :_LE1 since_LE1 BIOGENERAL_LE1 be_LE1 BIOGENERAL_LE1 it_LE1 be_LE1 possible_LE1 that_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 the_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 may_BE12 diminish_BE12 the_BE12 effectiveness_BE12 of_BE12 BIOENTITY 
Pramlintide|P|symlin|alpha glucosidase inhibitor|Due_LE1 to_LE1 its_LE1 effect_LE1 on_LE1 gastric_LE1 emptying_LE1 BIOENTITY therapy_BE12 shall_BE12 not_BE12 be_BE12 consider_BE12 for_BE12 patient_BE12 take_BE12 drug_BE12 that_BE12 alter_BE12 gastrointestinal_BE12 motility_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 agent_BE12 that_BE12 slow_BE12 the_BE12 intestinal_BE12 absorption_BE12 of_BE12 nutrient_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY rrb._RE2 
Pramlintide|P|symlin|alpha glucosidase inhibitor|Due_LE1 to_LE1 its_LE1 effect_LE1 on_LE1 gastric_LE1 emptying_LE1 BIOENTITY therapy_BE12 shall_BE12 not_BE12 be_BE12 consider_BE12 for_BE12 patient_BE12 take_BE12 drug_BE12 that_BE12 alter_BE12 gastrointestinal_BE12 motility_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 agent_BE12 that_BE12 slow_BE12 the_BE12 intestinal_BE12 absorption_BE12 of_BE12 nutrient_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY rrb._RE2 
Pramlintide|P|symlin|anticholinergic agent|Due_LE1 to_LE1 its_LE1 effect_LE1 on_LE1 gastric_LE1 emptying_LE1 BIOENTITY therapy_BE12 shall_BE12 not_BE12 be_BE12 consider_BE12 for_BE12 patient_BE12 take_BE12 drug_BE12 that_BE12 alter_BE12 gastrointestinal_BE12 motility_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 agent_RE2 that_RE2 slow_RE2 the_RE2 intestinal_RE2 absorption_RE2 of_RE2 nutrient_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 rrb._RE2 
Pramlintide|P|symlin|atropine|Due_LE1 to_LE1 its_LE1 effect_LE1 on_LE1 gastric_LE1 emptying_LE1 BIOENTITY therapy_BE12 shall_BE12 not_BE12 be_BE12 consider_BE12 for_BE12 patient_BE12 take_BE12 drug_BE12 that_BE12 alter_BE12 gastrointestinal_BE12 motility_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY -RRB-_RE2 and_RE2 agent_RE2 that_RE2 slow_RE2 the_RE2 intestinal_RE2 absorption_RE2 of_RE2 nutrient_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 rrb._RE2 
Pramlintide|P|analgesic|symlin|when_LE1 the_LE1 rapid_LE1 onset_LE1 of_LE1 concomitant_LE1 oral_LE1 administer_LE1 agent_LE1 be_LE1 critical_LE1 determinant_LE1 of_LE1 effectiveness_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOENTITY -RRB-_BE12 the_BE12 agent_BE12 shall_BE12 be_BE12 administer_BE12 at_BE12 little_BE12 NUM_BE12 hour_BE12 prior_BE12 to_BE12 or_BE12 NUM_BE12 hour_BE12 after_BE12 BIOENTITY injection_RE2 
Pramlintide|P|symlin|human insulin|mix_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 the_LE1 pharmacokinetic_LE1 parameter_LE1 of_LE1 BIOENTITY be_BE12 alter_BE12 when_BE12 mix_BE12 with_BE12 regular_BE12 nph_BE12 and_BE12 premix_BE12 formulation_BE12 of_BE12 recombinant_BE12 BIOENTITY immediate_RE2 prior_RE2 to_RE2 injection_RE2 
Prednisone|P|rifampin|corticosteroid|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 may_BE12 require_BE12 increase_BE12 in_BE12 BIOENTITY dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Prednisone|P|rifampin|corticosteroid|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 may_BE12 require_BE12 increase_BE12 in_BE12 BIOENTITY dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Prednisone|P|phenobarbital|corticosteroid|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY and_RE2 may_RE2 require_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Prednisone|P|phenobarbital|corticosteroid|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY and_RE2 may_RE2 require_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Prednisone|P|phenobarbital|corticosteroid|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 may_BE12 require_BE12 increase_BE12 in_BE12 BIOENTITY dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Prednisone|P|phenobarbital|corticosteroid|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 may_BE12 require_BE12 increase_BE12 in_BE12 BIOENTITY dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Prednisone|P|phenytoin|corticosteroid|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY and_RE2 may_RE2 require_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Prednisone|P|phenytoin|corticosteroid|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY and_RE2 may_RE2 require_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Prednisone|P|phenytoin|corticosteroid|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 may_BE12 require_BE12 increase_BE12 in_BE12 BIOENTITY dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Prednisone|P|phenytoin|corticosteroid|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 may_BE12 require_BE12 increase_BE12 in_BE12 BIOENTITY dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Prednisone|P|rifampin|corticosteroid|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY and_RE2 may_RE2 require_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Prednisone|P|rifampin|corticosteroid|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY and_RE2 may_RE2 require_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Prednisone|P|ketoconazole|corticosteroid|drug_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY and_RE2 thus_RE2 decrease_RE2 their_RE2 clearance_RE2 
Prednisone|P|troleandomycin|corticosteroid|drug_LE1 such_LE1 as_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY and_RE2 thus_RE2 decrease_RE2 their_RE2 clearance_RE2 
Prednisone|P|corticosteroid|aspirin|BIOENTITY may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 chronic_BE12 high_BE12 dose_BE12 BIOENTITY 
Prednisone|P|salicylate|corticosteroid|this_LE1 can_LE1 lead_LE1 to_LE1 decrease_LE1 BIOGENERAL_LE1 serum_LE1 level_LE1 or_LE1 increase_LE1 the_LE1 risk_LE1 of_LE1 BIOENTITY toxicity_BE12 when_BE12 BIOENTITY be_RE2 withdraw_RE2 
Prednisone|P|aspirin|corticosteroid|BIOENTITY shall_BE12 be_BE12 use_BE12 cautious_BE12 in_BE12 conjunction_BE12 with_BE12 BIOENTITY in_RE2 patient_RE2 suffer_RE2 from_RE2 hypoprothrombinemia_RE2 
Prednisone|P|corticosteroid|anticoagulant|the_LE1 effect_LE1 of_LE1 BIOENTITY on_BE12 oral_BE12 BIOENTITY be_RE2 variable_RE2 
Prednisone|P|anticoagulant|corticosteroid|there_LE1 be_LE1 report_LE1 of_LE1 enhance_LE1 as_LE1 well_LE1 as_LE1 diminish_LE1 effect_LE1 of_LE1 BIOENTITY when_BE12 give_BE12 concurrent_BE12 with_BE12 BIOENTITY 
Procaine|P|anticholinesterase|procaine hydrochloride|BIOGENERAL_LE1 :_LE1 concurrent_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 may_LE1 result_LE1 in_LE1 increase_LE1 systemic_LE1 toxicity_LE1 since_LE1 BIOENTITY inhibit_BE12 the_BE12 breakdown_BE12 of_BE12 BIOENTITY 
Procaine|P|procaine hydrochloride|anticholinesterase agent|BIOGENERAL_LE1 :_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 increase_RE2 systemic_RE2 toxicity_RE2 since_RE2 BIOGENERAL_RE2 inhibit_RE2 the_RE2 breakdown_RE2 of_RE2 BIOGENERAL_RE2 
Procaine|P|procaine hydrochloride|cns depressant medication|BIOGENERAL_LE1 medication_LE1 :_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 additive_RE2 depressant_RE2 effect_RE2 
Procaine|P|hyaluronidase|procaine hydrochloride|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 diffusion_BE12 rate_BE12 of_BE12 BIOENTITY result_RE2 in_RE2 decrease_RE2 time_RE2 of_RE2 onset_RE2 but_RE2 increase_RE2 in_RE2 systemic_RE2 toxicity_RE2 
Procaine|P|procaine hydrochloride|neuromuscular blocking agent|BIOGENERAL_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 prolongation_RE2 or_RE2 enhancement_RE2 of_RE2 the_RE2 neuromuscular_RE2 blockade_RE2 
Procaine|P|procaine hydrochloride|neuromuscular blocking agent|BIOGENERAL_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 prolongation_RE2 or_RE2 enhancement_RE2 of_RE2 the_RE2 neuromuscular_RE2 blockade_RE2 
Procaine|P|procaine hydrochloride|sulfonamide|BIOGENERAL_LE1 :_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 reduction_RE2 of_RE2 the_RE2 antibacterial_RE2 action_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 
Procaine|P|acetazolamide|procaine hydrochloride|BIOGENERAL_LE1 :_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 extend_RE2 the_RE2 plasma_RE2 halflife_RE2 of_RE2 BIOGENERAL_RE2 
Procarbazine|P|matulane|tyramine|because_LE1 BIOENTITY exhibit_BE12 some_BE12 monoamine_BE12 oxidase_BE12 inhibitory_BE12 activity_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 other_BE12 drug_BE12 and_BE12 food_BE12 with_BE12 known_BE12 high_BE12 BIOENTITY content_RE2 such_RE2 as_RE2 wine_RE2 yogurt_RE2 ripe_RE2 cheese_RE2 and_RE2 banana_RE2 shall_RE2 be_RE2 avoid_RE2 
Procarbazine|P|matulane|amitriptyline hcl|because_LE1 BIOENTITY exhibit_BE12 some_BE12 monoamine_BE12 oxidase_BE12 inhibitory_BE12 activity_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 and_RE2 other_RE2 drug_RE2 and_RE2 food_RE2 with_RE2 known_RE2 high_RE2 BIOGENERAL_RE2 content_RE2 such_RE2 as_RE2 wine_RE2 yogurt_RE2 ripe_RE2 cheese_RE2 and_RE2 banana_RE2 shall_RE2 be_RE2 avoid_RE2 
Procarbazine|P|matulane|imipramine hcl|because_LE1 BIOENTITY exhibit_BE12 some_BE12 monoamine_BE12 oxidase_BE12 inhibitory_BE12 activity_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 and_RE2 other_RE2 drug_RE2 and_RE2 food_RE2 with_RE2 known_RE2 high_RE2 BIOGENERAL_RE2 content_RE2 such_RE2 as_RE2 wine_RE2 yogurt_RE2 ripe_RE2 cheese_RE2 and_RE2 banana_RE2 shall_RE2 be_RE2 avoid_RE2 
Procarbazine|P|matulane|sympathomimetic drug|because_LE1 BIOENTITY exhibit_BE12 some_BE12 monoamine_BE12 oxidase_BE12 inhibitory_BE12 activity_BE12 BIOENTITY BIOGENERAL_RE2 drug_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 other_RE2 drug_RE2 and_RE2 food_RE2 with_RE2 known_RE2 high_RE2 BIOGENERAL_RE2 content_RE2 such_RE2 as_RE2 wine_RE2 yogurt_RE2 ripe_RE2 cheese_RE2 and_RE2 banana_RE2 shall_RE2 be_RE2 avoid_RE2 
Procarbazine|P|matulane|tricyclic antidepressant|because_LE1 BIOENTITY exhibit_BE12 some_BE12 monoamine_BE12 oxidase_BE12 inhibitory_BE12 activity_BE12 BIOGENERAL_BE12 BIOENTITY drug_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 other_RE2 drug_RE2 and_RE2 food_RE2 with_RE2 known_RE2 high_RE2 BIOGENERAL_RE2 content_RE2 such_RE2 as_RE2 wine_RE2 yogurt_RE2 ripe_RE2 cheese_RE2 and_RE2 banana_RE2 shall_RE2 be_RE2 avoid_RE2 
Prochlorperazine|P|thiazide diuretic|phenothiazine|BIOENTITY may_BE12 accentuate_BE12 the_BE12 orthostatic_BE12 hypotension_BE12 that_BE12 may_BE12 occur_BE12 with_BE12 BIOENTITY 
Prochlorperazine|P|thiazide diuretic|phenothiazine|BIOENTITY may_BE12 accentuate_BE12 the_BE12 orthostatic_BE12 hypotension_BE12 that_BE12 may_BE12 occur_BE12 with_BE12 BIOENTITY 
Prochlorperazine|P|guanethidine|phenothiazine|antihypertensive_LE1 effect_LE1 of_LE1 BIOENTITY and_BE12 related_BE12 compound_BE12 may_BE12 be_BE12 counteract_BE12 when_BE12 BIOENTITY be_RE2 use_RE2 concomitant_RE2 
Prochlorperazine|P|propranolol|phenothiazine|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY result_RE2 in_RE2 increase_RE2 plasma_RE2 level_RE2 of_RE2 both_RE2 drug_RE2 
Propofol|P|diprivan|morphine|the_LE1 induction_LE1 dose_LE1 requirement_LE1 of_LE1 BIOENTITY injectable_BE12 emulsion_BE12 may_BE12 be_BE12 reduce_BE12 in_BE12 patient_BE12 with_BE12 intramuscular_BE12 or_BE12 intravenous_BE12 premedication_BE12 particular_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 etc_RE2 .rrb_RE2 
Propofol|P|diprivan|meperidine|the_LE1 induction_LE1 dose_LE1 requirement_LE1 of_LE1 BIOENTITY injectable_BE12 emulsion_BE12 may_BE12 be_BE12 reduce_BE12 in_BE12 patient_BE12 with_BE12 intramuscular_BE12 or_BE12 intravenous_BE12 premedication_BE12 particular_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 etc_RE2 .rrb_RE2 
Propofol|P|diprivan|narcotic|the_LE1 induction_LE1 dose_LE1 requirement_LE1 of_LE1 BIOENTITY injectable_BE12 emulsion_BE12 may_BE12 be_BE12 reduce_BE12 in_BE12 patient_BE12 with_BE12 intramuscular_BE12 or_BE12 intravenous_BE12 premedication_BE12 particular_BE12 with_BE12 BIOENTITY -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 etc_RE2 .rrb_RE2 
Propofol|P|diprivan|fentanyl|the_LE1 induction_LE1 dose_LE1 requirement_LE1 of_LE1 BIOENTITY injectable_BE12 emulsion_BE12 may_BE12 be_BE12 reduce_BE12 in_BE12 patient_BE12 with_BE12 intramuscular_BE12 or_BE12 intravenous_BE12 premedication_BE12 particular_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY etc_RE2 .rrb_RE2 
Propofol|P|diprivan|opioid|During_LE1 maintenance_LE1 of_LE1 anesthesia_LE1 or_LE1 sedation_LE1 the_LE1 rate_LE1 of_LE1 BIOENTITY injectable_BE12 emulsion_BE12 administration_BE12 shall_BE12 be_BE12 adjust_BE12 according_BE12 to_BE12 the_BE12 desired_BE12 level_BE12 of_BE12 anesthesia_BE12 or_BE12 sedation_BE12 and_BE12 may_BE12 be_BE12 reduce_BE12 in_BE12 the_BE12 presence_BE12 of_BE12 supplemental_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY rrb._RE2 
Propofol|P|diprivan|analgesic agent|During_LE1 maintenance_LE1 of_LE1 anesthesia_LE1 or_LE1 sedation_LE1 the_LE1 rate_LE1 of_LE1 BIOENTITY injectable_BE12 emulsion_BE12 administration_BE12 shall_BE12 be_BE12 adjust_BE12 according_BE12 to_BE12 the_BE12 desired_BE12 level_BE12 of_BE12 anesthesia_BE12 or_BE12 sedation_BE12 and_BE12 may_BE12 be_BE12 reduce_BE12 in_BE12 the_BE12 presence_BE12 of_BE12 supplemental_BE12 BIOENTITY -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 rrb._RE2 
Propofol|P|diprivan|nitrous oxide|During_LE1 maintenance_LE1 of_LE1 anesthesia_LE1 or_LE1 sedation_LE1 the_LE1 rate_LE1 of_LE1 BIOENTITY injectable_BE12 emulsion_BE12 administration_BE12 shall_BE12 be_BE12 adjust_BE12 according_BE12 to_BE12 the_BE12 desired_BE12 level_BE12 of_BE12 anesthesia_BE12 or_BE12 sedation_BE12 and_BE12 may_BE12 be_BE12 reduce_BE12 in_BE12 the_BE12 presence_BE12 of_BE12 supplemental_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 rrb._RE2 
Propoxyphene|P|propoxyphene|cns depressant|the_LE1 cnsdepressant_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 additive_BE12 with_BE12 that_BE12 of_BE12 other_BE12 BIOENTITY including_RE2 BIOGENERAL_RE2 
Propoxyphene|P|propoxyphene|alcohol|the_LE1 cnsdepressant_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 additive_BE12 with_BE12 that_BE12 of_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 BIOENTITY 
Pseudoephedrine|P|beta adrenergic blocker|pseudoephedrine|BIOGENERAL_LE1 and_LE1 BIOENTITY increase_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY 
Pseudoephedrine|P|mao inhibitor|pseudoephedrine|BIOENTITY and_BE12 BIOGENERAL_BE12 increase_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY 
Pseudoephedrine|P|sympathomimetic|reserpine|BIOENTITY may_BE12 reduce_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Pseudoephedrine|P|sympathomimetic|veratrum alkaloid|BIOENTITY may_BE12 reduce_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Pseudoephedrine|P|sympathomimetic|methyldopa|BIOENTITY may_BE12 reduce_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Pseudoephedrine|P|sympathomimetic|mecamylamine|BIOENTITY may_BE12 reduce_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Pyrimethamine|P|lorazepam|pyrimethamine|mild_LE1 hepatotoxicity_LE1 have_LE1 be_LE1 report_LE1 in_LE1 some_LE1 patient_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 administer_RE2 concomitant_RE2 
Raloxifene|P|cholestyramine|raloxifene|BIOGENERAL_LE1 :_LE1 BIOENTITY cause_BE12 NUM_BE12 reduction_BE12 in_BE12 the_BE12 absorption_BE12 and_BE12 enterohepatic_BE12 cycling_BE12 of_BE12 BIOENTITY and_RE2 shall_RE2 not_RE2 be_RE2 coadminister_RE2 with_RE2 BIOGENERAL_RE2 
Raloxifene|P|cholestyramine|evista|BIOGENERAL_LE1 :_LE1 BIOENTITY cause_BE12 NUM_BE12 reduction_BE12 in_BE12 the_BE12 absorption_BE12 and_BE12 enterohepatic_BE12 cycling_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 shall_BE12 not_BE12 be_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Raloxifene|P|evista|warfarin|if_LE1 BIOENTITY be_BE12 give_BE12 concurrent_BE12 with_BE12 BIOENTITY prothrombin_RE2 time_RE2 shall_RE2 be_RE2 monitor_RE2 
Raloxifene|P|evista|ibuprofen|caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 other_BE12 high_BE12 proteinbound_BE12 drug_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Raloxifene|P|evista|diazepam|caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 other_BE12 high_BE12 proteinbound_BE12 drug_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Raloxifene|P|evista|diazoxide|caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 other_BE12 high_BE12 proteinbound_BE12 drug_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Raloxifene|P|evista|clofibrate|caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 other_BE12 high_BE12 proteinbound_BE12 drug_BE12 such_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Raloxifene|P|evista|indomethacin|caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 other_BE12 high_BE12 proteinbound_BE12 drug_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Raloxifene|P|evista|naproxen|caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 other_BE12 high_BE12 proteinbound_BE12 drug_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Ranitidine|P|tritec|clarithromycin|coadministration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY result_RE2 in_RE2 increase_RE2 plasma_RE2 BIOGENERAL_RE2 concentration_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 increase_RE2 plasma_RE2 bismuth_RE2 trough_RE2 concentration_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 and_RE2 increase_RE2 BIOGENERAL_RE2 plasma_RE2 concentration_RE2 -LRB-_RE2 %rrb._RE2 
Ranitidine|P|antacid|ranitidine|coadministration_LE1 with_LE1 high_LE1 dose_LE1 of_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 meq_BE12 -RRB-_BE12 result_BE12 in_BE12 NUM_BE12 decrease_BE12 in_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY and_RE2 may_RE2 decrease_RE2 plasma_RE2 concentration_RE2 of_RE2 bismuth_RE2 from_RE2 BIOGENERAL_RE2 
Ranitidine|P|antacid|tritec|coadministration_LE1 with_LE1 high_LE1 dose_LE1 of_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 meq_BE12 -RRB-_BE12 result_BE12 in_BE12 NUM_BE12 decrease_BE12 in_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 may_BE12 decrease_BE12 plasma_BE12 concentration_BE12 of_BE12 bismuth_BE12 from_BE12 BIOENTITY 
Retapamulin|P|ketoconazole|retapamulin|coadministration_LE1 of_LE1 oral_LE1 BIOENTITY NUM_BE12 mg_BE12 twice_BE12 daily_BE12 increase_BE12 BIOGENERAL_BE12 geometric_BE12 mean_BE12 auc_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 and_BE12 cmax_BE12 by_BE12 NUM_BE12 after_BE12 topical_BE12 application_BE12 of_BE12 BIOENTITY ointment_RE2 NUM_RE2 on_RE2 the_RE2 abraded_RE2 skin_RE2 of_RE2 healthy_RE2 adult_RE2 male_RE2 
Reteplase|P|vitamin k antagonist|retavase|In_LE1 addition_LE1 to_LE1 bleeding_LE1 associate_LE1 with_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY drug_BE12 that_BE12 alter_BE12 platelet_BE12 function_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 bleeding_BE12 if_BE12 administer_BE12 prior_BE12 to_BE12 or_BE12 after_BE12 BIOENTITY therapy_RE2 
Reteplase|P|heparin|retavase|In_LE1 addition_LE1 to_LE1 bleeding_LE1 associate_LE1 with_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 drug_BE12 that_BE12 alter_BE12 platelet_BE12 function_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 bleeding_BE12 if_BE12 administer_BE12 prior_BE12 to_BE12 or_BE12 after_BE12 BIOENTITY therapy_RE2 
Reteplase|P|dipyridamole|retavase|In_LE1 addition_LE1 to_LE1 bleeding_LE1 associate_LE1 with_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 drug_LE1 that_LE1 alter_LE1 platelet_LE1 function_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 bleeding_BE12 if_BE12 administer_BE12 prior_BE12 to_BE12 or_BE12 after_BE12 BIOENTITY therapy_RE2 
Reteplase|P|dipyridamole|retavase|In_LE1 addition_LE1 to_LE1 bleeding_LE1 associate_LE1 with_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 drug_LE1 that_LE1 alter_LE1 platelet_LE1 function_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 bleeding_BE12 if_BE12 administer_BE12 prior_BE12 to_BE12 or_BE12 after_BE12 BIOENTITY therapy_RE2 
Reteplase|P|abciximab|retavase|In_LE1 addition_LE1 to_LE1 bleeding_LE1 associate_LE1 with_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 drug_LE1 that_LE1 alter_LE1 platelet_LE1 function_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY -RRB-_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 bleeding_BE12 if_BE12 administer_BE12 prior_BE12 to_BE12 or_BE12 after_BE12 BIOENTITY therapy_RE2 
Reteplase|P|abciximab|retavase|In_LE1 addition_LE1 to_LE1 bleeding_LE1 associate_LE1 with_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 drug_LE1 that_LE1 alter_LE1 platelet_LE1 function_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY -RRB-_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 bleeding_BE12 if_BE12 administer_BE12 prior_BE12 to_BE12 or_BE12 after_BE12 BIOENTITY therapy_RE2 
Reteplase|P|aspirin|retavase|In_LE1 addition_LE1 to_LE1 bleeding_LE1 associate_LE1 with_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 drug_LE1 that_LE1 alter_LE1 platelet_LE1 function_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 bleeding_BE12 if_BE12 administer_BE12 prior_BE12 to_BE12 or_BE12 after_BE12 BIOENTITY therapy_RE2 
Reteplase|P|aspirin|retavase|In_LE1 addition_LE1 to_LE1 bleeding_LE1 associate_LE1 with_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 drug_LE1 that_LE1 alter_LE1 platelet_LE1 function_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 bleeding_BE12 if_BE12 administer_BE12 prior_BE12 to_BE12 or_BE12 after_BE12 BIOENTITY therapy_RE2 
Riboflavin|P|alcohol|riboflavin|interaction_LE1 for_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 BIOENTITY impair_BE12 the_BE12 intestinal_BE12 absorption_BE12 of_BE12 BIOENTITY 
Riboflavin|P|probenecid|riboflavin|BIOENTITY concurrent_BE12 use_BE12 decrease_BE12 gastrointestinal_BE12 absorption_BE12 of_BE12 BIOENTITY 
Riboflavin|P|riboflavin|probenecid|requirement_LE1 for_LE1 BIOENTITY may_BE12 be_BE12 increase_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Rimantadine|P|rimantadine hcl|cimetidine|when_LE1 single_LE1 NUM_LE1 mg_LE1 dose_LE1 of_LE1 BIOENTITY be_BE12 administer_BE12 one_BE12 hour_BE12 after_BE12 the_BE12 initiation_BE12 of_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 four_RE2 time_RE2 day_RE2 -RRB-_RE2 the_RE2 apparent_RE2 total_RE2 BIOGENERAL_RE2 clearance_RE2 of_RE2 this_RE2 single_RE2 dose_RE2 in_RE2 normal_RE2 healthy_RE2 adult_RE2 be_RE2 reduce_RE2 by_RE2 NUM_RE2 -LRB-_RE2 compare_RE2 to_RE2 the_RE2 apparent_RE2 total_RE2 BIOGENERAL_RE2 clearance_RE2 in_RE2 the_RE2 same_RE2 subject_RE2 in_RE2 the_RE2 absence_RE2 of_RE2 BIOGENERAL_RE2 rrb._RE2 
Rimantadine|P|acetaminophen|rimantadine|coadministration_LE1 with_LE1 BIOENTITY reduce_BE12 the_BE12 peak_BE12 concentration_BE12 and_BE12 auc_BE12 value_BE12 for_BE12 BIOENTITY by_RE2 approximate_RE2 NUM_RE2 %._RE2 
Rimantadine|P|rimantadine|aspirin|peak_LE1 plasma_LE1 concentration_LE1 and_LE1 auc_LE1 of_LE1 BIOENTITY be_BE12 reduce_BE12 approximate_BE12 NUM_BE12 in_BE12 the_BE12 presence_BE12 of_BE12 BIOENTITY 
Rivastigmine|P|cholinesterase inhibitor|anticholinergic medication|use_LE1 with_LE1 BIOGENERAL_LE1 :_LE1 Because_LE1 of_LE1 their_LE1 mechanism_LE1 of_LE1 action_LE1 BIOENTITY have_BE12 the_BE12 potential_BE12 to_BE12 interfere_BE12 with_BE12 the_BE12 activity_BE12 of_BE12 BIOENTITY 
Rivastigmine|P|cholinesterase inhibitor|neuromuscular blocking agent|use_LE1 with_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 BIOGENERAL_LE1 :_LE1 synergistic_LE1 effect_LE1 may_LE1 be_LE1 expect_LE1 when_LE1 BIOENTITY be_BE12 give_BE12 concurrent_BE12 with_BE12 BIOGENERAL_BE12 similar_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 
Rivastigmine|P|cholinesterase inhibitor|succinylcholine|use_LE1 with_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 BIOGENERAL_LE1 :_LE1 synergistic_LE1 effect_LE1 may_LE1 be_LE1 expect_LE1 when_LE1 BIOENTITY be_BE12 give_BE12 concurrent_BE12 with_BE12 BIOENTITY similar_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 
Rivastigmine|P|cholinesterase inhibitor|bethanechol|use_LE1 with_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 BIOGENERAL_LE1 :_LE1 synergistic_LE1 effect_LE1 may_LE1 be_LE1 expect_LE1 when_LE1 BIOENTITY be_BE12 give_BE12 concurrent_BE12 with_BE12 BIOGENERAL_BE12 similar_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY 
Rivastigmine|P|cholinesterase inhibitor|cholinergic agonist|use_LE1 with_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 BIOGENERAL_LE1 :_LE1 synergistic_LE1 effect_LE1 may_LE1 be_LE1 expect_LE1 when_LE1 BIOENTITY be_BE12 give_BE12 concurrent_BE12 with_BE12 BIOGENERAL_BE12 similar_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 
Rocuronium|P|zemuron|succinylcholine|if_LE1 BIOENTITY be_BE12 administer_BE12 following_BE12 administration_BE12 of_BE12 BIOENTITY it_RE2 shall_RE2 not_RE2 be_RE2 give_RE2 until_RE2 recovery_RE2 from_RE2 BIOGENERAL_RE2 have_RE2 be_RE2 observe_RE2 
Ropivacaine|P|ropivacaine|anesthetic|BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 receive_BE12 other_BE12 local_BE12 BIOENTITY or_RE2 agent_RE2 structural_RE2 related_RE2 to_RE2 BIOGENERAL_RE2 since_RE2 the_RE2 toxic_RE2 effect_RE2 of_RE2 these_RE2 drug_RE2 be_RE2 additive_RE2 
Ropivacaine|P|ropivacaine|fluvoxamine|in_LE1 vivo_LE1 the_LE1 plasma_LE1 clearance_LE1 of_LE1 BIOENTITY be_BE12 reduce_BE12 by_BE12 NUM_BE12 during_BE12 coadministration_BE12 of_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 bid_RE2 for_RE2 NUM_RE2 day_RE2 -RRB-_RE2 selective_RE2 and_RE2 potent_RE2 cypa_RE2 inhibitor_RE2 
Ropivacaine|P|fluvoxamine|ropivacaine|thus_LE1 strong_LE1 inhibitor_LE1 of_LE1 cytochrome_LE1 pa_LE1 such_LE1 as_LE1 BIOENTITY give_BE12 concomitant_BE12 during_BE12 administration_BE12 of_BE12 BIOENTITY can_RE2 interact_RE2 with_RE2 BIOGENERAL_RE2 lead_RE2 to_RE2 increase_RE2 BIOGENERAL_RE2 plasma_RE2 level_RE2 
Ropivacaine|P|ketoconazole|ropivacaine|coadministration_LE1 of_LE1 selective_LE1 and_LE1 potent_LE1 inhibitor_LE1 of_LE1 cypa_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 bid_BE12 for_BE12 NUM_BE12 day_BE12 with_BE12 BIOGENERAL_BE12 infusion_BE12 administer_BE12 NUM_BE12 hour_BE12 after_BE12 BIOGENERAL_BE12 -RRB-_BE12 cause_BE12 NUM_BE12 reduction_BE12 in_BE12 invivo_BE12 plasma_BE12 clearance_BE12 of_BE12 BIOENTITY 
Rosiglitazone|P|gemfibrozil|rosiglitazone|inhibitor_LE1 of_LE1 cypc_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOENTITY -RRB-_BE12 may_BE12 increase_BE12 the_BE12 auc_BE12 of_BE12 BIOENTITY and_RE2 inducer_RE2 of_RE2 cypc_RE2 -LRB-_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 decrease_RE2 the_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 
Rosiglitazone|P|rifampin|rosiglitazone|inhibitor_LE1 of_LE1 cypc_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 -RRB-_LE1 may_LE1 increase_LE1 the_LE1 auc_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 inducer_LE1 of_LE1 cypc_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOENTITY -RRB-_BE12 may_BE12 decrease_BE12 the_BE12 auc_BE12 of_BE12 BIOENTITY 
Roxithromycin|P|macrolide|terfenadine|concomitant_LE1 administration_LE1 not_LE1 recommend_LE1 :_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 certain_LE1 BIOENTITY interact_BE12 with_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 lead_RE2 to_RE2 increase_RE2 serum_RE2 concentration_RE2 of_RE2 the_RE2 latter_RE2 
Roxithromycin|P|macrolide|astemizole|concomitant_LE1 administration_LE1 not_LE1 recommend_LE1 :_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 certain_LE1 BIOENTITY interact_BE12 with_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY lead_RE2 to_RE2 increase_RE2 serum_RE2 concentration_RE2 of_RE2 the_RE2 latter_RE2 
Roxithromycin|P|roxithromycin|terfenadine|although_LE1 such_LE1 reaction_LE1 have_LE1 not_LE1 be_LE1 demonstrate_LE1 with_LE1 BIOGENERAL_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 be_RE2 not_RE2 recommend_RE2 
Roxithromycin|P|roxithromycin|astemizole|although_LE1 such_LE1 reaction_LE1 have_LE1 not_LE1 be_LE1 demonstrate_LE1 with_LE1 BIOGENERAL_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 
Roxithromycin|P|cisapride|macrolide antibacterial|BIOGENERAL_LE1 BIOGENERAL_LE1 :_LE1 other_LE1 drug_LE1 such_LE1 as_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 which_BE12 be_BE12 metabolize_BE12 by_BE12 hepatic_BE12 cypa_BE12 isozyme_BE12 have_BE12 be_BE12 associate_BE12 with_BE12 qt_BE12 interval_BE12 prolongation_BE12 and_BE12 cardiac_BE12 arrythmia_BE12 -LRB-_BE12 typical_BE12 torsade_BE12 de_BE12 pointe_BE12 -RRB-_BE12 as_BE12 result_BE12 of_BE12 increase_BE12 in_BE12 their_BE12 serum_BE12 level_BE12 subsequent_BE12 to_BE12 interaction_BE12 with_BE12 significant_BE12 inhibitor_BE12 of_BE12 the_BE12 isozyme_BE12 including_BE12 some_BE12 BIOENTITY 
Roxithromycin|P|pimozide|macrolide antibacterial|BIOGENERAL_LE1 BIOENTITY :_BE12 other_BE12 drug_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 which_BE12 be_BE12 metabolize_BE12 by_BE12 hepatic_BE12 cypa_BE12 isozyme_BE12 have_BE12 be_BE12 associate_BE12 with_BE12 qt_BE12 interval_BE12 prolongation_BE12 and_BE12 cardiac_BE12 arrythmia_BE12 -LRB-_BE12 typical_BE12 torsade_BE12 de_BE12 pointe_BE12 -RRB-_BE12 as_BE12 result_BE12 of_BE12 increase_BE12 in_BE12 their_BE12 serum_BE12 level_BE12 subsequent_BE12 to_BE12 interaction_BE12 with_BE12 significant_BE12 inhibitor_BE12 of_BE12 the_BE12 isozyme_BE12 including_BE12 some_BE12 BIOENTITY 
Salmon Calcitonin|P|diphosphonate|calcitonin (salmon)|however_LE1 in_LE1 patient_LE1 with_LE1 paget_LE1 's_LE1 disease_LE1 prior_LE1 BIOENTITY use_BE12 appear_BE12 to_BE12 reduce_BE12 the_BE12 antiresorptive_BE12 response_BE12 to_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 nasal_RE2 spray_RE2 
Salsalate|P|salicylate drug|disalcid|BIOGENERAL_LE1 AND_LE1 other_LE1 BIOENTITY will_BE12 be_BE12 additive_BE12 to_BE12 BIOENTITY AND_RE2 may_RE2 increase_RE2 plasma_RE2 concentration_RE2 OF_RE2 BIOGENERAL_RE2 to_RE2 toxic_RE2 level_RE2 
Salsalate|P|aspirin|disalcid|BIOENTITY AND_BE12 other_BE12 BIOGENERAL_BE12 will_BE12 be_BE12 additive_BE12 to_BE12 BIOENTITY AND_RE2 may_RE2 increase_RE2 plasma_RE2 concentration_RE2 OF_RE2 BIOGENERAL_RE2 to_RE2 toxic_RE2 level_RE2 
Salsalate|P|salicylate|anticoagulant drug|BIOENTITY give_BE12 concomitant_BE12 with_BE12 BIOENTITY may_RE2 predispose_RE2 to_RE2 systemic_RE2 bleeding_RE2 
Salsalate|P|salicylate|antidiabetic drug|BIOENTITY may_BE12 enhance_BE12 the_BE12 hypoglycemic_BE12 effect_BE12 of_BE12 oral_BE12 BIOENTITY of_RE2 the_RE2 sulfonylurea_RE2 class_RE2 
Salsalate|P|salicylate|triiodothyronine|BIOENTITY compete_BE12 with_BE12 number_BE12 of_BE12 drug_BE12 for_BE12 protein_BE12 binding_BE12 site_BE12 notable_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 possible_RE2 BIOGENERAL_RE2 
Salsalate|P|salicylate|phenytoin|BIOENTITY compete_BE12 with_BE12 number_BE12 of_BE12 drug_BE12 for_BE12 protein_BE12 binding_BE12 site_BE12 notable_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 possible_RE2 BIOGENERAL_RE2 
Salsalate|P|salicylate|thiopental|BIOENTITY compete_BE12 with_BE12 number_BE12 of_BE12 drug_BE12 for_BE12 protein_BE12 binding_BE12 site_BE12 notable_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 possible_RE2 BIOGENERAL_RE2 
Salsalate|P|salicylate|thyroxine|BIOENTITY compete_BE12 with_BE12 number_BE12 of_BE12 drug_BE12 for_BE12 protein_BE12 binding_BE12 site_BE12 notable_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 possible_RE2 BIOGENERAL_RE2 
Salsalate|P|salicylate|penicillin|BIOENTITY compete_BE12 with_BE12 number_BE12 of_BE12 drug_BE12 for_BE12 protein_BE12 binding_BE12 site_BE12 notable_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 possible_RE2 BIOGENERAL_RE2 
Salsalate|P|salicylate|naproxen|BIOENTITY compete_BE12 with_BE12 number_BE12 of_BE12 drug_BE12 for_BE12 protein_BE12 binding_BE12 site_BE12 notable_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 possible_RE2 BIOGENERAL_RE2 
Salsalate|P|salicylate|sulfinpyrazone|BIOENTITY compete_BE12 with_BE12 number_BE12 of_BE12 drug_BE12 for_BE12 protein_BE12 binding_BE12 site_BE12 notable_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 possible_RE2 BIOGENERAL_RE2 
Salsalate|P|salicylate|methotrexate|BIOENTITY compete_BE12 with_BE12 number_BE12 of_BE12 drug_BE12 for_BE12 protein_BE12 binding_BE12 site_BE12 notable_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 possible_RE2 BIOGENERAL_RE2 
Salsalate|P|salicylate|warfarin|BIOENTITY compete_BE12 with_BE12 number_BE12 of_BE12 drug_BE12 for_BE12 protein_BE12 binding_BE12 site_BE12 notable_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 possible_RE2 BIOGENERAL_RE2 
Salsalate|P|salicylate|corticosteroid|BIOENTITY compete_BE12 with_BE12 number_BE12 of_BE12 drug_BE12 for_BE12 protein_BE12 binding_BE12 site_BE12 notable_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 possible_BE12 BIOENTITY 
Sargramostim|P|leukine|corticosteroid|drug_LE1 which_LE1 may_LE1 potentiate_LE1 the_LE1 myeloproliferative_LE1 effect_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY shall_RE2 be_RE2 use_RE2 with_RE2 caution_RE2 
Sargramostim|P|leukine|corticosteroid|drug_LE1 which_LE1 may_LE1 potentiate_LE1 the_LE1 myeloproliferative_LE1 effect_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY shall_RE2 be_RE2 use_RE2 with_RE2 caution_RE2 
Sargramostim|P|leukine|lithium|drug_LE1 which_LE1 may_LE1 potentiate_LE1 the_LE1 myeloproliferative_LE1 effect_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 shall_RE2 be_RE2 use_RE2 with_RE2 caution_RE2 
Sargramostim|P|leukine|lithium|drug_LE1 which_LE1 may_LE1 potentiate_LE1 the_LE1 myeloproliferative_LE1 effect_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 shall_RE2 be_RE2 use_RE2 with_RE2 caution_RE2 
Scopolamine|P|scopolamine|sedative|BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 care_BE12 in_BE12 patient_BE12 take_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 capable_BE12 of_BE12 cause_BE12 cns_BE12 effect_BE12 such_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Scopolamine|P|scopolamine|sedative|BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 care_BE12 in_BE12 patient_BE12 take_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 capable_BE12 of_BE12 cause_BE12 cns_BE12 effect_BE12 such_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Scopolamine|P|scopolamine|alcohol|BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 care_BE12 in_BE12 patient_BE12 take_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 capable_BE12 of_BE12 cause_BE12 cns_BE12 effect_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Scopolamine|P|scopolamine|alcohol|BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 care_BE12 in_BE12 patient_BE12 take_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 capable_BE12 of_BE12 cause_BE12 cns_BE12 effect_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Scopolamine|P|scopolamine|tranquilizer|BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 care_BE12 in_BE12 patient_BE12 take_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 capable_BE12 of_BE12 cause_BE12 cns_BE12 effect_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Scopolamine|P|scopolamine|tranquilizer|BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 care_BE12 in_BE12 patient_BE12 take_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 capable_BE12 of_BE12 cause_BE12 cns_BE12 effect_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Secobarbital|P|barbiturate|corticosteroid|BIOENTITY may_BE12 decrease_BE12 the_BE12 effectiveness_BE12 of_BE12 oral_BE12 BIOGENERAL_BE12 certain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Secobarbital|P|barbiturate|anticoagulant|BIOENTITY may_BE12 decrease_BE12 the_BE12 effectiveness_BE12 of_BE12 oral_BE12 BIOGENERAL_BE12 certain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Secobarbital|P|barbiturate|beta blocker|BIOENTITY may_BE12 decrease_BE12 the_BE12 effectiveness_BE12 of_BE12 oral_BE12 BIOGENERAL_BE12 certain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Secobarbital|P|barbiturate|contraceptive|BIOENTITY may_BE12 decrease_BE12 the_BE12 effectiveness_BE12 of_BE12 oral_BE12 BIOENTITY certain_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Secobarbital|P|barbiturate|antibiotic|BIOENTITY may_BE12 decrease_BE12 the_BE12 effectiveness_BE12 of_BE12 oral_BE12 BIOGENERAL_BE12 certain_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Secobarbital|P|barbiturate|quinidine|BIOENTITY may_BE12 decrease_BE12 the_BE12 effectiveness_BE12 of_BE12 oral_BE12 BIOGENERAL_BE12 certain_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Secobarbital|P|barbiturate|theophylline|BIOENTITY may_BE12 decrease_BE12 the_BE12 effectiveness_BE12 of_BE12 oral_BE12 BIOGENERAL_BE12 certain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Selegiline|P|selegiline|meperidine|the_LE1 occurrence_LE1 of_LE1 stupor_LE1 muscular_LE1 rigidity_LE1 severe_LE1 agitation_LE1 and_LE1 elevated_LE1 temperature_LE1 have_LE1 be_LE1 report_LE1 in_LE1 some_LE1 patient_LE1 receive_LE1 the_LE1 combination_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY 
Selegiline|P|meperidine|maoi|this_LE1 be_LE1 typical_LE1 of_LE1 the_LE1 interaction_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY 
Selegiline|P|selective serotonin reuptake inhibitor|eldepryl|severe_LE1 toxicity_LE1 have_LE1 also_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 receive_LE1 the_LE1 combination_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY and_BE12 BIOENTITY 
Selegiline|P|tricyclic antidepressant|eldepryl|severe_LE1 toxicity_LE1 have_LE1 also_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 receive_LE1 the_LE1 combination_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Selegiline|P|selegiline|ephedrine|one_LE1 case_LE1 of_LE1 hypertensive_LE1 crisis_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 take_LE1 the_LE1 recommend_LE1 dose_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY 
Selegiline|P|selegiline|sympathomimetic medication|one_LE1 case_LE1 of_LE1 hypertensive_LE1 crisis_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 take_LE1 the_LE1 recommend_LE1 dose_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 
Sitagliptin|P|digoxin|sitagliptin|BIOGENERAL_LE1 :_LE1 there_LE1 be_LE1 slight_LE1 increase_LE1 in_LE1 the_LE1 area_LE1 under_LE1 the_LE1 curve_LE1 -LRB-_LE1 auc_LE1 NUM_LE1 -RRB-_LE1 and_LE1 mean_LE1 peak_LE1 drug_LE1 concentration_LE1 -LRB-_LE1 cmax_LE1 NUM_LE1 -RRB-_LE1 of_LE1 BIOENTITY with_BE12 the_BE12 coadministration_BE12 of_BE12 NUM_BE12 mg_BE12 BIOENTITY for_RE2 NUM_RE2 day_RE2 
Sodium bicarbonate|P|norepinephrine|sodium bicarbonate|BIOENTITY and_BE12 BIOGENERAL_BE12 be_BE12 incompatible_BE12 with_BE12 BIOENTITY solution_RE2 
Sodium bicarbonate|P|dobutamine|sodium bicarbonate|BIOGENERAL_LE1 and_LE1 BIOENTITY be_BE12 incompatible_BE12 with_BE12 BIOENTITY solution_RE2 
Solifenacin|P|vesicare|ketoconazole|do_LE1 not_LE1 exceed_LE1 NUM_LE1 mg_LE1 daily_LE1 dose_LE1 of_LE1 BIOENTITY when_BE12 administer_BE12 with_BE12 therapeutic_BE12 dose_BE12 of_BE12 BIOENTITY or_RE2 other_RE2 potent_RE2 cypa_RE2 inhibitor_RE2 
Somatropin recombinant|P|gh|antipyrine|limited_LE1 publish_LE1 datum_LE1 indicate_LE1 that_LE1 BIOENTITY treatment_BE12 increase_BE12 cytochrome_BE12 -LRB-_BE12 cp_BE12 -RRB-_BE12 mediated_BE12 BIOENTITY clearance_RE2 in_RE2 man_RE2 
Somatropin recombinant|P|gh|corticosteroid|these_LE1 datum_LE1 suggest_LE1 that_LE1 BIOENTITY administration_BE12 may_BE12 alter_BE12 the_BE12 clearance_BE12 of_BE12 compound_BE12 know_BE12 to_BE12 be_BE12 metabolize_BE12 by_BE12 cp_BE12 liver_BE12 enzyme_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Somatropin recombinant|P|gh|cyclosporin|these_LE1 datum_LE1 suggest_LE1 that_LE1 BIOENTITY administration_BE12 may_BE12 alter_BE12 the_BE12 clearance_BE12 of_BE12 compound_BE12 know_BE12 to_BE12 be_BE12 metabolize_BE12 by_BE12 cp_BE12 liver_BE12 enzyme_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY rrb._RE2 
Somatropin recombinant|P|gh|anticonvulsant|these_LE1 datum_LE1 suggest_LE1 that_LE1 BIOENTITY administration_BE12 may_BE12 alter_BE12 the_BE12 clearance_BE12 of_BE12 compound_BE12 know_BE12 to_BE12 be_BE12 metabolize_BE12 by_BE12 cp_BE12 liver_BE12 enzyme_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 rrb._RE2 
Somatropin recombinant|P|gh|sex steroid|these_LE1 datum_LE1 suggest_LE1 that_LE1 BIOENTITY administration_BE12 may_BE12 alter_BE12 the_BE12 clearance_BE12 of_BE12 compound_BE12 know_BE12 to_BE12 be_BE12 metabolize_BE12 by_BE12 cp_BE12 liver_BE12 enzyme_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 rrb._RE2 
Sorafenib|P|nexavar|irinotecan|caution_LE1 be_LE1 recommend_LE1 when_LE1 administer_LE1 BIOENTITY with_BE12 compound_BE12 that_BE12 be_BE12 metabolized_BE12 predominant_BE12 by_BE12 the_BE12 ugta_BE12 pathway_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY rrb._RE2 
Sorafenib|P|nexavar|irinotecan|caution_LE1 be_LE1 recommend_LE1 when_LE1 administer_LE1 BIOENTITY with_BE12 compound_BE12 that_BE12 be_BE12 metabolized_BE12 predominant_BE12 by_BE12 the_BE12 ugta_BE12 pathway_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY rrb._RE2 
Sorafenib|P|nexavar|doxorubicin|concomitant_LE1 treatment_LE1 with_LE1 BIOENTITY result_BE12 in_BE12 NUM_BE12 increase_BE12 in_BE12 the_BE12 auc_BE12 of_BE12 BIOENTITY 
Sorafenib|P|doxorubicin|nexavar|caution_LE1 be_LE1 recommend_LE1 when_LE1 administer_LE1 BIOENTITY with_BE12 BIOENTITY 
Stavudine|P|zidovudine|stavudine|BIOENTITY competitive_BE12 inhibit_BE12 the_BE12 intracellular_BE12 phosphorylation_BE12 of_BE12 BIOENTITY 
Stavudine|P|zidovudine|zerit|therefore_LE1 use_LE1 of_LE1 BIOENTITY in_BE12 combination_BE12 with_BE12 BIOENTITY shall_RE2 be_RE2 avoid_RE2 
Stavudine|P|stavudine|doxorubicin|in_LE1 vitro_LE1 datum_LE1 indicate_LE1 that_LE1 the_LE1 phosphorylation_LE1 of_LE1 BIOENTITY be_BE12 also_BE12 inhibit_BE12 at_BE12 relevant_BE12 concentration_BE12 by_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Stavudine|P|stavudine|ribavirin|in_LE1 vitro_LE1 datum_LE1 indicate_LE1 that_LE1 the_LE1 phosphorylation_LE1 of_LE1 BIOENTITY be_BE12 also_BE12 inhibit_BE12 at_BE12 relevant_BE12 concentration_BE12 by_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Streptokinase|P|streptase|antiplatelet agent|use_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 --_LE1 BIOENTITY BIOGENERAL_BE12 alone_BE12 or_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 may_RE2 cause_RE2 bleeding_RE2 complication_RE2 
Streptokinase|P|streptase|anticoagulant|use_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 --_LE1 BIOENTITY BIOGENERAL_BE12 alone_BE12 or_BE12 in_BE12 combination_BE12 with_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY may_RE2 cause_RE2 bleeding_RE2 complication_RE2 
Streptokinase|P|streptokinase|antiplatelet agent|use_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 --_LE1 BIOGENERAL_LE1 BIOENTITY alone_BE12 or_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 may_RE2 cause_RE2 bleeding_RE2 complication_RE2 
Streptokinase|P|streptokinase|anticoagulant|use_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 --_LE1 BIOGENERAL_LE1 BIOENTITY alone_BE12 or_BE12 in_BE12 combination_BE12 with_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY may_RE2 cause_RE2 bleeding_RE2 complication_RE2 
Streptokinase|P|aspirin|streptokinase|the_LE1 addition_LE1 of_LE1 BIOENTITY to_BE12 BIOENTITY cause_RE2 minimal_RE2 increase_RE2 in_RE2 the_RE2 risk_RE2 of_RE2 minor_RE2 bleeding_RE2 -LRB-_RE2 vs._RE2 -RRB-_RE2 but_RE2 do_RE2 not_RE2 appear_RE2 to_RE2 increase_RE2 the_RE2 incidence_RE2 of_RE2 major_RE2 bleeding_RE2 -LRB-_RE2 see_RE2 
Streptozocin|P|streptozocin|doxorubicin|BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 prolong_BE12 the_BE12 elimination_BE12 halflife_BE12 of_BE12 BIOENTITY and_RE2 may_RE2 lead_RE2 to_RE2 severe_RE2 bone_RE2 marrow_RE2 suppression_RE2 
Streptozocin|P|doxorubicin|zanosar|reduction_LE1 of_LE1 the_LE1 BIOENTITY dosage_BE12 shall_BE12 be_BE12 consider_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY concurrent_RE2 
Streptozocin|P|streptozocin|phenytoin|the_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY have_RE2 be_RE2 report_RE2 in_RE2 one_RE2 case_RE2 to_RE2 result_RE2 in_RE2 reduce_RE2 BIOGENERAL_RE2 cytotoxicity_RE2 
Succimer|P|chemet|cana 2 edta|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 chelation_BE12 therapy_BE12 such_BE12 as_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 
Sulfamethizole|P|sulfamethizole|barbiturate|BIOENTITY may_BE12 increase_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Sulfamethizole|P|sulfamethizole|tolbutamide|BIOENTITY may_BE12 increase_BE12 the_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Sulfamethizole|P|sulfamethizole|uricosuric|BIOENTITY may_BE12 increase_BE12 the_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Sulfamethoxazole|P|sulfamethoxazole|warfarin|it_LE1 have_LE1 be_LE1 report_LE1 that_LE1 BIOENTITY may_BE12 prolong_BE12 the_BE12 prothrombin_BE12 time_BE12 in_BE12 patient_BE12 who_BE12 be_BE12 receive_BE12 the_BE12 BIOGENERAL_BE12 BIOENTITY 
Sulfamethoxazole|P|sulfamethoxazole|warfarin|it_LE1 have_LE1 be_LE1 report_LE1 that_LE1 BIOENTITY may_BE12 prolong_BE12 the_BE12 prothrombin_BE12 time_BE12 in_BE12 patient_BE12 who_BE12 be_BE12 receive_BE12 the_BE12 BIOGENERAL_BE12 BIOENTITY 
Sulfamethoxazole|P|sulfamethoxazole|phenytoin|BIOENTITY may_BE12 inhibit_BE12 the_BE12 hepatic_BE12 metabolism_BE12 of_BE12 BIOENTITY 
Sulfamethoxazole|P|sulfamethoxazole|phenytoin|At_LE1 .g_LE1 dose_LE1 BIOENTITY produce_BE12 slight_BE12 but_BE12 significant_BE12 increase_BE12 in_BE12 the_BE12 halflife_BE12 of_BE12 BIOENTITY but_RE2 do_RE2 not_RE2 produce_RE2 corresponding_RE2 decrease_RE2 in_RE2 the_RE2 metabolic_RE2 clearance_RE2 rate_RE2 
Sulfamethoxazole|P|sulfonamide|methotrexate|BIOENTITY can_BE12 also_BE12 displace_BE12 BIOENTITY from_RE2 plasma_RE2 proteinbinding_RE2 site_RE2 thus_RE2 increase_RE2 free_RE2 BIOGENERAL_RE2 concentration_RE2 
Sulfasalazine|P|digoxin|sulfasalazine|reduce_LE1 absorption_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 when_BE12 those_BE12 agent_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY 
Sulfasalazine|P|folic acid|sulfasalazine|reduce_LE1 absorption_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 have_BE12 be_BE12 report_BE12 when_BE12 those_BE12 agent_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY 
Sulfoxone|P|sulfoxone|barbiturate|BIOENTITY may_BE12 increase_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Sulfoxone|P|sulfoxone|tolbutamide|BIOENTITY may_BE12 increase_BE12 the_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Sulfoxone|P|sulfoxone|uricosuric|BIOENTITY may_BE12 increase_BE12 the_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Sumatriptan|P|dihydroergotamine|sumatriptan|because_LE1 there_LE1 be_LE1 theoretical_LE1 basis_LE1 that_LE1 these_LE1 effect_LE1 may_LE1 be_LE1 additive_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 -LRB-_LE1 like_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY within_RE2 NUM_RE2 hour_RE2 of_RE2 each_RE2 other_RE2 shall_RE2 be_RE2 avoid_RE2 
Sumatriptan|P|methysergide|sumatriptan|because_LE1 there_LE1 be_LE1 theoretical_LE1 basis_LE1 that_LE1 these_LE1 effect_LE1 may_LE1 be_LE1 additive_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 -LRB-_LE1 like_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY -RRB-_BE12 and_BE12 BIOENTITY within_RE2 NUM_RE2 hour_RE2 of_RE2 each_RE2 other_RE2 shall_RE2 be_RE2 avoid_RE2 
Sumatriptan|P|ergotamine|sumatriptan|because_LE1 there_LE1 be_LE1 theoretical_LE1 basis_LE1 that_LE1 these_LE1 effect_LE1 may_LE1 be_LE1 additive_LE1 use_LE1 of_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 -LRB-_BE12 like_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY within_RE2 NUM_RE2 hour_RE2 of_RE2 each_RE2 other_RE2 shall_RE2 be_RE2 avoid_RE2 
Sumatriptan|P|ergot-type medication|sumatriptan|because_LE1 there_LE1 be_LE1 theoretical_LE1 basis_LE1 that_LE1 these_LE1 effect_LE1 may_LE1 be_LE1 additive_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY -LRB-_BE12 like_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY within_RE2 NUM_RE2 hour_RE2 of_RE2 each_RE2 other_RE2 shall_RE2 be_RE2 avoid_RE2 
Sumatriptan|P|mao-a inhibitor|sumatriptan|BIOENTITY reduce_BE12 BIOENTITY clearance_RE2 significant_RE2 increase_RE2 systemic_RE2 exposure_RE2 
Sumatriptan|P|sertraline|sumatriptan|therefore_LE1 the_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 tablet_LE1 in_LE1 patient_LE1 receive_LE1 BIOGENERAL_LE1 be_LE1 contraindicate_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 have_BE12 be_BE12 report_BE12 rare_BE12 to_BE12 cause_BE12 weakness_BE12 hyperreflexia_BE12 and_BE12 incoordination_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Sumatriptan|P|paroxetine|sumatriptan|therefore_LE1 the_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 tablet_LE1 in_LE1 patient_LE1 receive_LE1 BIOGENERAL_LE1 be_LE1 contraindicate_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 have_BE12 be_BE12 report_BE12 rare_BE12 to_BE12 cause_BE12 weakness_BE12 hyperreflexia_BE12 and_BE12 incoordination_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Sumatriptan|P|fluvoxamine|sumatriptan|therefore_LE1 the_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 tablet_LE1 in_LE1 patient_LE1 receive_LE1 BIOGENERAL_LE1 be_LE1 contraindicate_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 have_BE12 be_BE12 report_BE12 rare_BE12 to_BE12 cause_BE12 weakness_BE12 hyperreflexia_BE12 and_BE12 incoordination_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Sumatriptan|P|fluoxetine|sumatriptan|therefore_LE1 the_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 tablet_LE1 in_LE1 patient_LE1 receive_LE1 BIOGENERAL_LE1 be_LE1 contraindicate_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 have_BE12 be_BE12 report_BE12 rare_BE12 to_BE12 cause_BE12 weakness_BE12 hyperreflexia_BE12 and_BE12 incoordination_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Sumatriptan|P|ssri|sumatriptan|therefore_LE1 the_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 tablet_LE1 in_LE1 patient_LE1 receive_LE1 BIOGENERAL_LE1 be_LE1 contraindicate_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 have_BE12 be_BE12 report_BE12 rare_BE12 to_BE12 cause_BE12 weakness_BE12 hyperreflexia_BE12 and_BE12 incoordination_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Sumatriptan|P|sumatriptan succinate|mao-a inhibitor|therefore_LE1 the_LE1 use_LE1 of_LE1 BIOENTITY tablet_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY be_RE2 contraindicate_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 have_RE2 be_RE2 report_RE2 rare_RE2 to_RE2 cause_RE2 weakness_RE2 hyperreflexia_RE2 and_RE2 incoordination_RE2 when_RE2 coadminister_RE2 with_RE2 BIOGENERAL_RE2 
Sumatriptan|P|selective serotonin reuptake inhibitor|sumatriptan|therefore_LE1 the_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 tablet_LE1 in_LE1 patient_LE1 receive_LE1 BIOGENERAL_LE1 be_LE1 contraindicate_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 have_BE12 be_BE12 report_BE12 rare_BE12 to_BE12 cause_BE12 weakness_BE12 hyperreflexia_BE12 and_BE12 incoordination_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Sumatriptan|P|sumatriptan|ssri|if_LE1 concomitant_LE1 treatment_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 clinical_RE2 warrant_RE2 appropriate_RE2 observation_RE2 of_RE2 the_RE2 patient_RE2 be_RE2 advise_RE2 
Sunitinib|P|sutent|clarithromycin|coadministration_LE1 of_LE1 BIOENTITY with_BE12 strong_BE12 inhibitor_BE12 of_BE12 the_BE12 cypa_BE12 family_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 increase_RE2 BIOGENERAL_RE2 concentration_RE2 
Sunitinib|P|sutent|voriconizole|coadministration_LE1 of_LE1 BIOENTITY with_BE12 strong_BE12 inhibitor_BE12 of_BE12 the_BE12 cypa_BE12 family_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 may_RE2 increase_RE2 BIOGENERAL_RE2 concentration_RE2 
Sunitinib|P|sutent|itraconazole|coadministration_LE1 of_LE1 BIOENTITY with_BE12 strong_BE12 inhibitor_BE12 of_BE12 the_BE12 cypa_BE12 family_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 increase_RE2 BIOGENERAL_RE2 concentration_RE2 
Sunitinib|P|sutent|ketoconazole|coadministration_LE1 of_LE1 BIOENTITY with_BE12 strong_BE12 inhibitor_BE12 of_BE12 the_BE12 cypa_BE12 family_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 increase_RE2 BIOGENERAL_RE2 concentration_RE2 
Sunitinib|P|sutent|nelfinavir|coadministration_LE1 of_LE1 BIOENTITY with_BE12 strong_BE12 inhibitor_BE12 of_BE12 the_BE12 cypa_BE12 family_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 increase_RE2 BIOGENERAL_RE2 concentration_RE2 
Sunitinib|P|sutent|nefazodone|coadministration_LE1 of_LE1 BIOENTITY with_BE12 strong_BE12 inhibitor_BE12 of_BE12 the_BE12 cypa_BE12 family_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 increase_RE2 BIOGENERAL_RE2 concentration_RE2 
Sunitinib|P|sutent|indinavir|coadministration_LE1 of_LE1 BIOENTITY with_BE12 strong_BE12 inhibitor_BE12 of_BE12 the_BE12 cypa_BE12 family_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 increase_RE2 BIOGENERAL_RE2 concentration_RE2 
Sunitinib|P|sutent|atazanavir|coadministration_LE1 of_LE1 BIOENTITY with_BE12 strong_BE12 inhibitor_BE12 of_BE12 the_BE12 cypa_BE12 family_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 increase_RE2 BIOGENERAL_RE2 concentration_RE2 
Sunitinib|P|sutent|telithromycin|coadministration_LE1 of_LE1 BIOENTITY with_BE12 strong_BE12 inhibitor_BE12 of_BE12 the_BE12 cypa_BE12 family_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 may_RE2 increase_RE2 BIOGENERAL_RE2 concentration_RE2 
Sunitinib|P|sutent|ritonavir|coadministration_LE1 of_LE1 BIOENTITY with_BE12 strong_BE12 inhibitor_BE12 of_BE12 the_BE12 cypa_BE12 family_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 increase_RE2 BIOGENERAL_RE2 concentration_RE2 
Sunitinib|P|sutent|saquinavir|coadministration_LE1 of_LE1 BIOENTITY with_BE12 strong_BE12 inhibitor_BE12 of_BE12 the_BE12 cypa_BE12 family_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 increase_RE2 BIOGENERAL_RE2 concentration_RE2 
Sunitinib|P|sutent|dexamethasone|coadministration_LE1 of_LE1 BIOENTITY with_BE12 inducer_BE12 of_BE12 the_BE12 cypa_BE12 family_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 st._RE2 john_RE2 wort_RE2 -RRB-_RE2 may_RE2 decrease_RE2 BIOGENERAL_RE2 concentration_RE2 
Sunitinib|P|sutent|phenobarbital|coadministration_LE1 of_LE1 BIOENTITY with_BE12 inducer_BE12 of_BE12 the_BE12 cypa_BE12 family_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY st._RE2 john_RE2 wort_RE2 -RRB-_RE2 may_RE2 decrease_RE2 BIOGENERAL_RE2 concentration_RE2 
Sunitinib|P|sutent|rifapentin|coadministration_LE1 of_LE1 BIOENTITY with_BE12 inducer_BE12 of_BE12 the_BE12 cypa_BE12 family_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 st._RE2 john_RE2 wort_RE2 -RRB-_RE2 may_RE2 decrease_RE2 BIOGENERAL_RE2 concentration_RE2 
Sunitinib|P|sutent|carbamazepine|coadministration_LE1 of_LE1 BIOENTITY with_BE12 inducer_BE12 of_BE12 the_BE12 cypa_BE12 family_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 st._RE2 john_RE2 wort_RE2 -RRB-_RE2 may_RE2 decrease_RE2 BIOGENERAL_RE2 concentration_RE2 
Sunitinib|P|sutent|phenytoin|coadministration_LE1 of_LE1 BIOENTITY with_BE12 inducer_BE12 of_BE12 the_BE12 cypa_BE12 family_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 st._RE2 john_RE2 wort_RE2 -RRB-_RE2 may_RE2 decrease_RE2 BIOGENERAL_RE2 concentration_RE2 
Sunitinib|P|sutent|rifabutin|coadministration_LE1 of_LE1 BIOENTITY with_BE12 inducer_BE12 of_BE12 the_BE12 cypa_BE12 family_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 st._RE2 john_RE2 wort_RE2 -RRB-_RE2 may_RE2 decrease_RE2 BIOGENERAL_RE2 concentration_RE2 
Sunitinib|P|sutent|rifampin|coadministration_LE1 of_LE1 BIOENTITY with_BE12 inducer_BE12 of_BE12 the_BE12 cypa_BE12 family_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 st._RE2 john_RE2 wort_RE2 -RRB-_RE2 may_RE2 decrease_RE2 BIOGENERAL_RE2 concentration_RE2 
Suprofen|P|carbachol|suprofen|other_LE1 eye_LE1 drop_LE1 or_LE1 medication_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 and_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 decrease_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY ophthalmic_RE2 
Suprofen|P|isopto carbachol|suprofen|other_LE1 eye_LE1 drop_LE1 or_LE1 medication_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 and_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 may_BE12 decrease_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY ophthalmic_RE2 
Suprofen|P|carboptic|suprofen|other_LE1 eye_LE1 drop_LE1 or_LE1 medication_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 and_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 may_BE12 decrease_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY ophthalmic_RE2 
Suprofen|P|miochol|suprofen|other_LE1 eye_LE1 drop_LE1 or_LE1 medication_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 and_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 decrease_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY ophthalmic_RE2 
Suprofen|P|acetylcholine chloride|suprofen|other_LE1 eye_LE1 drop_LE1 or_LE1 medication_LE1 such_LE1 as_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 decrease_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY ophthalmic_RE2 
Tamsulosin|P|flomax|alpha-adrenergic blocking agent|however_LE1 interaction_LE1 may_LE1 be_LE1 expect_LE1 and_LE1 BIOENTITY capsule_BE12 shall_BE12 not_BE12 be_BE12 use_BE12 in_BE12 combination_BE12 with_BE12 other_BE12 BIOENTITY 
Tamsulosin|P|flomax|cimetidine|therefore_LE1 BIOENTITY capsule_BE12 shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY particular_RE2 at_RE2 dose_RE2 high_RE2 than_RE2 mg_RE2 
Tamsulosin|P|warfarin|flomax|therefore_LE1 caution_LE1 shall_LE1 be_LE1 exercise_LE1 with_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY capsule_RE2 
Temozolomide|P|valproic acid|temozolomide|administration_LE1 of_LE1 BIOENTITY decrease_BE12 oral_BE12 clearance_BE12 of_BE12 BIOENTITY by_RE2 about_RE2 NUM_RE2 %._RE2 
Tenecteplase|P|anticoagulant|tnkase|BIOENTITY -LRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 drug_BE12 that_BE12 alter_BE12 platelet_BE12 function_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 gp_BE12 iib_BE12 inhibitor_BE12 -RRB-_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 bleeding_BE12 if_BE12 administer_BE12 prior_BE12 to_BE12 during_BE12 or_BE12 after_BE12 BIOENTITY therapy_RE2 
Tenecteplase|P|dipyridamole|tnkase|BIOGENERAL_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -RRB-_LE1 and_LE1 drug_LE1 that_LE1 alter_LE1 platelet_LE1 function_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 gp_BE12 iib_BE12 inhibitor_BE12 -RRB-_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 bleeding_BE12 if_BE12 administer_BE12 prior_BE12 to_BE12 during_BE12 or_BE12 after_BE12 BIOENTITY therapy_RE2 
Tenecteplase|P|acetylsalicylic acid|tnkase|BIOGENERAL_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -RRB-_LE1 and_LE1 drug_LE1 that_LE1 alter_LE1 platelet_LE1 function_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 gp_BE12 iib_BE12 inhibitor_BE12 -RRB-_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 bleeding_BE12 if_BE12 administer_BE12 prior_BE12 to_BE12 during_BE12 or_BE12 after_BE12 BIOENTITY therapy_RE2 
Tenecteplase|P|heparin|tnkase|BIOGENERAL_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 drug_BE12 that_BE12 alter_BE12 platelet_BE12 function_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 gp_BE12 iib_BE12 inhibitor_BE12 -RRB-_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 bleeding_BE12 if_BE12 administer_BE12 prior_BE12 to_BE12 during_BE12 or_BE12 after_BE12 BIOENTITY therapy_RE2 
Tenecteplase|P|vitamin k antagonist|tnkase|BIOGENERAL_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY -RRB-_BE12 and_BE12 drug_BE12 that_BE12 alter_BE12 platelet_BE12 function_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 gp_BE12 iib_BE12 inhibitor_BE12 -RRB-_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 bleeding_BE12 if_BE12 administer_BE12 prior_BE12 to_BE12 during_BE12 or_BE12 after_BE12 BIOENTITY therapy_RE2 
Teniposide|P|tolbutamide|teniposide|In_LE1 study_LE1 in_LE1 which_LE1 NUM_LE1 different_LE1 drug_LE1 be_LE1 test_LE1 therapeutic_LE1 relevant_LE1 concentration_LE1 of_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 displace_BE12 proteinbound_BE12 BIOENTITY in_RE2 fresh_RE2 human_RE2 serum_RE2 to_RE2 small_RE2 but_RE2 significant_RE2 extent_RE2 
Teniposide|P|sulfamethizole|teniposide|In_LE1 study_LE1 in_LE1 which_LE1 NUM_LE1 different_LE1 drug_LE1 be_LE1 test_LE1 therapeutic_LE1 relevant_LE1 concentration_LE1 of_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY displace_BE12 proteinbound_BE12 BIOENTITY in_RE2 fresh_RE2 human_RE2 serum_RE2 to_RE2 small_RE2 but_RE2 significant_RE2 extent_RE2 
Teniposide|P|sodium salicylate|teniposide|In_LE1 study_LE1 in_LE1 which_LE1 NUM_LE1 different_LE1 drug_LE1 be_LE1 test_LE1 therapeutic_LE1 relevant_LE1 concentration_LE1 of_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 displace_BE12 proteinbound_BE12 BIOENTITY in_RE2 fresh_RE2 human_RE2 serum_RE2 to_RE2 small_RE2 but_RE2 significant_RE2 extent_RE2 
Teniposide|P|methotrexate|teniposide|increase_LE1 in_LE1 intracellular_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 observe_BE12 in_BE12 vitro_BE12 in_BE12 the_BE12 presence_BE12 of_BE12 BIOENTITY 
Terbinafine|P|terbinafine|caffeine|BIOENTITY decrease_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY by_RE2 NUM_RE2 %._RE2 
Terbinafine|P|terbinafine|cyclosporine|BIOENTITY increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY by_RE2 NUM_RE2 %._RE2 
Terbinafine|P|terbinafine|warfarin|there_LE1 have_LE1 be_LE1 spontaneous_LE1 report_LE1 of_LE1 increase_LE1 or_LE1 decrease_LE1 in_LE1 prothrombin_LE1 time_LE1 in_LE1 patient_LE1 concomitant_LE1 take_LE1 oral_LE1 BIOENTITY and_BE12 BIOENTITY however_RE2 causal_RE2 relationship_RE2 between_RE2 BIOGENERAL_RE2 tablet_RE2 and_RE2 these_RE2 change_RE2 have_RE2 not_RE2 be_RE2 establish_RE2 
Terbinafine|P|terbinafine|rifampin|BIOENTITY clearance_BE12 be_BE12 increase_BE12 NUM_BE12 by_BE12 BIOENTITY cyp_RE2 enzyme_RE2 inducer_RE2 and_RE2 decrease_RE2 NUM_RE2 by_RE2 BIOGENERAL_RE2 cyp_RE2 enzyme_RE2 inhibitor_RE2 
Terbinafine|P|terbinafine|cimetidine|BIOENTITY clearance_BE12 be_BE12 increase_BE12 NUM_BE12 by_BE12 BIOGENERAL_BE12 cyp_BE12 enzyme_BE12 inducer_BE12 and_BE12 decrease_BE12 NUM_BE12 by_BE12 BIOENTITY cyp_RE2 enzyme_RE2 inhibitor_RE2 
Terfenadine|P|ketoconazole|terfenadine|BIOGENERAL_LE1 :_LE1 spontaneous_LE1 adverse_LE1 reaction_LE1 report_LE1 of_LE1 patient_LE1 take_LE1 concomitant_LE1 BIOENTITY with_BE12 recommend_BE12 dose_BE12 of_BE12 BIOENTITY demonstrate_RE2 qt_RE2 interval_RE2 prolongation_RE2 and_RE2 rare_RE2 serious_RE2 cardiac_RE2 event_RE2 e.g._RE2 
Terfenadine|P|ketoconazole|terfenadine|pharmacokinetic_LE1 datum_LE1 indicate_LE1 that_LE1 BIOENTITY marked_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY result_RE2 in_RE2 elevated_RE2 plasma_RE2 BIOGENERAL_RE2 level_RE2 
Terfenadine|P|ketoconazole|terfenadine|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 contraindicate_RE2 
Terfenadine|P|terfenadine|itraconazole|BIOGENERAL_LE1 :_LE1 torsade_LE1 de_LE1 pointes_LE1 and_LE1 elevated_LE1 parent_LE1 BIOGENERAL_LE1 level_LE1 have_LE1 be_LE1 report_LE1 during_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY in_RE2 clinical_RE2 trial_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 from_RE2 foreign_RE2 postmarketing_RE2 source_RE2 
Terfenadine|P|itraconazole|terfenadine|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 contraindicate_RE2 
Terfenadine|P|miconazole|terfenadine|Due_LE1 to_LE1 the_LE1 chemical_LE1 similarity_LE1 of_LE1 other_LE1 BIOGENERAL_LE1 -LRB-_LE1 include_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY -RRB-_BE12 to_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 concomitant_BE12 use_BE12 of_BE12 these_BE12 product_BE12 with_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 pend_RE2 full_RE2 examination_RE2 of_RE2 potential_RE2 interaction_RE2 
Terfenadine|P|metronidazole|terfenadine|Due_LE1 to_LE1 the_LE1 chemical_LE1 similarity_LE1 of_LE1 other_LE1 BIOGENERAL_LE1 -LRB-_LE1 include_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -RRB-_BE12 to_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 concomitant_BE12 use_BE12 of_BE12 these_BE12 product_BE12 with_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 pend_RE2 full_RE2 examination_RE2 of_RE2 potential_RE2 interaction_RE2 
Terfenadine|P|fluconazole|terfenadine|Due_LE1 to_LE1 the_LE1 chemical_LE1 similarity_LE1 of_LE1 other_LE1 BIOGENERAL_LE1 -LRB-_LE1 include_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 to_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 concomitant_BE12 use_BE12 of_BE12 these_BE12 product_BE12 with_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 pend_RE2 full_RE2 examination_RE2 of_RE2 potential_RE2 interaction_RE2 
Terfenadine|P|azole-type antifungal agent|terfenadine|Due_LE1 to_LE1 the_LE1 chemical_LE1 similarity_LE1 of_LE1 other_LE1 BIOENTITY -LRB-_BE12 include_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 to_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 concomitant_BE12 use_BE12 of_BE12 these_BE12 product_BE12 with_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 pend_RE2 full_RE2 examination_RE2 of_RE2 potential_RE2 interaction_RE2 
Terfenadine|P|erythromycin|terfenadine|BIOGENERAL_LE1 :_LE1 clinical_LE1 drug_LE1 interaction_LE1 study_LE1 indicate_LE1 that_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 can_BE12 exert_BE12 effect_BE12 on_BE12 BIOENTITY metabolism_RE2 by_RE2 mechanism_RE2 which_RE2 may_RE2 be_RE2 similar_RE2 to_RE2 that_RE2 of_RE2 BIOGENERAL_RE2 but_RE2 to_RE2 less_RE2 extent_RE2 
Terfenadine|P|clarithromycin|terfenadine|BIOGENERAL_LE1 :_LE1 clinical_LE1 drug_LE1 interaction_LE1 study_LE1 indicate_LE1 that_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY can_BE12 exert_BE12 effect_BE12 on_BE12 BIOENTITY metabolism_RE2 by_RE2 mechanism_RE2 which_RE2 may_RE2 be_RE2 similar_RE2 to_RE2 that_RE2 of_RE2 BIOGENERAL_RE2 but_RE2 to_RE2 less_RE2 extent_RE2 
Terfenadine|P|terfenadine|azithromycin|concomitant_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 with_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 be_LE1 contraindicate_LE1 :_LE1 pend_LE1 full_LE1 characterization_LE1 of_LE1 potential_LE1 interaction_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 
Terfenadine|P|terfenadine|troleandomycin|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY be_RE2 contraindicate_RE2 :_RE2 pend_RE2 full_RE2 characterization_RE2 of_RE2 potential_RE2 interaction_RE2 concomitant_RE2 administration_RE2 of_RE2 BIOGENERAL_RE2 with_RE2 other_RE2 BIOGENERAL_RE2 including_RE2 BIOGENERAL_RE2 be_RE2 not_RE2 recommend_RE2 
Terfenadine|P|terfenadine|erythromycin|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 be_RE2 contraindicate_RE2 :_RE2 pend_RE2 full_RE2 characterization_RE2 of_RE2 potential_RE2 interaction_RE2 concomitant_RE2 administration_RE2 of_RE2 BIOGENERAL_RE2 with_RE2 other_RE2 BIOGENERAL_RE2 including_RE2 BIOGENERAL_RE2 be_RE2 not_RE2 recommend_RE2 
Terfenadine|P|terfenadine|clarithromycin|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 be_RE2 contraindicate_RE2 :_RE2 pend_RE2 full_RE2 characterization_RE2 of_RE2 potential_RE2 interaction_RE2 concomitant_RE2 administration_RE2 of_RE2 BIOGENERAL_RE2 with_RE2 other_RE2 BIOGENERAL_RE2 including_RE2 BIOGENERAL_RE2 be_RE2 not_RE2 recommend_RE2 
Terfenadine|P|terfenadine|macrolide antibiotic|concomitant_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 with_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 be_LE1 contraindicate_LE1 :_LE1 pend_LE1 full_LE1 characterization_LE1 of_LE1 potential_LE1 interaction_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 BIOENTITY including_RE2 BIOGENERAL_RE2 be_RE2 not_RE2 recommend_RE2 
Testolactone|P|testolactone|anticoagulant|when_LE1 administer_LE1 concurrent_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 effect_BE12 of_BE12 oral_BE12 BIOENTITY 
Thalidomide|P|thalidomide|barbiturate|BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 enhance_BE12 the_BE12 sedative_BE12 activity_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Thalidomide|P|john's wort|hormonal contraceptive agent|john_LE1 's_LE1 BIOENTITY with_BE12 BIOENTITY may_RE2 reduce_RE2 the_RE2 effectiveness_RE2 of_RE2 the_RE2 contraception_RE2 and_RE2 up_RE2 to_RE2 one_RE2 month_RE2 after_RE2 discontinuation_RE2 of_RE2 these_RE2 concomitant_RE2 therapy_RE2 
Thiabendazole|P|thiabendazole|theophylline|BIOENTITY may_BE12 compete_BE12 with_BE12 other_BE12 drug_BE12 such_BE12 as_BE12 BIOENTITY for_RE2 site_RE2 of_RE2 metabolism_RE2 in_RE2 the_RE2 liver_RE2 thus_RE2 elevate_RE2 the_RE2 serum_RE2 level_RE2 of_RE2 such_RE2 compound_RE2 to_RE2 potential_RE2 toxic_RE2 level_RE2 
Thiabendazole|P|thiabendazole|xanthine derivative|therefore_LE1 when_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 anticipate_RE2 it_RE2 may_RE2 be_RE2 necessary_RE2 to_RE2 monitor_RE2 blood_RE2 level_RE2 and_RE2 reduce_RE2 the_RE2 dosage_RE2 of_RE2 such_RE2 compound_RE2 
Thiamine|P|thiamine|tricyclic antidepressant|interaction_LE1 for_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 :_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY 
Thiamine|P|thiamine|stavudine|interaction_LE1 for_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 :_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 
Thiamine|P|thiamine|contraceptive|interaction_LE1 for_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 :_BE12 BIOGENERAL_BE12 oral_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 
Thiamine|P|thiamine|loop diuretic|interaction_LE1 for_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 :_BE12 BIOENTITY oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Thiamine|P|vitamin b1|tricyclic antidepressant|interaction_LE1 for_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 :_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY 
Thiamine|P|vitamin b1|stavudine|interaction_LE1 for_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 :_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 
Thiamine|P|vitamin b1|contraceptive|interaction_LE1 for_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 :_BE12 BIOGENERAL_BE12 oral_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 
Thiamine|P|vitamin b1|loop diuretic|interaction_LE1 for_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 :_BE12 BIOENTITY oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Thiethylperazine|P|phenothiazine|anesthetic|BIOENTITY be_BE12 capable_BE12 of_BE12 potentiating_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 etc_RE2 .rrb_RE2 
Thiethylperazine|P|phenothiazine|barbiturate|BIOENTITY be_BE12 capable_BE12 of_BE12 potentiating_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 etc_RE2 .rrb_RE2 
Thiethylperazine|P|phenothiazine|alcohol|BIOENTITY be_BE12 capable_BE12 of_BE12 potentiating_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY etc_RE2 .rrb_RE2 
Thiethylperazine|P|phenothiazine|opiate|BIOENTITY be_BE12 capable_BE12 of_BE12 potentiating_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 etc_RE2 .rrb_RE2 
Thiethylperazine|P|phenothiazine|cns depressant|BIOENTITY be_BE12 capable_BE12 of_BE12 potentiating_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 etc_RE2 .rrb_RE2 
Thioguanine|P|mercaptopurine|thioguanine|there_LE1 be_LE1 usual_LE1 complete_LE1 crossresistance_LE1 between_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 and_BE12 BIOGENERAL_BE12 brand_BE12 BIOENTITY 
Thioguanine|P|mercaptopurine|tabloid|there_LE1 be_LE1 usual_LE1 complete_LE1 crossresistance_LE1 between_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 and_BE12 BIOENTITY brand_RE2 BIOGENERAL_RE2 
Thioguanine|P|purinethol|thioguanine|there_LE1 be_LE1 usual_LE1 complete_LE1 crossresistance_LE1 between_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOGENERAL_BE12 brand_BE12 BIOENTITY 
Thioguanine|P|purinethol|tabloid|there_LE1 be_LE1 usual_LE1 complete_LE1 crossresistance_LE1 between_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY brand_RE2 BIOGENERAL_RE2 
Thioguanine|P|aminosalicylate derivative|thioguanine|as_LE1 there_LE1 be_LE1 in_LE1 vitro_LE1 evidence_LE1 that_LE1 BIOENTITY -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 inhibit_BE12 the_BE12 tpmt_BE12 enzyme_BE12 they_BE12 shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 to_BE12 patient_BE12 receive_BE12 concurrent_BE12 BIOENTITY therapy_RE2 
Thioguanine|P|sulphasalazine|thioguanine|as_LE1 there_LE1 be_LE1 in_LE1 vitro_LE1 evidence_LE1 that_LE1 BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY -RRB-_BE12 inhibit_BE12 the_BE12 tpmt_BE12 enzyme_BE12 they_BE12 shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 to_BE12 patient_BE12 receive_BE12 concurrent_BE12 BIOENTITY therapy_RE2 
Thioguanine|P|olsalazine|thioguanine|as_LE1 there_LE1 be_LE1 in_LE1 vitro_LE1 evidence_LE1 that_LE1 BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 inhibit_BE12 the_BE12 tpmt_BE12 enzyme_BE12 they_BE12 shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 to_BE12 patient_BE12 receive_BE12 concurrent_BE12 BIOENTITY therapy_RE2 
Thioguanine|P|mesalazine|thioguanine|as_LE1 there_LE1 be_LE1 in_LE1 vitro_LE1 evidence_LE1 that_LE1 BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 -RRB-_BE12 inhibit_BE12 the_BE12 tpmt_BE12 enzyme_BE12 they_BE12 shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 to_BE12 patient_BE12 receive_BE12 concurrent_BE12 BIOENTITY therapy_RE2 
Thymalfasin|P|zadaxin|immunomodulating drug|caution_LE1 shall_LE1 be_LE1 exercise_LE1 when_LE1 administer_LE1 BIOENTITY therapy_BE12 in_BE12 combination_BE12 with_BE12 other_BE12 BIOENTITY 
Tigecycline|P|tigecycline|warfarin|prothrombin_LE1 time_LE1 or_LE1 other_LE1 suitable_LE1 anticoagulation_LE1 test_LE1 shall_LE1 be_LE1 monitor_LE1 if_LE1 BIOENTITY be_BE12 administer_BE12 with_BE12 BIOENTITY 
Tigecycline|P|antibacterial drug|contraceptive|concurrent_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 oral_BE12 BIOENTITY may_RE2 render_RE2 oral_RE2 BIOGENERAL_RE2 little_RE2 effective_RE2 
Tiludronate|P|skelid|calcium|the_LE1 bioavailability_LE1 of_LE1 BIOENTITY be_BE12 decrease_BE12 NUM_BE12 by_BE12 BIOENTITY when_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 be_RE2 administer_RE2 at_RE2 the_RE2 same_RE2 time_RE2 and_RE2 NUM_RE2 by_RE2 some_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 when_RE2 administer_RE2 NUM_RE2 hour_RE2 before_RE2 BIOGENERAL_RE2 
Tiludronate|P|aluminum|skelid|the_LE1 bioavailability_LE1 of_LE1 BIOGENERAL_LE1 be_LE1 decrease_LE1 NUM_LE1 by_LE1 BIOGENERAL_LE1 when_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 be_LE1 administer_LE1 at_LE1 the_LE1 same_LE1 time_LE1 and_LE1 NUM_LE1 by_LE1 some_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 when_BE12 administer_BE12 NUM_BE12 hour_BE12 before_BE12 BIOENTITY 
Tiludronate|P|magnesium|skelid|the_LE1 bioavailability_LE1 of_LE1 BIOGENERAL_LE1 be_LE1 decrease_LE1 NUM_LE1 by_LE1 BIOGENERAL_LE1 when_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 be_LE1 administer_LE1 at_LE1 the_LE1 same_LE1 time_LE1 and_LE1 NUM_LE1 by_LE1 some_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY BIOGENERAL_BE12 when_BE12 administer_BE12 NUM_BE12 hour_BE12 before_BE12 BIOENTITY 
Tiludronate|P|aspirin|skelid|BIOENTITY may_BE12 decrease_BE12 bioavailability_BE12 of_BE12 BIOENTITY by_RE2 up_RE2 to_RE2 NUM_RE2 when_RE2 take_RE2 NUM_RE2 hour_RE2 after_RE2 BIOGENERAL_RE2 
Tiludronate|P|skelid|indomethacin|the_LE1 bioavailability_LE1 of_LE1 BIOENTITY be_BE12 increase_BE12 NUM_BE12 fold_BE12 by_BE12 BIOENTITY but_RE2 be_RE2 not_RE2 significant_RE2 alter_RE2 by_RE2 coadministration_RE2 of_RE2 BIOGENERAL_RE2 
Tiotropium|P|spiriva|anticholinergic|however_LE1 the_LE1 co_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 BIOENTITY containing_RE2 drug_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 have_RE2 not_RE2 be_RE2 study_RE2 and_RE2 be_RE2 therefore_RE2 not_RE2 recommend_RE2 
Tiotropium|P|spiriva|ipratropium|however_LE1 the_LE1 co_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 BIOGENERAL_BE12 containing_BE12 drug_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY -RRB-_RE2 have_RE2 not_RE2 be_RE2 study_RE2 and_RE2 be_RE2 therefore_RE2 not_RE2 recommend_RE2 
Tirofiban|P|aggrastat|heparin|the_LE1 use_LE1 of_LE1 BIOENTITY in_BE12 combination_BE12 with_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 have_RE2 be_RE2 associate_RE2 with_RE2 increase_RE2 in_RE2 bleeding_RE2 compare_RE2 to_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 alone_RE2 -LRB-_RE2 see_RE2 
Tirofiban|P|aggrastat|aspirin|the_LE1 use_LE1 of_LE1 BIOENTITY in_BE12 combination_BE12 with_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY have_RE2 be_RE2 associate_RE2 with_RE2 increase_RE2 in_RE2 bleeding_RE2 compare_RE2 to_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 alone_RE2 -LRB-_RE2 see_RE2 
Tobramycin|P|tobi|anti-pseudomonal antibiotic|In_LE1 clinical_LE1 study_LE1 of_LE1 BIOGENERAL_LE1 patient_LE1 take_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 genentech_BE12 -RRB-_BE12 -LRB-_BE12 beta_BE12 -RRB-_BE12 BIOGENERAL_BE12 inhaled_BE12 BIOGENERAL_BE12 other_BE12 BIOENTITY or_RE2 parenteral_RE2 BIOGENERAL_RE2 demonstrate_RE2 adverse_RE2 experience_RE2 profile_RE2 similar_RE2 to_RE2 the_RE2 study_RE2 population_RE2 as_RE2 whole_RE2 
Tobramycin|P|tobi|corticosteroid|In_LE1 clinical_LE1 study_LE1 of_LE1 BIOGENERAL_LE1 patient_LE1 take_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 genentech_BE12 -RRB-_BE12 -LRB-_BE12 beta_BE12 -RRB-_BE12 BIOGENERAL_BE12 inhaled_BE12 BIOENTITY other_RE2 BIOGENERAL_RE2 or_RE2 parenteral_RE2 BIOGENERAL_RE2 demonstrate_RE2 adverse_RE2 experience_RE2 profile_RE2 similar_RE2 to_RE2 the_RE2 study_RE2 population_RE2 as_RE2 whole_RE2 
Tobramycin|P|tobi|aminoglycoside|In_LE1 clinical_LE1 study_LE1 of_LE1 BIOGENERAL_LE1 patient_LE1 take_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 genentech_BE12 -RRB-_BE12 -LRB-_BE12 beta_BE12 -RRB-_BE12 BIOGENERAL_BE12 inhaled_BE12 BIOGENERAL_BE12 other_BE12 BIOGENERAL_BE12 or_BE12 parenteral_BE12 BIOENTITY demonstrate_RE2 adverse_RE2 experience_RE2 profile_RE2 similar_RE2 to_RE2 the_RE2 study_RE2 population_RE2 as_RE2 whole_RE2 
Tobramycin|P|tobi|(beta)-agonist|In_LE1 clinical_LE1 study_LE1 of_LE1 BIOGENERAL_LE1 patient_LE1 take_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 genentech_BE12 -RRB-_BE12 -LRB-_BE12 beta_BE12 -RRB-_BE12 BIOENTITY inhaled_RE2 BIOGENERAL_RE2 other_RE2 BIOGENERAL_RE2 or_RE2 parenteral_RE2 BIOGENERAL_RE2 demonstrate_RE2 adverse_RE2 experience_RE2 profile_RE2 similar_RE2 to_RE2 the_RE2 study_RE2 population_RE2 as_RE2 whole_RE2 
Tobramycin|P|tobi|dornase alfa|In_LE1 clinical_LE1 study_LE1 of_LE1 BIOGENERAL_LE1 patient_LE1 take_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 genentech_RE2 -RRB-_RE2 -LRB-_RE2 beta_RE2 -RRB-_RE2 BIOGENERAL_RE2 inhaled_RE2 BIOGENERAL_RE2 other_RE2 BIOGENERAL_RE2 or_RE2 parenteral_RE2 BIOGENERAL_RE2 demonstrate_RE2 adverse_RE2 experience_RE2 profile_RE2 similar_RE2 to_RE2 the_RE2 study_RE2 population_RE2 as_RE2 whole_RE2 
Tobramycin|P|tobi|pulmozyme|In_LE1 clinical_LE1 study_LE1 of_LE1 BIOGENERAL_LE1 patient_LE1 take_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY genentech_RE2 -RRB-_RE2 -LRB-_RE2 beta_RE2 -RRB-_RE2 BIOGENERAL_RE2 inhaled_RE2 BIOGENERAL_RE2 other_RE2 BIOGENERAL_RE2 or_RE2 parenteral_RE2 BIOGENERAL_RE2 demonstrate_RE2 adverse_RE2 experience_RE2 profile_RE2 similar_RE2 to_RE2 the_RE2 study_RE2 population_RE2 as_RE2 whole_RE2 
Tobramycin|P|diuretic|aminoglycoside|some_LE1 BIOENTITY can_BE12 enhance_BE12 BIOENTITY toxicity_RE2 by_RE2 alter_RE2 BIOGENERAL_RE2 concentration_RE2 in_RE2 serum_RE2 and_RE2 tissue_RE2 
Tobramycin|P|tobi|urea|BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Tobramycin|P|tobi|mannitol|BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Tobramycin|P|tobi|ethacrynic acid|BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Tobramycin|P|tobi|furosemide|BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Tolmetin|P|tolectin|warfarin|however_LE1 increase_LE1 prothrombin_LE1 time_LE1 and_LE1 bleeding_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 on_LE1 concomitant_LE1 BIOENTITY and_BE12 BIOENTITY therapy_RE2 
Tolmetin|P|tolectin|anticoagulant|therefore_LE1 caution_LE1 shall_LE1 be_LE1 exercise_LE1 when_LE1 administer_LE1 BIOENTITY to_BE12 patient_BE12 on_BE12 BIOENTITY 
Tolmetin|P|tolectin|methotrexate|caution_LE1 shall_LE1 be_LE1 use_LE1 if_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY 
Tolmetin|P|nonsteroidal anti-inflammatory drug|methotrexate|BIOGENERAL_LE1 and_LE1 other_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 reduce_BE12 the_BE12 tubular_BE12 secretion_BE12 of_BE12 BIOENTITY in_RE2 animal_RE2 model_RE2 possible_RE2 enhance_RE2 the_RE2 toxicity_RE2 of_RE2 BIOGENERAL_RE2 
Tolmetin|P|tolectin|methotrexate|BIOENTITY and_BE12 other_BE12 BIOGENERAL_BE12 have_BE12 be_BE12 report_BE12 to_BE12 reduce_BE12 the_BE12 tubular_BE12 secretion_BE12 of_BE12 BIOENTITY in_RE2 animal_RE2 model_RE2 possible_RE2 enhance_RE2 the_RE2 toxicity_RE2 of_RE2 BIOGENERAL_RE2 
Tolterodine|P|ketoconazole|tolterodine|cypa_LE1 inhibitor_LE1 :_LE1 BIOENTITY inhibitor_BE12 of_BE12 the_BE12 drug_BE12 metabolizing_BE12 enzyme_BE12 cypa_BE12 significant_BE12 increase_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY when_RE2 coadminister_RE2 to_RE2 subject_RE2 who_RE2 be_RE2 poor_RE2 metabolizer_RE2 -LRB-_RE2 see_RE2 clinical_RE2 pharmacology_RE2 variability_RE2 in_RE2 metabolism_RE2 and_RE2 drugdrug_RE2 interaction_RE2 rrb._RE2 
Tolterodine|P|macrolide antibiotic|detrol la|For_LE1 patient_LE1 receive_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 potent_LE1 cypa_LE1 inhibitor_LE1 such_LE1 as_LE1 other_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 BIOENTITY -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 the_BE12 recommend_BE12 dose_BE12 of_BE12 BIOENTITY be_RE2 NUM_RE2 mg_RE2 daily_RE2 
Tolterodine|P|erythromycin|detrol la|For_LE1 patient_LE1 receive_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 potent_LE1 cypa_LE1 inhibitor_LE1 such_LE1 as_LE1 other_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 the_BE12 recommend_BE12 dose_BE12 of_BE12 BIOENTITY be_RE2 NUM_RE2 mg_RE2 daily_RE2 
Tolterodine|P|azole antifungal|detrol la|For_LE1 patient_LE1 receive_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 potent_LE1 cypa_LE1 inhibitor_LE1 such_LE1 as_LE1 other_LE1 BIOENTITY -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 the_BE12 recommend_BE12 dose_BE12 of_BE12 BIOENTITY be_RE2 NUM_RE2 mg_RE2 daily_RE2 
Tolterodine|P|clarithromycin|detrol la|For_LE1 patient_LE1 receive_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 potent_LE1 cypa_LE1 inhibitor_LE1 such_LE1 as_LE1 other_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 or_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 the_BE12 recommend_BE12 dose_BE12 of_BE12 BIOENTITY be_RE2 NUM_RE2 mg_RE2 daily_RE2 
Tolterodine|P|itraconazole|detrol la|For_LE1 patient_LE1 receive_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 potent_LE1 cypa_LE1 inhibitor_LE1 such_LE1 as_LE1 other_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 the_BE12 recommend_BE12 dose_BE12 of_BE12 BIOENTITY be_RE2 NUM_RE2 mg_RE2 daily_RE2 
Tolterodine|P|cyclosporine|detrol la|For_LE1 patient_LE1 receive_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 potent_LE1 cypa_LE1 inhibitor_LE1 such_LE1 as_LE1 other_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 the_BE12 recommend_BE12 dose_BE12 of_BE12 BIOENTITY be_RE2 NUM_RE2 mg_RE2 daily_RE2 
Tolterodine|P|vinblastine|detrol la|For_LE1 patient_LE1 receive_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 potent_LE1 cypa_LE1 inhibitor_LE1 such_LE1 as_LE1 other_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY the_BE12 recommend_BE12 dose_BE12 of_BE12 BIOENTITY be_RE2 NUM_RE2 mg_RE2 daily_RE2 
Tolterodine|P|vinblastine|detrol la|For_LE1 patient_LE1 receive_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 potent_LE1 cypa_LE1 inhibitor_LE1 such_LE1 as_LE1 other_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY the_BE12 recommend_BE12 dose_BE12 of_BE12 BIOENTITY be_RE2 NUM_RE2 mg_RE2 daily_RE2 
Tolterodine|P|ketoconazole|detrol la|For_LE1 patient_LE1 receive_LE1 BIOENTITY or_BE12 other_BE12 potent_BE12 cypa_BE12 inhibitor_BE12 such_BE12 as_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 the_BE12 recommend_BE12 dose_BE12 of_BE12 BIOENTITY be_RE2 NUM_RE2 mg_RE2 daily_RE2 
Tolterodine|P|miconazole|detrol la|For_LE1 patient_LE1 receive_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 potent_LE1 cypa_LE1 inhibitor_LE1 such_LE1 as_LE1 other_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 the_BE12 recommend_BE12 dose_BE12 of_BE12 BIOENTITY be_RE2 NUM_RE2 mg_RE2 daily_RE2 
Trastuzumab|P|paclitaxel|herceptin|administration_LE1 of_LE1 BIOENTITY in_BE12 combination_BE12 with_BE12 BIOENTITY result_RE2 in_RE2 twofold_RE2 decrease_RE2 in_RE2 BIOGENERAL_RE2 clearance_RE2 in_RE2 nonhuman_RE2 primate_RE2 study_RE2 and_RE2 in_RE2 .fold_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 serum_RE2 level_RE2 in_RE2 clinical_RE2 study_RE2 
Trilostane|P|trilostane|mitotane|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY -LRB-_RE2 cause_RE2 too_RE2 great_RE2 decrease_RE2 in_RE2 adrenal_RE2 function_RE2 rrb._RE2 
Trilostane|P|trilostane|aminoglutethimide|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 -LRB-_RE2 cause_RE2 too_RE2 great_RE2 decrease_RE2 in_RE2 adrenal_RE2 function_RE2 rrb._RE2 
Trimethoprim|P|trimethoprim|phenytoin|BIOENTITY may_BE12 inhibit_BE12 the_BE12 hepatic_BE12 metabolism_BE12 of_BE12 BIOENTITY 
Trimethoprim|P|trimethoprim|phenytoin|BIOENTITY give_BE12 at_BE12 common_BE12 clinical_BE12 dosage_BE12 increase_BE12 the_BE12 BIOENTITY halflife_RE2 by_RE2 NUM_RE2 and_RE2 decrease_RE2 the_RE2 BIOGENERAL_RE2 metabolic_RE2 clearance_RE2 rate_RE2 by_RE2 NUM_RE2 %._RE2 
Trimethoprim|P|trimethoprim|phenytoin|BIOENTITY give_BE12 at_BE12 common_BE12 clinical_BE12 dosage_BE12 increase_BE12 the_BE12 BIOGENERAL_BE12 halflife_BE12 by_BE12 NUM_BE12 and_BE12 decrease_BE12 the_BE12 BIOENTITY metabolic_RE2 clearance_RE2 rate_RE2 by_RE2 NUM_RE2 %._RE2 
Trimetrexate|P|trimetrexate|erythromycin|agent_LE1 that_LE1 may_LE1 be_LE1 coadminister_LE1 with_LE1 BIOENTITY in_BE12 aids_BE12 patient_BE12 for_BE12 other_BE12 indication_BE12 that_BE12 can_BE12 elicit_BE12 this_BE12 activity_BE12 include_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Trimetrexate|P|trimetrexate|erythromycin|agent_LE1 that_LE1 may_LE1 be_LE1 coadminister_LE1 with_LE1 BIOENTITY in_BE12 aids_BE12 patient_BE12 for_BE12 other_BE12 indication_BE12 that_BE12 can_BE12 elicit_BE12 this_BE12 activity_BE12 include_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Trimetrexate|P|trimetrexate|rifabutin|agent_LE1 that_LE1 may_LE1 be_LE1 coadminister_LE1 with_LE1 BIOENTITY in_BE12 aids_BE12 patient_BE12 for_BE12 other_BE12 indication_BE12 that_BE12 can_BE12 elicit_BE12 this_BE12 activity_BE12 include_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Trimetrexate|P|trimetrexate|rifabutin|agent_LE1 that_LE1 may_LE1 be_LE1 coadminister_LE1 with_LE1 BIOENTITY in_BE12 aids_BE12 patient_BE12 for_BE12 other_BE12 indication_BE12 that_BE12 can_BE12 elicit_BE12 this_BE12 activity_BE12 include_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Trimetrexate|P|trimetrexate|rifampin|agent_LE1 that_LE1 may_LE1 be_LE1 coadminister_LE1 with_LE1 BIOENTITY in_BE12 aids_BE12 patient_BE12 for_BE12 other_BE12 indication_BE12 that_BE12 can_BE12 elicit_BE12 this_BE12 activity_BE12 include_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Trimetrexate|P|trimetrexate|rifampin|agent_LE1 that_LE1 may_LE1 be_LE1 coadminister_LE1 with_LE1 BIOENTITY in_BE12 aids_BE12 patient_BE12 for_BE12 other_BE12 indication_BE12 that_BE12 can_BE12 elicit_BE12 this_BE12 activity_BE12 include_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Trimetrexate|P|trimetrexate|fluconazole|agent_LE1 that_LE1 may_LE1 be_LE1 coadminister_LE1 with_LE1 BIOENTITY in_BE12 aids_BE12 patient_BE12 for_BE12 other_BE12 indication_BE12 that_BE12 can_BE12 elicit_BE12 this_BE12 activity_BE12 include_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Trimetrexate|P|trimetrexate|fluconazole|agent_LE1 that_LE1 may_LE1 be_LE1 coadminister_LE1 with_LE1 BIOENTITY in_BE12 aids_BE12 patient_BE12 for_BE12 other_BE12 indication_BE12 that_BE12 can_BE12 elicit_BE12 this_BE12 activity_BE12 include_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Trimetrexate|P|trimetrexate|ketoconazole|agent_LE1 that_LE1 may_LE1 be_LE1 coadminister_LE1 with_LE1 BIOENTITY in_BE12 aids_BE12 patient_BE12 for_BE12 other_BE12 indication_BE12 that_BE12 can_BE12 elicit_BE12 this_BE12 activity_BE12 include_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Trimetrexate|P|trimetrexate|ketoconazole|agent_LE1 that_LE1 may_LE1 be_LE1 coadminister_LE1 with_LE1 BIOENTITY in_BE12 aids_BE12 patient_BE12 for_BE12 other_BE12 indication_BE12 that_BE12 can_BE12 elicit_BE12 this_BE12 activity_BE12 include_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Trimetrexate|P|cimetidine|trimetrexate|in_LE1 vitro_LE1 perfusion_LE1 of_LE1 isolate_LE1 rat_LE1 liver_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY cause_BE12 significant_BE12 reduction_BE12 in_BE12 BIOENTITY metabolism_RE2 and_RE2 that_RE2 BIOGENERAL_RE2 alter_RE2 the_RE2 relative_RE2 concentration_RE2 of_RE2 trimetrexate_RE2 metabolite_RE2 possible_RE2 by_RE2 compete_RE2 for_RE2 sulfate_RE2 metabolite_RE2 
Trimetrexate|P|ketoconazole|trimetrexate|Based_LE1 on_LE1 in_LE1 vitro_LE1 rat_LE1 liver_LE1 model_LE1 nitrogen_LE1 substitute_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 be_BE12 potent_BE12 noncompetitive_BE12 inhibitor_BE12 of_BE12 BIOENTITY metabolism_RE2 
Trimetrexate|P|miconazole|trimetrexate|Based_LE1 on_LE1 in_LE1 vitro_LE1 rat_LE1 liver_LE1 model_LE1 nitrogen_LE1 substitute_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 be_BE12 potent_BE12 noncompetitive_BE12 inhibitor_BE12 of_BE12 BIOENTITY metabolism_RE2 
Trimetrexate|P|imidazole drug|trimetrexate|Based_LE1 on_LE1 in_LE1 vitro_LE1 rat_LE1 liver_LE1 model_LE1 nitrogen_LE1 substitute_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 be_BE12 potent_BE12 noncompetitive_BE12 inhibitor_BE12 of_BE12 BIOENTITY metabolism_RE2 
Trimetrexate|P|clotrimazole|trimetrexate|Based_LE1 on_LE1 in_LE1 vitro_LE1 rat_LE1 liver_LE1 model_LE1 nitrogen_LE1 substitute_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 be_BE12 potent_BE12 noncompetitive_BE12 inhibitor_BE12 of_BE12 BIOENTITY metabolism_RE2 
Triprolidine|P|triprolidine|narcotic analgesic|BIOENTITY may_BE12 enhance_BE12 the_BE12 sedative_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Triprolidine|P|triprolidine|hypnotic|BIOENTITY may_BE12 enhance_BE12 the_BE12 sedative_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Triprolidine|P|triprolidine|barbiturate|BIOENTITY may_BE12 enhance_BE12 the_BE12 sedative_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 including_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Triprolidine|P|triprolidine|alcohol|BIOENTITY may_BE12 enhance_BE12 the_BE12 sedative_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 including_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Triprolidine|P|triprolidine|tranquilliser|BIOENTITY may_BE12 enhance_BE12 the_BE12 sedative_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Triprolidine|P|triprolidine|sedative|BIOENTITY may_BE12 enhance_BE12 the_BE12 sedative_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Triprolidine|P|triprolidine|central nervous system depressant|BIOENTITY may_BE12 enhance_BE12 the_BE12 sedative_BE12 effect_BE12 of_BE12 BIOENTITY including_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Triprolidine|P|tricyclic antidepressant|triprolidine|the_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 be_BE12 enhance_BE12 by_BE12 the_BE12 concomitant_BE12 administration_BE12 of_BE12 BIOENTITY 
Triprolidine|P|atropine|triprolidine|the_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 be_BE12 enhance_BE12 by_BE12 the_BE12 concomitant_BE12 administration_BE12 of_BE12 BIOENTITY 
Triprolidine|P|anticholinergic drug|triprolidine|the_LE1 effect_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 be_BE12 enhance_BE12 by_BE12 the_BE12 concomitant_BE12 administration_BE12 of_BE12 BIOENTITY 
Trospium|P|sanctura|anticholinergic agent|the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 BIOENTITY that_RE2 produce_RE2 dry_RE2 mouth_RE2 constipation_RE2 and_RE2 other_RE2 anticholinergic_RE2 pharmacological_RE2 effect_RE2 may_RE2 increase_RE2 the_RE2 frequency_RE2 and_RE2 severity_RE2 of_RE2 such_RE2 effect_RE2 
Trospium|P|sanctura|pancuronium|drug_LE1 eliminate_LE1 by_LE1 active_LE1 tubular_LE1 secretion_LE1 :_LE1 although_LE1 study_LE1 to_LE1 assess_LE1 drugdrug_LE1 interaction_LE1 with_LE1 BIOGENERAL_LE1 have_LE1 not_LE1 be_LE1 conduct_LE1 BIOENTITY have_BE12 the_BE12 potential_BE12 for_BE12 pharmacokinetic_BE12 interaction_BE12 with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 eliminate_BE12 by_BE12 active_BE12 tubular_BE12 secretion_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 rrb._RE2 
Trospium|P|sanctura|tenofovir|drug_LE1 eliminate_LE1 by_LE1 active_LE1 tubular_LE1 secretion_LE1 :_LE1 although_LE1 study_LE1 to_LE1 assess_LE1 drugdrug_LE1 interaction_LE1 with_LE1 BIOGENERAL_LE1 have_LE1 not_LE1 be_LE1 conduct_LE1 BIOENTITY have_BE12 the_BE12 potential_BE12 for_BE12 pharmacokinetic_BE12 interaction_BE12 with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 eliminate_BE12 by_BE12 active_BE12 tubular_BE12 secretion_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY rrb._RE2 
Trospium|P|sanctura|metformin|drug_LE1 eliminate_LE1 by_LE1 active_LE1 tubular_LE1 secretion_LE1 :_LE1 although_LE1 study_LE1 to_LE1 assess_LE1 drugdrug_LE1 interaction_LE1 with_LE1 BIOGENERAL_LE1 have_LE1 not_LE1 be_LE1 conduct_LE1 BIOENTITY have_BE12 the_BE12 potential_BE12 for_BE12 pharmacokinetic_BE12 interaction_BE12 with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 eliminate_BE12 by_BE12 active_BE12 tubular_BE12 secretion_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 rrb._RE2 
Trospium|P|sanctura|vancomycin|drug_LE1 eliminate_LE1 by_LE1 active_LE1 tubular_LE1 secretion_LE1 :_LE1 although_LE1 study_LE1 to_LE1 assess_LE1 drugdrug_LE1 interaction_LE1 with_LE1 BIOGENERAL_LE1 have_LE1 not_LE1 be_LE1 conduct_LE1 BIOENTITY have_BE12 the_BE12 potential_BE12 for_BE12 pharmacokinetic_BE12 interaction_BE12 with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 eliminate_BE12 by_BE12 active_BE12 tubular_BE12 secretion_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 rrb._RE2 
Trospium|P|sanctura|morphine|drug_LE1 eliminate_LE1 by_LE1 active_LE1 tubular_LE1 secretion_LE1 :_LE1 although_LE1 study_LE1 to_LE1 assess_LE1 drugdrug_LE1 interaction_LE1 with_LE1 BIOGENERAL_LE1 have_LE1 not_LE1 be_LE1 conduct_LE1 BIOENTITY have_BE12 the_BE12 potential_BE12 for_BE12 pharmacokinetic_BE12 interaction_BE12 with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 eliminate_BE12 by_BE12 active_BE12 tubular_BE12 secretion_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 rrb._RE2 
Trospium|P|sanctura|procainamide|drug_LE1 eliminate_LE1 by_LE1 active_LE1 tubular_LE1 secretion_LE1 :_LE1 although_LE1 study_LE1 to_LE1 assess_LE1 drugdrug_LE1 interaction_LE1 with_LE1 BIOGENERAL_LE1 have_LE1 not_LE1 be_LE1 conduct_LE1 BIOENTITY have_BE12 the_BE12 potential_BE12 for_BE12 pharmacokinetic_BE12 interaction_BE12 with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 eliminate_BE12 by_BE12 active_BE12 tubular_BE12 secretion_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 rrb._RE2 
Trospium|P|sanctura|digoxin|drug_LE1 eliminate_LE1 by_LE1 active_LE1 tubular_LE1 secretion_LE1 :_LE1 although_LE1 study_LE1 to_LE1 assess_LE1 drugdrug_LE1 interaction_LE1 with_LE1 BIOGENERAL_LE1 have_LE1 not_LE1 be_LE1 conduct_LE1 BIOENTITY have_BE12 the_BE12 potential_BE12 for_BE12 pharmacokinetic_BE12 interaction_BE12 with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 eliminate_BE12 by_BE12 active_BE12 tubular_BE12 secretion_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 rrb._RE2 
Vancomycin|P|vancomycin|anesthetic agent|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY have_RE2 be_RE2 associate_RE2 with_RE2 erythema_RE2 and_RE2 histaminelike_RE2 flush_RE2 and_RE2 anaphylactoid_RE2 reaction_RE2 
Vigabatrin|P|vigabatrin|carbamazepine|study_LE1 publish_LE1 in_LE1 NUM_LE1 find_LE1 that_LE1 BIOENTITY cause_BE12 statistical_BE12 significant_BE12 increase_BE12 in_BE12 plasma_BE12 clearance_BE12 of_BE12 BIOENTITY 
Vigabatrin|P|vigabatrin|phenytoin|In_LE1 NUM_LE1 drs_LE1 rimmer_LE1 and_LE1 richens_LE1 at_LE1 the_LE1 university_LE1 of_LE1 wales_LE1 report_LE1 that_LE1 administer_LE1 BIOENTITY with_BE12 BIOENTITY lower_RE2 the_RE2 serum_RE2 BIOGENERAL_RE2 concentration_RE2 in_RE2 patient_RE2 with_RE2 treatmentresistant_RE2 epilepsy_RE2 
Vindesine|P|vindesine|live virus vaccine|BIOENTITY can_BE12 interact_BE12 with_BE12 the_BE12 drug_BE12 of_BE12 the_BE12 following_BE12 category_BE12 :_BE12 blood_BE12 dyscrasia_BE12 :_BE12 can_BE12 cause_BE12 unpredictable_BE12 myelotoxicity_BE12 bone_BE12 marrow_BE12 depressant_BE12 :_BE12 can_BE12 cause_BE12 predictable_BE12 doserelated_BE12 myelotoxicity_BE12 radiation_BE12 therapy_BE12 :_BE12 may_BE12 cause_BE12 marrow_BE12 depression_BE12 neurotoxic_BE12 medication_BE12 :_BE12 can_BE12 cause_BE12 neurologic_BE12 toxicity_BE12 BIOGENERAL_BE12 :_BE12 can_BE12 increase_BE12 seizure_BE12 activity_BE12 BIOENTITY :_RE2 may_RE2 potentiate_RE2 the_RE2 replication_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 virus_RE2 may_RE2 increase_RE2 the_RE2 side_RE2 effect_RE2 of_RE2 the_RE2 vaccination_RE2 and_RE2 decrease_RE2 patient_RE2 's_RE2 response_RE2 to_RE2 the_RE2 vaccine_RE2 BIOGENERAL_RE2 :_RE2 may_RE2 cause_RE2 shortness_RE2 of_RE2 breath_RE2 and_RE2 bronchospasm_RE2 BIOGENERAL_RE2 :_RE2 may_RE2 decrease_RE2 patient_RE2 's_RE2 response_RE2 to_RE2 the_RE2 BIOGENERAL_RE2 
Vindesine|P|vindesine|phenytoin|BIOENTITY can_BE12 interact_BE12 with_BE12 the_BE12 drug_BE12 of_BE12 the_BE12 following_BE12 category_BE12 :_BE12 blood_BE12 dyscrasia_BE12 :_BE12 can_BE12 cause_BE12 unpredictable_BE12 myelotoxicity_BE12 bone_BE12 marrow_BE12 depressant_BE12 :_BE12 can_BE12 cause_BE12 predictable_BE12 doserelated_BE12 myelotoxicity_BE12 radiation_BE12 therapy_BE12 :_BE12 may_BE12 cause_BE12 marrow_BE12 depression_BE12 neurotoxic_BE12 medication_BE12 :_BE12 can_BE12 cause_BE12 neurologic_BE12 toxicity_BE12 BIOENTITY :_RE2 can_RE2 increase_RE2 seizure_RE2 activity_RE2 BIOGENERAL_RE2 :_RE2 may_RE2 potentiate_RE2 the_RE2 replication_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 virus_RE2 may_RE2 increase_RE2 the_RE2 side_RE2 effect_RE2 of_RE2 the_RE2 vaccination_RE2 and_RE2 decrease_RE2 patient_RE2 's_RE2 response_RE2 to_RE2 the_RE2 vaccine_RE2 BIOGENERAL_RE2 :_RE2 may_RE2 cause_RE2 shortness_RE2 of_RE2 breath_RE2 and_RE2 bronchospasm_RE2 BIOGENERAL_RE2 :_RE2 may_RE2 decrease_RE2 patient_RE2 's_RE2 response_RE2 to_RE2 the_RE2 BIOGENERAL_RE2 
Vindesine|P|vindesine|mitomycin-c|BIOENTITY can_BE12 interact_BE12 with_BE12 the_BE12 drug_BE12 of_BE12 the_BE12 following_BE12 category_BE12 :_BE12 blood_BE12 dyscrasia_BE12 :_BE12 can_BE12 cause_BE12 unpredictable_BE12 myelotoxicity_BE12 bone_BE12 marrow_BE12 depressant_BE12 :_BE12 can_BE12 cause_BE12 predictable_BE12 doserelated_BE12 myelotoxicity_BE12 radiation_BE12 therapy_BE12 :_BE12 may_BE12 cause_BE12 marrow_BE12 depression_BE12 neurotoxic_BE12 medication_BE12 :_BE12 can_BE12 cause_BE12 neurologic_BE12 toxicity_BE12 BIOGENERAL_BE12 :_BE12 can_BE12 increase_BE12 seizure_BE12 activity_BE12 BIOGENERAL_BE12 :_BE12 may_BE12 potentiate_BE12 the_BE12 replication_BE12 of_BE12 the_BE12 BIOGENERAL_BE12 virus_BE12 may_BE12 increase_BE12 the_BE12 side_BE12 effect_BE12 of_BE12 the_BE12 vaccination_BE12 and_BE12 decrease_BE12 patient_BE12 's_BE12 response_BE12 to_BE12 the_BE12 vaccine_BE12 BIOENTITY :_RE2 may_RE2 cause_RE2 shortness_RE2 of_RE2 breath_RE2 and_RE2 bronchospasm_RE2 BIOGENERAL_RE2 :_RE2 may_RE2 decrease_RE2 patient_RE2 's_RE2 response_RE2 to_RE2 the_RE2 BIOGENERAL_RE2 
Vindesine|P|vindesine|killed virus vaccine|BIOENTITY can_BE12 interact_BE12 with_BE12 the_BE12 drug_BE12 of_BE12 the_BE12 following_BE12 category_BE12 :_BE12 blood_BE12 dyscrasia_BE12 :_BE12 can_BE12 cause_BE12 unpredictable_BE12 myelotoxicity_BE12 bone_BE12 marrow_BE12 depressant_BE12 :_BE12 can_BE12 cause_BE12 predictable_BE12 doserelated_BE12 myelotoxicity_BE12 radiation_BE12 therapy_BE12 :_BE12 may_BE12 cause_BE12 marrow_BE12 depression_BE12 neurotoxic_BE12 medication_BE12 :_BE12 can_BE12 cause_BE12 neurologic_BE12 toxicity_BE12 BIOGENERAL_BE12 :_BE12 can_BE12 increase_BE12 seizure_BE12 activity_BE12 BIOGENERAL_BE12 :_BE12 may_BE12 potentiate_BE12 the_BE12 replication_BE12 of_BE12 the_BE12 BIOGENERAL_BE12 virus_BE12 may_BE12 increase_BE12 the_BE12 side_BE12 effect_BE12 of_BE12 the_BE12 vaccination_BE12 and_BE12 decrease_BE12 patient_BE12 's_BE12 response_BE12 to_BE12 the_BE12 vaccine_BE12 BIOGENERAL_BE12 :_BE12 may_BE12 cause_BE12 shortness_BE12 of_BE12 breath_BE12 and_BE12 bronchospasm_BE12 BIOENTITY :_RE2 may_RE2 decrease_RE2 patient_RE2 's_RE2 response_RE2 to_RE2 the_RE2 BIOGENERAL_RE2 
Vitamin A|P|contraceptive|vitamin a|drug_LE1 interaction_LE1 :_LE1 woman_LE1 on_LE1 oral_LE1 BIOENTITY have_BE12 show_BE12 significant_BE12 increase_BE12 in_BE12 plasma_BE12 BIOENTITY level_RE2 
Vitamin C|P|ascorbic acid|bishydroxycoumarin|limited_LE1 evidence_LE1 suggest_LE1 that_LE1 BIOENTITY may_BE12 influence_BE12 the_BE12 intensity_BE12 and_BE12 duration_BE12 of_BE12 action_BE12 of_BE12 BIOENTITY 
Vorinostat|P|zolinza|coumarin-derivative anticoagulant|BIOGENERAL_LE1 :_LE1 prolongation_LE1 of_LE1 prothrombin_LE1 time_LE1 -LRB-_LE1 pt_LE1 -RRB-_LE1 and_LE1 international_LE1 normalize_LE1 ratio_LE1 -LRB-_LE1 inr_LE1 -RRB-_LE1 be_LE1 observe_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOENTITY 
Vorinostat|P|zolinza|coumarin derivative|physician_LE1 shall_LE1 careful_LE1 monitor_LE1 pt_LE1 and_LE1 inr_LE1 in_LE1 patient_LE1 concurrent_LE1 administer_LE1 BIOENTITY and_BE12 BIOENTITY 
Vorinostat|P|zolinza|valproic acid|other_LE1 BIOGENERAL_LE1 severe_LE1 thrombocytopenia_LE1 and_LE1 gastrointestinal_LE1 bleeding_LE1 have_LE1 be_LE1 report_LE1 with_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY rrb._RE2 
Vorinostat|P|zolinza|hdac inhibitor|other_LE1 BIOGENERAL_LE1 severe_LE1 thrombocytopenia_LE1 and_LE1 gastrointestinal_LE1 bleeding_LE1 have_LE1 be_LE1 report_LE1 with_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 other_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 rrb._RE2 
